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Abstract 
Group A streptococcus (Group A streptococci; GAS; Streptococcus pyogenes) is a Gram 
positive bacterium which is responsible for a wide range of non-invasive and invasive 
diseases. Reports over the last three decades have indicated resurgences in GAS infection 
worldwide. The cell surface M protein is the most extensively studied GAS virulence factor 
with over 220 variants of this protein being described. Coded by the emm gene, the M protein 
mediates invasive GAS infection by binding to a diverse range of host proteins across its 
entire length. The diverse function of this protein promotes GAS colonisation while also 
facilitating the bacterium to overcome the host innate immune response. To date, M protein is 
the most commonly used substrate for epidemiological typing and is a commonly utilised 
vaccine antigen in GAS vaccine development. Studies investigating the global distribution of 
M-types have found that while the M-type distribution of GAS in high income settings is 
restricted to a few predominant M-types, the distribution in low-income settings is much 
greater. GAS typing is dependent on a small portion (10-15%) of the M protein. Prior studies 
analysing the sequence diversity of M-types in a low-income settings have found that they are 
highly similar in sequence, subsequently raising questions of type-specific immunity. In this 
study 1086 GAS isolates collected from 31 countries representing 175 M-types were 
phylogenetically assessed on their full length mature M protein sequence, with the aim of 
developing a new cluster-based classification system which would support future vaccine 
development and functional studies. Phylogenetic analysis identified that 175 M-types could 
be grouped in to 2 clades, 2 sub-clades and 48 clusters, 16 of which encompassed 82% of all 
analysed M-types. To evaluate the utility of this novel classification system as a tool for 
identification of M protein function, 26 M proteins representing 24 distinct M-types 
encompassing all major cluster groups were recombinantly expressed and screened for 
v 
 
binding against a select range of host proteins. Surface plasmon resonance (SPR) binding 
experiments identified that both fibrinogen and plasminogen binding function was restricted 
to clade-Y. Plasminogen binding was further restricted to cluster D4 whereby all M protein 
contained the highly predictive plasminogen binding motif. High affinity IgA binding was 
observed only by M proteins associated with emm-clusters E1 and E6 whereas IgG binding 
was observed by emm-clusters E1, E3, E4, E6, A-C3 and non-clustered M proteins M57 and 
M14. Complement inhibitor C4-binding protein was shown to only bind clade-X M protein 
representatives, specifically emm-clusters E1, E3, E4 and E6. Although all M proteins in 
study were shown to express the previously characterised human serum albumin binding 
domain, emm-cluster E4 and D4 M protein representatives M53 and M98 were shown not to 
bind human serum albumin. The ability of GAS vaccine candidate ‘Streptococcal vaccine 1’ 
(SV1) to effectively opsonise the C-repeat targeted domains of the M proteins in this study 
was assessed in the presence of IgG, IgA, plasminogen, fibrinogen and albumin. Competitive 
SPR binding analysis identified that α-SV1 IgG binding did not compete for binding with the 
respective host proteins. Only IgA binding by E1 M proteins was shown to both inhibit and 
outcompete α-SV1 IgG binding interactions. These results clearly demonstrate the utility of 
this GAS classification system based on full length M protein sequence with applications of 
facilitating future M protein functional studies, epidemiological surveillance and vaccine 
development.   
Interactions between M protein and host proteins are central to multiple stages of GAS 
disease. Plasminogen acquisition mediated by the M protein PAM, and activation by SK is 
central to GAS pathogenesis. Two predominant glycoforms of plasminogen circulate in the 
host. Glycoform I plasminogen (GI-plasminogen) contains glycosylation sites at Asn289 and 
Thr346, whereas glycoform II plasminogen (GII-plasminogen) is exclusively glycosylated at 
Thr346. SPR experiments demonstrated that plasminogen binding group A streptococcal M 
vi 
 
protein (PAM; M53; emm-cluster D4) exhibits relatively equal affinity for GI- and GII-
plasminogen in the ‘closed’ conformation (GII-plasminogen, KD = 27.4 nM; GI-plasminogen, 
KD = 37.0 nM). When plasminogen was in the ‘open’ conformation, PAM exhibited an 11 
fold increase in affinity for GII-plasminogen (KD = 2.8 nM) compared with GI- plasminogen 
(KD = 33.2 nM). The interaction of PAM with plasminogen is believed to be mediated by 
lysine binding sites within kringle (KR) 2 of plasminogen. PAM and GI-plasminogen 
interactions were fully inhibited with 100 mM of lysine analogue ε-aminocaproic acid 
(εACA), whereas PAM-GII-plasminogen interactions were shown to be reduced but not 
inhibited in the presence of 400 mM εACA. In contrast, binding to the KR1-3 domains of 
GII- plasminogen (angiostatin) by PAM were completely inhibited in the presence 5 mM 
εACA. Along with PAM, emm pattern D GAS isolates express a phenotypically distinct SK 
variant (type-2b SK) which requires plasminogen ligands such as PAM to activate 
plasminogen. Type-2b SK was able to generate an active site and activate GII-plasminogen at 
a significantly higher rate than GI-plasminogen when bound to PAM. Taken together, these 
data suggest that GAS selectively recruits and activates GII- plasminogen. Furthermore, it is 
proposed that the interaction between PAM and plasminogen may be partially mediated by a 
secondary binding site outside of kringle 2, affected by glycosylation at Asn289.   
Aside from protein-protein interactions, carbohydrates (glycans) have also been shown to 
play an important role in host-pathogen interactions for select bacterial species. As the 
dominant GAS cell surface protein, M protein is a strong candidate for mediating GAS-
glycan interactions, however, to date, M protein-glycan interactions have not been 
comprehensively explored. Through the use of newly developed glycan microarray 
technology, the glycan binding profile of each emm-cluster was characterised against 319 
distinct glycan structures. M protein representatives from each emm-cluster were shown to 
have distinct glycan binding profiles, with several emm-cluster groups demonstrating broad 
vii 
 
specificity for multiple terminal galactose, glucose, fucose, mannose, sialic acid and 
glycosaminoglycan containing structures. To evaluate the physiological relevance of these M 
protein-glycan interactions in GAS pathogenesis, globally disseminated M1T1 GAS strain, 
5448, and isogenic mutant 5448ΔM1 were selected for further characterisation. Whole GAS 
cell glycan microarray screening identified that 5448 could bind 19 different glycan 
structures in an M1 protein dependant manner. Due to the expression of lacto-N-tetraose and 
blood group H antigen type I structures on human tissue and in mucosal fluid, interactions of 
these structures with M1 were further investigated. SPR analysis identified that binding of 
lacto-N-tetraose (KD = 127.3 ± 26.2 µM) and blood group H antigen type I (KD = 307.2 ± 
168.9 nM) were both localised to the B-repeat domains of M1 whereby Galβ1-4Gal was the 
minimum carbohydrate residue required for recognition. Following pre-incubation with lacto-
N-tetraose, 5448 was shown to significantly associate more with Detroit-562 pharyngeal cells 
in a concentration dependant and tissue specific manner (P < 0.01). No significant differences 
in association of 5448 to Detroit-562 cells were observed in the presence of blood group H 
antigen type I. To assess the potential role of blood group antigen structures in upper 
respiratory tract colonisation by M1 serotypes, buccal epithelial cell and saliva samples from 
20 individuals of unknown blood type were collected. Blood group status and expression 
were assessed via LC-ESI MS analysis of donor saliva and differences in association of 
5448eGFP and 5448ΔM1eGFP to buccal cells from each donor were examined via flow 
cytometry. Blood group antigen expression analysis identified that 5448eGFP was able to 
associate with buccal epithelial cells expressing H antigen structures at a significantly higher 
level than cells expressing A (P < 0.05) and AB (P < 0.01) antigen structures. No significant 
differences in association were observed between 5448ΔM1eGFP and buccal epithelial cells 
expressing various blood group antigen structures. As only 1 subject was shown to express 
the B antigen, no statistical inferences were able to be made. Although preliminary, this data 
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suggests blood group antigen related structures play a role in GAS colonisation, further 
highlighting the complex nature of GAS disease. 
This study clearly demonstrates the development and utility of the newly implemented GAS 
classification system. Furthermore, we have identified novel M protein functions which may 
contribute to the different stages during GAS infection. These results illustrate the 
homologous genetic and functional properties of distinct M-types in regions where the 
epidemiology of infection is diverse. A better understanding of M protein interaction with the 
host will broaden our knowledge of GAS disease progression, facilitating the development of 
future therapeutics. 
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1.1 Overview 
 
Group A streptococcus (Group A streptococci; Streptococcus pyogenes; GAS) is a human 
pathogen which can cause a diverse range of both invasive and non-invasive infections. The 
ability of this Gram positive bacterium to colonise both deep and superficial sites has resulted 
in the World Health Organisation categorising GAS within the ‘top 10’ most lethal 
pathogens, exceeded only by pathogens causing HIV, tuberculosis, malaria and pneumonia 
(WHO 2005). The Australian Indigenous community living in remote and rural settings such 
as the Northern Territory (NT), experience significantly higher incidence and mortality rates 
due to invasive GAS infections than non-indigenous Australians. Reports indicate that GAS 
infection rates among Aboriginal children in these regions are as high as 70% (Carapetis et 
al. 1999).  
M protein is coded by the emm gene, and is the major surface protein and virulence factor of 
GAS. Currently, M protein is used for the classification of GAS, and is a major therapeutic 
target. GAS mediate binding to a wide range of proteins found within the host’s extracellular 
matrix (ECM) via the M protein, including fibrinogen, plasminogen, C4-binding protein 
(C4BP), IgG and IgA (Ringdahl et al. 2000). To date, over 220 M protein serotypes have 
been defined, exhibiting sequence variation primarily in the first 10-15% portion of the M 
protein. As a result of sequence diversity between M protein serotypes the specificity for host 
proteins is varied. A wide range of M serotypes are associated with invasive GAS infection in 
the NT of Australia. Study of the sequence identity and binding characteristics of M proteins 
expressed by invasive clinical GAS isolates from this region may lead to a better 
understanding of the mechanisms underlying invasive infection. 
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1.2 Classification of Group A Streptococcus 
 
Streptococcal emm and emm-like genes which encode cell bound M and M-like proteins are 
clustered together at the vir (also known as mga) locus of the GAS chromosome and are 
divided into the mrp, emm, and enn gene groups on the basis of differences in conserved 5’ 
and 3’ regions (Beall et al. 1996). M protein, a major surface protein and virulence factor of 
GAS, is anchored to the cell wall peptidoglycan through the LPxTG motif (Fischetti et al. 
1990; Barnett et al. 2002). Structural characterisation has revealed that the M protein is a 
fibrillary coiled-coil dimer that extends beyond the GAS cell surface as hairlike projections, 
typically consisting of 4 repeat regions (designated A to D) that vary in size and amino acid 
composition (Phillips et al. 1981; Smeesters et al. 2008). Differences in emm nucleotide and 
translated amino acid sequence, along with emm and emm-like gene patterns, have given rise 
to a range of GAS classification techniques which have functioned to categorise over 220 
GAS emm-types to date (Walker et al. 2014).  
1.2.1 M-serotyping classification system 
M proteins universally exhibit the general structure of an elongated coil coiled alpha-helix 
containing a conserved C-terminus, with a variable N-terminus. The N-terminus is comprised 
of a signal sequence that targets protein expression to the cell surface and a series of 
hypervariable repeat domains (Hollingshead et al. 1986). Immunogenic bacterial surface 
determinants such as the M protein have been historically used to type GAS via serotype-
specific antiserum raised against the M protein. The antigenic heterogeneity displayed in the 
N-terminus of M proteins provides the basis for serological typing via M protein antisera. 
Even though this form of classification has been used to identify a wide range of serotypes, it 
is not appropriate to evaluate the genetic diversity of a full length M protein based on this 
method. Furthermore, M-serotyping is unable to classify a number of isolates owing to their 
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lack of M-protein expression (Fischetti 1989). To combat this problem, molecular techniques 
such as vir-typing and emm-typing have been employed to provide further discrimination 
between GAS serotypes. 
1.2.2 T-typing classification system 
 
The T protein, encoded by the tee gene is a GAS surface protein expressed and presented 
alongside the M protein. The T protein, named after its observed resistance to trypsin 
digestion has been shown to be stable at the GAS cell surface throughout the multiple stages 
of GAS disease (Lancefield et al. 1946; Cunningham 2000). Prior studies analysing the 
sequence homology between tee genes found that they exhibit significantly greater sequence 
diversity compared to emm genes (Schneewind et al. 1990). Because of these factors, T-
proteins have proved to be epidemiologically valuable for sub-classifying strains of GAS. T-
typing classification is performed as an agglutination test using T-specific antisera. Initially, 
GAS are treated with trypsin, enabling the digestion of surface expressed trypsin-sensitive 
proteins, including the M protein, leaving the T protein exposed for interaction with T-
specific antibody. Most (over 95%) GAS strains have well defined T-type antigens which are 
associated with specific M protein serotypes (Beall et al. 1998). When M-type is not 
identifiable, T-typing serves as an important classification tool, especially in the in the 
identification of GAS strains associated with disease outbreak (Cunningham 2000).    
1.2.3 Vir/Mga-typing classification system 
The virulence regulatory network found within the Mga of GAS houses and activates the 
transcription of several genes, including those for M protein (emm) and M-like proteins (mrp, 
enn, and fcR) (Podbielski et al. 1996). Mga expression is regulated by positive feedback, and 
regulation is controlled via the mga gene (alternatively mry/virR). As a result of intragenic 
and intergenic recombination events, Mga varies from serotype to serotype. This in turn, 
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allows for sequence divergence to occur among gene species, and ultimately facilitates the 
expression of different gene patterns to be housed within an Mga (Whatmore et al. 1995). 
Vir/Mga-typing is a powerful technique which utilises long polymerase chain reactions 
(PCR) and restriction enzyme digestion to characterise the 5-7 kb mga regulon found within 
the GAS genome (Gardiner et al. 1998). This highly discriminatory procedure is able to 
differentiate between all M-non-type-able strains of GAS. The ability of this technique to be 
highly effective and reproducible has allowed previously uncharacterised strains to be 
classified, such as those found within the NT (Carapetis et al. 1999).  
1.2.4 emm-typing classification system 
emm-typing is based on the nucleotide sequence of the emm gene which encodes the M 
protein. emm-typing is able to differentiate between GAS strains due to insertions, deletions 
and frameshift mutations within different emm genes. Mutational events within the 5’ region 
of emm contributes variability within the M protein, and thus provide subsequent grounds for 
discrimination between GAS strains (Facklam et al. 1999). The degree of sequence 
conservation between emm genes, particularly at the 3’ end, is thought to be responsible for 
the cross-reactivity between specific GAS strains and reference antisera. Although the emm 
typing system is a useful and reliable epidemiological tool for classification of GAS, this 
technique does not evaluate the genetic diversity of a full length emm gene/M protein. 
Previous attempts to link emm-type with the phenotypic characteristics of GAS have failed to 
account for sequence differences downstream of the emm-type region. Prior classification 
systems have failed to take full length M protein sequence into account and thus novel 
classification techniques based on full length sequence must be implemented.  
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1.2.5 emm-Pattern classification 
GAS strains can encode multiple emm or emm-family genes within the Mga regulon. The 
number of emm and emm-like genes, their sub-family content and respective positioning on 
the chromosome forms the basis of 5 different emm patterns designated A through to E  (Fig 
1.1) (Hollingshead et al. 1993). emm-patterns A, B and C are typically associated with 
pharyngeal infections, where D strains are predominately associated with cutaneous skin 
infections. Pattern E strains have been found to be associated with both pharyngeal and 
cutaneous skin infections, and as such are termed generalists (Bessen et al. 1997; Smeesters 
et al. 2006). 
 
 
 
 
 
 
 
 
Figure 1.1: Assembly of emm and emm-like gene patterns, A-E. emm pattern groups are classified 
based on  gene amplification using emm, mrp, or enn subfamily (SF) specific primers. emm and emm-
family genes are expressed between mga and scpA (C5a peptidase) genes. Tissue tropism associated 
with each emm-pattern is indicated on the side. Figure was appended from Hollingshead et al. (1993) 
and Cunningham (2000).  
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1.3 GAS diseases 
1.3.1 Non-invasive GAS diseases 
Non-invasive GAS diseases are localised uncomplicated infections of pharyngeal or skin 
tissue. Common non-invasive GAS infections include pharyngitis, impetigo, and scarlet 
fever.             
Pharyngitis commonly affects mucosal membrane sites such as the pharynx, larynx, and 
tonsils. Symptoms usually include inflammation of the infected area, headaches, nausea, 
abdominal pain and vomiting. Rapid antigen detection testing or a throat culture can be 
undertaken to clarify the diagnosis where by antibiotics such as amoxicillin or erythromycin 
will be prescribed for treatment purposes (Cunningham 2000). Impetigo usually occurs on 
areas such as the face and other points of contact where superficial skin layers may be 
broken. Lesions first begin as vesicles preceding the formation of pustules. Upon rupture, 
pustules form a yellow crust on the surface of the lesion (Gardiner et al. 1998). Scarlet fever 
often occurs in correlation with pharyngitis. Symptoms of scarlet fever include a 
characteristic red tongue, sand-paper like rash on the neck, chest, elbows and inner surface of 
the thighs (Gidaris et al. 2008). In 2011, an outbreak of scarlet fever hit Hong Kong where by 
600 cases of scarlet fever were reported, with two resulting in death (Hsieha et al. 2011). 
Diseases proceeding scarlet fever such as kidney damage and rheumatic fever are considered 
much more severe than the original disease itself and although the disease is rarely observed 
in the Western world, it is still a serious communicable disease with the potential to cause 
severe epidemics (Gidaris et al. 2008). 
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1.3.2 Invasive GAS diseases  
Invasive GAS diseases are typically restricted to sterile areas such as the blood and deep 
tissue. Although no single GAS serotype has been associated with a specific invasive disease, 
prior research has identified a general association between serotypes M1 and M3 with 
invasive infections (Johnson et al. 2002).  
Cellulitis and bacteremia are the two most common invasive infections caused by GAS. 
Cellulitis is an infection which affects subcutaneous tissues and is characterised by 
inflammation of the skin with associated pain and swelling (Bernard 2008; Walker et al. 
2014). Bacteraemia is defined by the presence of bacteria within the bloodstream which in 
turn can elicit a vigorous immune response (Bisno et al. 1996; Sriskandan et al. 2008). The 
presence of GAS within the blood stream facilitates spread of the bacteria away from the 
original site of infection, resulting in high fever, blood coagulation and organ failure (Jensen 
et al. 2010). Erysipelas is an acute bacterial infection commonly caused by GAS which 
affects dermal and hypodermal layers of the skin. Erysipelas infection can be easily defined 
by raised inflammation around the infected site. Recent studies have identified that between 
7-29% of patients suffering from erysipelas experience repeated episodes of the disease 
(Leclerc et al. 2006). Chronic recurrence of erysipelas is considered to be the diseases most 
frequent complication as each additional episode raises the risk of further deterioration of 
underlying systemic conditions (e.g. cardiovascular and respiratory conditions), as well as 
local abnormalities affecting the lymphatic system (Leclerc et al. 2006).     
Streptococcal toxic shock syndrome (STSS) is characterised by severe hypotension, multiple 
organ failure, systemic toxicity, and severe local pain making it one of the most severe GAS 
diseases. Initiation of infection occurs upon entry of GAS via mild trauma to the skin. 
Disease progression stems from a series of super-antigenic toxins secreted by GAS which 
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mediate binding of major histocompatibility complex (MHC) class II molecules with T cell 
receptors. This results in polyclonal T cell activation. The rapid amplification in T cell 
numbers induces high level release of cytokines within the body resulting in various bodily 
systems being affected (Holub et al. 2004). Necrotizing fasciitis which is normally 
accompanied by STSS, is a rare disease characterised by such symptoms as rapid necrosis of 
subcutaneous skin, gangrene and inflammation. Predisposing factors include varicella, 
penetrating injuries, surgical procedures and mild superficial trauma to the skin (Bisno et al. 
1996).  
1.3.3 Post infection sequelae 
Infection with GAS can give rise to serious nonsuppurative sequelae such as acute rheumatic 
fever (ARF) and acute post-streptococcal glomerulonephritis (APSGN), whereby the highest 
morbidity and mortality rates are present within the Indigenous population of Australia 
(Carapetis et al. 1996; Jackson et al. 2011).  
While ARF can be associated with GAS infection of the skin, the disease typically develops 
following GAS pharyngeal infection, with related symptoms affecting several tissues within 
the body. Common symptoms of ARF include migratory polyarthritis (inflammation of one 
or more joints), carditis (inflammation of heart tissue) and Sydenham’s chorea (inflammation 
of the central nervous system). Although migratory polyarthritis is the most common 
symptom experienced by people suffering from ARF (approximately 75%), carditis is the 
most severe. Carditis, which forms a symptom of rheumatic heart disease (RHD) significantly 
increases the risk of endocarditis developing in patients. In rare cases, carditis can lead to 
heart failure, stroke, and eventually death (Cabell et al. 2003). 
Molecular mimicry between GAS and host antigens has been a suggested mechanism for the 
pathology and manifestation of ARF (Johnson et al. 1992; Quinn et al. 2001). GAS induced 
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RHD is characterised by the presence of high levels of anti-group A carbohydrate epitope,  
and N-acetyl-beta-D-glucosamine (GlcNAc) antibodies which are cross reactive with both 
cardiac myosin in the myocardium and valve endothelium (Galvin et al. 2000). Autoimmune 
B-cell induced antibody responses against the Group A antigen have been correlated to the 
terminal O-linked GlcNAc residue which shares structural similarity to multiple host 
glycoconjugates (Fung et al. 1982). M protein has also been well documented to be involved 
in initiating RHD due to its highly homologous structure to select host glycoproteins (Ellis et 
al. 2005; Fae et al. 2006). T-cells have been shown to cross-react with M protein, cardiac 
myosin and laminin epitopes allowing T-cell infiltration into valve endothelium, 
subsequently triggering downstream inflammatory responses (Cunningham 2012). Although 
the rate of ARF in developed countries is low, rates among the Indigenous population of 
Australia remain high. Between 2005 and 2010, 98% of all recorded ARF cases in the NT of 
Australia were for Aboriginal of Torres Strait Islander people. The prevalence of infection 
during this time period for Indigenous Australians from the NT was 26 times higher than the 
rate for non-Indigenous people (AIHW 2013).  
Acute post-streptococcal glomerulonephritis (APSGN) is commonly associated with GAS 
throat or skin infections occurring primarily in young children and adults with males affected 
twice as much as females. The latency period after primary infection may range from 1-4 
weeks (Cunningham 2000). Common symptoms of APSGN include the sudden appearance of 
edema, hematuria, hypertension, urinary abnormalities and decreased serum complement 
levels (Rodriguez-Iturbe et al. 2007). The direct mechanism by which APSGN occurs is 
unknown, but GAS receptors glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and 
streptococcal pyogenic toxin (SpeB) have been implicated in inflammatory and complement 
deposition processes resulting in immune complex-mediated glomerulonephritis (Batsford et 
al. 2005). Only a sub-set of M-types have been identified as causative agents of 
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glomerulonephritis. M serotypes commonly associated with skin or throat infections such as 
1, 2, 4, 12, 18, 25, 49, 55, 57, and 60 have been found to be highly nephritogenic (Nissenson 
et al. 1979; Bisno et al. 1996; Rodriguez-Iturbe et al. 2007). The early stages of APSGN are 
reversible and easily treated. Latter stages of disease progression often require renal 
replacement accounting for morbidity rates of approximately 1 % in all diagnosed cases 
(Hricik et al. 1998; WHO 2005).  
1.4 Global burden of Group A Streptococcal diseases 
GAS causes a substantial burden of disease on a global scale, effecting predominantly 
children and young adults in both developed and non-developed countries. Over 620 million 
people suffer from non-invasive GAS infections such as pharyngitis and pyoderma each year. 
Complicated diseases encompassing invasive GAS infections such as necrotizing fasciitis and 
STSS affect over 660 000 people each year, contributing to approximately 163 000 deaths. It 
is currently estimated that 15.6 million cases of post-sequelae rheumatic heart disease exist 
resulting in 233 000 deaths per year (Carapetis et al. 2005; WHO 2005). In total, invasive 
GAS diseases and diseases related to post infection sequelae contribute to over 500,000 
deaths per year worldwide (Table 1.1). 
The financial impacts of GAS diseases are quite significant in non-invasive diseases such as 
pyoderma and pharyngitis which eclipse invasive diseases in relation to total cases per year. 
Costs associated with antibiotic use, symptomatic medications and economic costs arising 
from absenteeism, place a significant burden on both families and healthcare systems. In the 
United States, the cost attributed to GAS pharyngitis alone is estimated to be up to $539 
million per year (Pfoh et al. 2008). 
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1.5 Disease history and epidemiology 
The turn of the twentieth-century coincided with a dramatic decline in the prevalence of 
serious infection caused by GAS in the Western world, with the majority of GAS infections 
resulting in only minor non-invasive disease (Carapetis et al. 1999). Since the mid-1980’s an 
unexplained resurgence in severe GAS infection has been observed. One of the initial 
indications of this resurgence was an outbreak of the post infectious sequelae, rheumatic 
fever, which effected approximately 200 children in the USA over a five year period (Veasy 
et al. 1987). Towards the late 1980’s, diseases such as STSS, bacteraemia, and severe 
invasive GAS skin and soft tissue infections were reported throughout USA and Europe 
(Pandey et al. 2009). In addition, the NT of Australia currently has a 70% incidence of skin 
infections such as impetigo in children below the age of five, along with one of the highest 
rates of rheumatic fever in the world (Cook et al. 2007; Middleton et al. 2014). Even though 
many M types have been responsible for the varying outbreaks, serotypes M1 and M3 have 
been found to be the most dominant in Western populations (Aziz et al. 2008). The fact that 
these strains are most frequently isolated from infected patients may reflect an 
epidemiological shift towards newly sequestered virulence factors within the bacterial 
species. The mechanisms underlying this epidemiological shift are yet to be fully determined. 
However, recent research indicates that the acquisition of bacteriophage encoded virulence 
factors may play a significant role (Walker et al. 2007; Davies et al. 2014). 
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Table 1.1: The global burden of Group A streptococcal diseases. Numbers relating to existing cases, new cases each year and morbidity rates were 
defined from the following regions: Sub-Saharan Africa, Indian Subcontinent, People’s Republic of China, other countries in Asia (excluding 
Japan), Latin America, Middle East and North Africa, Eastern Europe, Pacific Island countries and indigenous Australian and New Zealand, and 
Established Market Economies. Table was appended from WHO/FCH/CAH/05.07 (WHO 2005).  
Disease Number of existing cases Number of new cases each year Number of deaths each year 
Rheumatic heart disease 15.6 million 282,000 233,000 
History of acute rheumatic fever without 
carditis, requiring secondary prophylaxis 
1.88 million 188,000 - 
RHD-related infective endocarditis - 34,000 8000 
RHD-related stroke 640 000 144,000 108 000 
Acute post-streptococcal glomerulonephritis - 472,000 5000 
Invasive group A streptococcal diseases - 663,000 163 000 
Total severe cases 18.1 million 1.78 million 517 000 
Pyoderma 111 million - - 
Pharyngitis - 616 million - 
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In low socio-economic regions such as Brazil as well as in the NT, Australia, the 
epidemiology of GAS infection is less well defined. Infection in these regions is often linked 
to a variety of GAS serotypes, and neither M1 nor M3 appear to dominate (Stollerman 1997; 
Smeesters et al. 2006). Furthermore, in cases of non-invasive infection, GAS are highly 
susceptible to antibiotic treatment. Treatment options for invasive disease are limited to 
extremely high doses of intravenous penicillin and surgical debridement (Walker et al. 2014). 
Despite intensive research efforts, GAS vaccines remain elusive, however, M protein is still 
the most pursued vaccine target. It is for these reasons that there is a need to characterise the 
function of diverse M proteins associated with GAS from regions where the burden of 
infection is the highest.  
1.6 M protein  
1.6.1 M protein structure 
M protein molecules appear as hair-like projections extending from the cell wall through the 
GAS capsule into the ECM (Fig 1.2). The protein structure itself is known to have an α-
helical coiled coil amino acid arrangement whereby the first and fourth amino acids within 
the chain are hydrophobic making up the protein core, thus allowing for protein stability 
(McNamara et al. 2008). Additional biochemical support for the coiled coil structure of M 
protein became apparent when partial sequences of M5, M6, and M24 proteins were 
compared with tropomyosin. The sequences within these three M protein molecules contain a 
repeating seven residue periodicity of non-polar amino acids, a general characteristic of α-
helical coiled coil proteins such as tropomyosin (Manjula et al. 1980). 
Further studies analysing M protein structure through the use of X-ray diffraction indicated 
that M proteins were of similar width to tropomyosin and that a coiled coil structure was 
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present within the M protein (Phillips et al. 1981). Irregularities and instabilities throughout 
the α-helical coiled coil conformation have been found to be required for function, especially 
in the hypervariable regions of M1, where irregularities in conformation are required for 
fibrinogen binding, and subsequent downstream pro-inflammatory effects (McNamara et al. 
2008). Similar structural irregularities occur in myosin and tropomyosin, and may partially 
explain the patterns of cross-reactivity seen in auto immune sequelae of GAS infection (Ellis 
et al. 2005; Fae et al. 2006). 
Analysis of sequence data from various M protein serotypes has led to the development of a 
general model of M protein structure: an extended central coiled coil rod domain flanked by 
functional end domains. Within the central helical coiled coil region, sequence variances have 
been observed in M protein molecules. Based on these variances, the central rod region is 
divided into A, B, C, and D repeat blocks with a pepsin cleavage region between repeat B and 
repeat C (Fig 1.2) (Fischetti et al. 1988). The A and B repeat regions reside immediately 
downstream of the amino terminus which is exposed to the ECM, while the D repeat domain 
exists adjacent to the anchor region just above the peptidoglycan membrane of the bacterial 
cell (Fischetti 1989). Both the A and B repeat domains are highly variable among M protein 
serotypes. The size and serotype variation between M proteins is based on the number and 
sequence of repeating units in the A and B repeat regions, with over 200 described to date 
(ftp://ftp.cdc.gov/pub/infectious_diseases/biotech/tsemm/). The A repeat domain of different 
M proteins have been found to bind plasminogen, IgA, IgG, C4BP and factor H, whilst the B 
repeat domain has been found to mediate binding to fibrinogen and fibronectin (Ringdahl et 
al. 2000; Persson et al. 2006). 
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Figure 1.2: Proposed model of GAS M protein. The M protein structure is similar to 
tropomyosin whereby there is a repeating seven residue periodicity of non-polar amino acids, 
a general characteristic of α-helical coiled coil proteins. The A and B repeats are located at 
the N-terminal and are hypervariable among M protein serotypes, providing the basis for 
emm-typing. The C, D and anchor domains situated closer to the C-terminal are conserved 
across M protein serotypes (Fischetti 1989). 
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Incorporation of the protein into the peptidoglycan layer of the cell wall is mediated by the C-
terminal anchor region. This region is highly conserved among M protein serotypes. It is 
postulated that the C-terminal cell-wall anchor may be necessary to keep the M protein 
molecule attached in the right orientation until the peptidoglycan is able to be cross linked 
around the proline-glycine region of the M protein (Fischetti 1989). This conserved C-
terminal region extends throughout one-third of the molecule and aids in binding ECM 
proteins such as factor H, as well as human serum albumin (Ringdahl et al. 2000). The C-
terminal homology is shared among most M protein serotypes, suggesting the functional 
importance of this region (Hollingshead et al. 1987).  
1.7 Interactions of M protein with host ECM and plasma proteins 
GAS pathogenesis involves multiple stages including adherence to, and colonisation of the 
skin, pharynx. Immediately upon colonisation, the pathogen must adapt to the new 
environment, necessitating the need to evade the host immune response. For some strains of 
GAS, colonisation is directly followed by tissue invasion, involving penetration of host 
mucosal layers. As a major virulence component of GAS, M protein is able to interact with a 
multitude of host factors involved in each stage of disease, highlighting the importance of M 
protein in GAS pathogenesis (Table 1.2). 
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Table 1.2: M proteins and known ligands. Table was adapted from Smeesters et al. 2006. 
emm-pattern M-type Binding location Ligand References 
A-C M1 N-terminal Fibronectin 
(Akesson et al. 1994; Ben Nasr et al. 1995; 
Cue et al. 2001) 
  Sub N-terminal Kininogen 
  Sub N-terminal Fibrinogen 
  Sub N-terminal IgG3 
  C-repeat Albumin 
 M3 N-terminal Fibronectin 
(Reichardt et al. 1995; Reichardt et al. 1997; 
Cue et al. 2001) 
  Sub N-terminal Fibrinogen 
   C-repeat Albumin 
 M5 B-repeat Fibrinogen 
(Kotarsky et al. 2001; Sandin et al. 2006; 
Waldemarsson et al. 2009) 
  C-repeat Factor H 
  C-repeat Albumin 
 M6 N-terminal Kininogen 
(Horstmann et al. 1992; Ben Nasr et al. 1995; 
Fischetti et al. 1995; Cue et al. 2001) 
  N-terminal Fibronectin 
  Sub N-terminal Fibrinogen 
  C-repeat Factor H 
 M12 Sub N-terminal IgG3 
(Retnoningrum et al. 1994) 
  C-repeat Albumin 
 M24 Sub N-terminal Fibrinogen (Whitnack et al. 1985) 
 M46 N-terminal Kininogen (Ben Nasr et al. 1995) 
 M55 Unknown Albumin 
(Boyle et al. 1995)   Unknown Fibrinogen 
  Unknown IgG1,2,3,4 
D M33 Sub N-terminal Plasminogen (Wistedt et al. 1995) 
 M41 Sub N-terminal Plasminogen (Wistedt et al. 1995) 
 M52 Sub N-terminal Plasminogen (Wistedt et al. 1995) 
 M53 Sub N-terminal Plasminogen (Wistedt et al. 1995) 
 M56 Sub N-terminal Plasminogen (Wistedt et al. 1995) 
 M98 Sub N-terminal Plasminogen (Wistedt et al. 1995; Sanderson-Smith et al. 
2007) 
E M2 N-terminal C4BP 
(Boyle et al. 1995; Morfeldt et al. 2001) 
  Unknown IgG1,2,3,4 
 M4 N-terminal C4BP  
(Stenberg et al. 1992; Johnsson et al. 1996)   N-terminal IgA 
  Unknown IgG3 
 M22 N-terminal C4BP 
(Stenberg et al. 1992; Berggard et al. 2001)   Sub N-terminal IgA 
  Unknown IgG1,2,3,4 
 M28 Unknown IgA 
(Stenberg et al. 1992) 
  Unknown IgG1,2,3,4 
 M49 C-repeat Albumin 
(Frick et al. 1994) 
  Unknown IgG 
 M50 Unknown IgG (Yung et al. 1996) 
 M60 N-terminal C4BP 
(Stenberg et al. 1992; Johnsson et al. 1996)   Unknown IgA 
  Unknown IgG3 
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1.7.1 The role of M protein in GAS adhesion 
Adhesion to the nasopharynx and skin is an important step in GAS virulence, impeding 
bacterial clearance via cilia and epithelial shedding. M protein mediated binding to epithelial 
cells has been well documented using human epithelial HEp-2 cells (Wang et al. 1994; 
Courtney et al. 1997). Courtney et al. have suggested a two-step model of GAS adherence 
whereby a low affinity primary adhesin, lipoteichoic acid, mediates a weak initial attachment, 
followed by a stronger more specific M protein or fibronectin binding protein (Sfb1) 
mediated interaction. Although fibronectin binding proteins are heavily implicated in 
adherence, clinically important GAS serotypes, M1 and M3, which are associated with 
invasive infection, do not express these surface proteins (Natanson et al. 1995).  
In GAS serotypes deficient in Sfb1 such as M1 and M3, respective M proteins have been 
found to bind fibronectin through hypervariable B repeat domains. The ability of M1 to bind 
the glycoprotein, fibronectin, facilitates adhesion and internalisation into a range of epithelial 
cells. M1-fibronectin interactions act as a molecular bridge to bind integrin α5β1 present at 
the epithelial cell surface, ultimately stimulating internalisation into the host cell. In vitro 
experiments showed that M1 protein can associate with integrin α5β1, but only if the integrin 
is complexed with fibronectin (Fig 1.3). It is theorised that M1 protein binding changes the 
structural conformation of fibronectin, in turn affecting the interaction between fibronectin 
and host cell surface integrins (Cue et al. 2001).  
Carbohydrates (glycans) have also been shown to play a vital role in cell recognition events, 
especially those involved in bacterial adherence to host cells (Crocker et al. 2007). 
Mammalian cells are distinguished by a dense diversity of cell surface glycans. Specific 
surface glycosylation patterns are indicative features of certain cell types such as pharyngal, 
kidney, and ABO blood group antigens (Arndt et al. 2011). The vast structural diversity 
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coalesced with accessibility at the cell surface makes glycan structures an effective medium 
for bacterial-host interactions. Protein-glycan interactions have been identified as adherence 
factors for a variety of commensal and pathogenic bacteria, including Pseudomonas 
aeruginosa, Helicobacter pylori, and Escherichia coli (Blixt et al. 2004; Walz et al. 2005; 
Wu et al. 2006).  
A specific sub-set of glycans, glycosaminoglycans (GAGs), have been shown to interact with 
a large cohort of M protein serotypes including clinically relevant M-types M1, M3 and M12. 
Frick et al. (2003) were able to demonstrate that dermatan sulphate, highly sulphated 
fractions of heparin sulphate, and heparin, are able to bind to  a range of M protein serotypes. 
Strains deficient in M protein surface expression failed to interact with this assembly of 
GAGs, and significantly reduced adhesion of GAS to GAG expressing human epithelial cells 
and skin fibroblasts. To date, M protein-glycan interactions and their potential role in GAS 
virulence have not been completely explored. 
1.7.2 M Protein and the host immune response 
The propensity of GAS to cause systemic disease reflects the pathogens diverse ability to 
evade phagocytic defences of the innate immune response. M protein contributes to this via 
interaction with a range of host factors such as Ig, factor H, fibrinogen and C4BP, which are 
able to both regulate and conceal GAS from host innate immunity. The role of each of these 
interactions in GAS infection will be discussed below.  
Ig’s are glycoprotein molecules which are produced by plasma cells in response to an 
immunogen, aiding in the neutralisation of foreign objects and pathogens. Although Ig 
structures vary, they typically consist of two large heavy chains and two small light chains. 
The base of the two heavy chains is termed the fragment crystallisation (Fc) region. This 
region interacts with Fc cell surface receptors along with some proteins of the complement 
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system, subsequently stimulating immune mechanisms such as opsonisation and 
degranulation of mast cells. There are five different Ig isotype variants (IgA, IgD, IgE, IgG, 
and IgM) each performing different roles in directing the appropriate immune response 
against pathogens (Munthe et al. 1972).   
GAS can be divided into two major groups based on immunoreactivity with a pair of 
monoclonal antibodies (MAbs) directed at a specific epitope within the M protein. Class I 
isolates are able to bind one or both MAbs whereas Class II are unable to bind to either. In 
class I GAS, IgG binding activity is a means to distinguish between nasopharyngeal and 
impetigo isolates whereas IgA binding activity is a specific property of class II isolates 
(Bessen et al. 1992). Both IgA and IgG bind to the hypervariable N-terminus-repeat regions 
of the M protein via variable Fc regions. Although the M protein N-terminal is hypervariable, 
it is still able to bind Ig, suggesting that the tertiary structure of the M protein remains the 
same despite sequence heterogeneity (Akesson et al. 1994). Furthermore, M1 has been found 
to bind IgG through its S-region (Akesson et al. 1994) suggesting that different M protein 
serotypes may have evolved different IgG binding domains. 
M protein-Ig binding interactions are thought to block the recognition of bacterial cells by the 
immune system, subsequently hiding them from host defences, facilitating the evasion of 
phagocytic uptake (O'Toole et al. 1992; Cunningham 2000). Although GAS Ig binding 
contributes to bacterial persistence in the host, studies have shown that antibodies raised 
against Ig binding M proteins are effective against the anti-phagocytic properties of the 
bacteria (Bessen et al. 1988). α-M6-IgA bound to an M6 GAS strain was shown to 
significantly decrease the adherence of this strain to pharyngeal cells where as α-M6-IgG was 
able to reduce bacterial internalisation following binding to the M6 protein (Fluckiger et al. 
1998). The orientation in which Ig, specifically IgG, interacts with M protein has been shown 
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to be critical in evading phagocytosis. M1 binding the fragment crystallisable (Fc) region of 
IgG has been shown to allow the bacterium to persist in the host, blocking interaction with 
phagocytic cells. Alternatively, M1 interaction with the fragment antigen-binding (Fab) domain 
of IgG, a common interaction in blood, significantly increases the susceptibility of GAS to 
phagocytic uptake by neutrophils (Nordenfelt et al. 2012).  
The capacity of certain M proteins to bind fibrinogen and factor H is thought to be an 
important mode of action in resisting phagocytosis. Factor H is a regulatory component of the 
alternative complement pathway. Factor H bound to the GAS cell wall inhibits activation of 
the alternative complement pathway by restricting the deposition of C3b on the cell surface 
(Cunningham 2000). Abrogation of factor H binding by M protein following deletion of the 
C1 and C2 domains suggest that factor H binds to the C repeat region of the M protein 
(Perez-Casal et al. 1995). Although factor H binding plays an important antiphagocytic role, 
it alone cannot prevent phagocytosis. Jack-Weis et al. (1982) quantified the amount of C3b 
deposition on the cell surface of M+ and M- GAS strains and found that even though M- 
strains exhibited greater levels of C3b deposition on the cell surface, the amount of C3b 
deposited on M+ strains was still sufficient for phagocytosis. In conjunction with factor H, 
the binding of fibrinogen has also been shown to assist in restricting phagocytosis (Fig 1.3). 
Fibrinogen, a well characterised plasma glycoprotein, is composed of three pairs of disulfide-
bonded polypeptides with a combined molecular mass of 340 kDa. This soluble plasma 
protein contains a series of functional domains which interact with a variety of substrates 
such as hyaluronic acid, thrombin, and fibronectin. Several GAS proteins have also been 
found to bind fibrinogen, including M proteins and M related proteins (Ringdahl et al. 2000). 
Similar to factor H, it is suggested that fibrinogen is able to block the interaction of GAS with 
polymorphonuclear leukocytes via disrupting the alternative complement pathway (Whitnack 
et al. 1984). Although not completely understood it is thought that fibrinogen can interfere 
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with the opsonisation process in several ways. The first system proposes that fibrinogen is 
able to mask the conserved cell wall components of GAS which are either targets for 
antibodies or regions capable of fixing microbial opsonin, C3b. An alternative explanation 
may be that fibrinogen along with C3b competitively binds receptors such as CD11b/CD18 
which are major receptors for activated C3 thus preventing output signals required for 
phagocytosis (Ringdahl et al. 2000). Studies analysing M5 and M6 serotypes show that 
fibrinogen binds to both the type-specific and cross-reactive regions of the M protein. To 
explain the common anti-phagocytic property of M proteins, it was suggested that the 
fibrinogen binding site may be conserved among different serotypes (Cunningham 2000).  
A key regulator of the classical complement pathway is C4BP. C4BP which is selectively 
acquired by M protein at the cell surface interferes with membrane-bound C3 convertase 
(Gigi et al. 1979). Interactions between M protein and C4BP are thought to occur at the 
hypervariable region of M protein. Berggard et al. (2001) investigated the capacity of M22 to 
bind C4BP, and contribute to phagocytosis resistance. Through deletion of the hypervariable 
region, the ability of M22 to bind C4BP was lost, and phagocytosis resistance was 
significantly reduced. Furthermore, M protein-C4BP interactions were shown to completely 
block the effect of opsonising hypervariable-targeted antibodies. The lack of sequence 
consensus among hypervariable M protein-C4BP binding motifs infers that interactions are 
dependent on protein structure rather than amino acid sequence identity.  
The host zymogen, plasminogen, has also been shown to mediate interactions which facilitate 
the evasion of the innate immune response. Plasminogen is a single chain glycoprotein 
zymogen of the broad spectrum serine protease plasmin. Glycosylation of plasminogen gives 
rise to two major species of the zymogen; glycoform I plasminogen (GI-plasminogen) and 
glycoform II plasminogen (GII-plasminogen). GI-plasminogen possesses carbohydrate chains 
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N-linked to Asn289 and O-linked to Thr346, while GII-plasminogen contains a sole O-linked 
carbohydrate at Thr346. GI-plasminogen and GII-plasminogen exist in humans at an 
approximate ratio of 2:3, respectively (Law et al. 2012). Plasminogen is found within plasma 
and extracellular fluids at concentrations of ~2 μM (Ponting et al. 1992; Andreasen et al. 
1997). Cleavage of the peptide bond between Arg560 and Val561 of plasminogen by 
plasminogen activators results in the formation of active plasmin, a key regulator of GAS 
invasion (see below: section 1.7.3). Prior studies have demonstrated that plasmin at the GAS 
cell surface results in the degradation of C3b. Furthermore, plasminogen acquisition at the 
bacterial surface was shown to prevent C3b opsonisation and phagocytic uptake of GAS by 
neutrophils (Ly et al. 2014). 
1.7.3 The role of M protein in invasion and the inflammatory response 
To instigate invasive disease, GAS must invade and penetrate host tissues, facilitating the 
dissemination of GAS away from the initial site of infection. The ability of M protein to 
interact with multiple host proteins involved in fibrinolysis and inflammation, such as 
plasmin(ogen) and fibrinogen, is central to invasive disease initiation. Plasmin plays a key 
role in the fibrinolytic system as it is able to degrade fibrin clots, fibronectin, laminin and 
proteoglycans. Plasminogen activation is mediated by the plasminogen activators tissue type 
plasminogen activator (tPA) and urokinase plasminogen activator (uPA) which cleave the 92-
kDa protein into a two-chain active plasmin molecule (Ponting et al. 1992). Plasminogen has 
five kringle domains with lysine binding sites located in kringles 1, 2, 4 and 5 which are 
responsible for the binding of plasminogen to plasminogen receptors (Ponting et al. 1992). 
The acquisition of plasminogen by GAS can be achieved via two main pathways: direct and 
indirect binding (Fig 1.3). Over the last 12 years studies have shown that the direct binding of 
plasminogen is mediated by three known receptors; plasminogen binding M proteins (PAM 
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and Prp), surface enolase (SEN), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
(Ringdahl et al. 2000). Plasminogen binding by M proteins is mediated by two characteristic 
tandem repeats within the M protein. These 13-amino-acid repeats are designated A1/A2 and 
have been found to interact with plasminogens kringle 2 domain (Ringdahl et al. 2000; 
Cnudde et al. 2006). Plasminogen binding by PAM is mediated by lysine, arginine, and 
histidine residues within this repeat domain (Sanderson-Smith et al. 2006). Similar 
plasminogen binding motifs have also been identified in other M proteins such as the PAM-
related protein (Prp) found in GAS strain NS88.2 (McKay et al. 2004). Once bound on the 
GAS cell surface, plasminogen can be activated by the host activators uPA and tPA, and the 
secreted GAS plasminogen activator, streptokinase (Sanderson-Smith et al. 2012). 
The indirect pathway of plasminogen binding utilises a tri-molecular complex consisting of 
the polymorphic bacterial plasminogen activator streptokinase, plasminogen and fibrinogen 
(Cook et al. 2012). Although streptokinase is secreted by GAS, streptokinase itself has no 
protease activity, but instead forms a 1:1 complex with plasminogen (Wang et al. 1995). The 
complex is then able to adhere to fibrinogen molecules which have bound to fibrinogen 
binding receptors on the GAS cell surface. Indirect binding is dependent on the streptokinase-
plasminogen activator complex. Once bound to the cell surface, plasminogen can then be 
converted to the protease plasmin via streptokinase (Walker et al. 2005).  
Inflammation and systemic reactions that accompany ECM degradation are a hallmark of 
severe and invasive infection, and are frequently associated with M protein-fibrinogen 
interactions. Fibrinogen binding by M proteins were first described over 50 years ago when 
Kantor (1965) found that fibrinogen could be co-precipitated with M protein by acid 
precipitation. Further studies analysing the capacity of M1 and M5 to bind fibrinogen 
identified that binding was dependant on the B1 and B2 repeats within the M1 and M5 
protein even though they were shown to not share homologous B1 and B2 sequences 
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(Ringdahl et al. 2000). These findings suggest that GAS may have evolved different 
fibrinogen-binding sequences within their M proteins, while retaining the same function. 
M protein-interaction with fibrinogen is associated with inflammatory responses due to the 
activation of neutrophils. Upon release from the bacterial cell, M proteins are able to form 
complexes with fibrinogen, binding to β2 integrins of polymorphonuclear neutrophils 
(PMN’s) subsequently activating them. As a result, PMN’s release heparin binding protein 
(HBP), a mediator of pulmonary vascular leakage (Herwald et al. 2004). This in turn helps to 
explain symptoms associated with GAS infections such as STSS and necrotizing fasciitis, 
whereby high levels of M protein-fibrinogen complexes are commonly detected within 
biopsy samples. M proteins also play a dual role as a potent activator of monocytes, inducing 
the release of pro-inflammatory cytokines such as IL-1β, IL-6, and TNFα through 
interactions with TLR2 receptors (Påhlman et al. 2006). Patients with severe GAS soft tissue 
infections can experience high concentrations of cytokines (>10 μg/ml) which is enhanced in 
the presence of HBP (Holub et al. 2004). Thus, binding of M protein to fibrinogen initiates a 
twofold reaction in the inflammatory response (Fig 1.3).   
1.8 M protein as a vaccine candidate 
M protein is the major GAS cell wall protein, and is expressed by a significant portion of 
GAS strains. Therefore, a major focus of research in the GAS field is on M protein derived 
prophylactic vaccines. Whole cell vaccines have been deemed impractical as T cells and 
antibodies targeting GAS cross-react with human tissue leading to autoimmune diseases such 
as rheumatic fever, rheumatic heart disease, and glomerulonephritis (Carapetis et al. 2005; 
Smeesters et al. 2010).  
GAS vaccines centred on the hypervariable N-terminal portion of M protein are currently a 
major focus in GAS vaccine development. A 26-valent GAS vaccine encompassing the 
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hypervariable domains of 26 distinct M-types circulating North America has recently passed 
phase I and II trials (Hu et al. 2002; McNeil et al. 2005). The geographic distribution and 
subsequent isolation of these M-types has proven a major limitation in providing cross-
protection against a wider range of clinically relevant M-types. Through further 
epidemiological surveillance of North America and Europe, this GAS vaccine candidate was 
redefined into a 30-valent vaccine which more adequately represented GAS serotypes 
associated with pharyngitis and invasive disease (Dale et al. 2011). Besides evoking an 
immunogenic against all 30 vaccine GAS serotypes, the 30-valent vaccine antisera was also 
shown to contain bactericidal antibodies against 24 of 40 non-vaccine GAS serotypes. One of 
the major implications of this 30-valent GAS vaccine is the selective pressure is places on 
non-detectable GAS serotypes to emerge, especially in regions of high emm-type diversity.  
In industrialised countries M-types 1, 3, 12 and 28 account for approximately 40% of all 
GAS infections (Steer et al. 2009). In non-developed regions such as the NT of Australia, the 
epidemiology of GAS infection is less defined, whereby emm types are constantly expanding 
and subsiding, dependant on host immune selective pressures (Walker et al. 2014). A GAS 
vaccine based on the hypervariable region of the M protein is well suited for producing 
protection against specific homologous serotypes in particular industrialised geographic 
locations, but not for the development of a successful global vaccine encompassing all 
serotypes. Thus, vaccine strategies targeting the C-terminal domain have tried to overcome 
these limitations. Recent research has utilised a 29mer-peptide (named J-14) GAS vaccine 
candidate containing 14 amino acids from the conserved M protein C region enclosed in non-
streptococcal peptide sequences designed to retain the native alpha-helix conformation 
(Hayman et al. 2002).  
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Figure 1.3: Role of M protein in GAS virulence. M protein interactions localised at the cell surface are involved in four main processes; 1) Fibrin clot and 
ECM degradation; 2) Adherence to host cells via direct and non-direct interactions with host cell surface receptors; 3) Inflammatory response through 
neutrophil and monocyte activation; 4) Immune evasion via hindering and degrading complement deposition. C4BP: C4 binding protein; ECM: Extra cellular 
matrix; HBP: Heparin binding protein; IgG: Immunoglobulin G; IL-1β: Interleukin-1β; IL-6: Interleukin-6; PMN: Polymorphic neutrophil; SK: 
Streptokinase; TLR2: Toll-like receptor-2; TMN: Tumour necrosis factorα; uPA: urokinase plasminogen activator; tPA: tissue-type plasminogen activator. 
Adapted from Sanderson-Smith et al. (2012).   
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When conjugated to the cholera toxin, the chimeric peptide induces murine antibody 
responses that kill GAS and protect mice from intraperitoneal and intranasal challenge (Dunn 
et al. 2002). The J-14 epitope, is derived from the C3 repeat domain of M protein. In highly 
mucoid strains, it is not known whether the C3 repeat domain is able to project far enough 
beyond the capsule for recognition by antibodies. This is further supported by recent studies 
which have identified that antibodies raised against the J-14 peptide alone, lack cross-
reactivity with M protein antigens across a wide range of GAS serotypes (Penfound et al. 
2010). To overcome these restrictions, variant J-14-like sequences have been found in 
multiple M-types, expressed within C1 and C2 repeats domains. A hybrid construct has 
therefore been developed utilising five common J-14 variant sequences found in 77 different 
M-types, termed SV1 (Bauer et al. 2012).  
It is well established that different M-types have been shown to exhibit a diverse range of 
antigenic and functional properties (Stenberg et al. 1992; Johnsson et al. 1996; Sanderson-
Smith et al. 2006). The ability of human plasma proteins to block opsonisation is a critical 
factor which should be carefully considered in the development of an M protein directed 
GAS vaccine. Prior research analysing the domains of M5 revealed that binding of M5 B-
repeat and C-repeat specific antisera was abrogated by human fibrinogen and human serum 
albumin respectively (Akesson et al. 1994; Retnoningrum et al. 1994; Sandin et al. 2006). It 
is also important to note, that different host proteins may be present at different stages of 
GAS infection. To date, prior work has focused on plasma proteins which may be present in 
inflamed mucosal and skin infection sites, but it remains to be seen whether host proteins 
present during early stage GAS infection may interfere with host opsoninic processes 
(Retnoningrum et al. 1994; McArthur et al. 2006; Sandin et al. 2006). Although there is a 
great deal of focus on SV1 in relation to its viability in producing an effective immunogenic 
response, it is unknown whether SV1 can compete out M protein-host interactions required 
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for GAS virulence. Furthermore, the propensity of SV1 to bind M protein in the presence of 
other host factors is unknown, which consequently could provide a potential limitation to the 
candidature of this novel vaccine.  
1.9 Aims and Objectives 
The vast array of M protein interactions with host proteins has been shown to play a 
significant role in causing invasive GAS infection. The resurgence of GAS infections over 
the last two decades has demonstrated that current prevention and treatment techniques are 
inadequate. Although a large amount of research has been undertaken to understand the 
interactions between M protein and plasma/ECM proteins, M protein-glycan interactions 
remain under investigated. In general, M protein studies have focused on the small number of 
M serotypes responsible for infections in Western countries. The NT of Australia has one of 
the highest rates of GAS infection in the world and these rates of infection can be attributed 
to a diverse range of M serotypes. Although epidemiological studies have found positive 
correlations between host-M protein interactions and invasive disease, the large diversity of 
M types from this region and their interactions with host proteins remain largely unexplored. 
Furthermore, no prior study has made comparisons between related M proteins of different 
M-type and their ability to interact with common host factors, thus identifying if specific M-
types are indicative of function and ultimately a specific state of disease. Given that M 
protein is the major focus of current prophylactic vaccine development for GAS infection, 
there is a need to better understand the role of diverse M proteins in virulence. As such, the 
aims of this study were to investigate sequence and binding properties of the M proteins from 
26 clinical GAS isolates originating from the NT and other low-income setting regions which 
are associated with invasive infection. Specifically, the aims of this project are: 
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I. Conduct sequence analysis of 26 M proteins in order to phylogenetically classify each 
M protein and identify potential novel binding motifs. 
II. Functionally characterise the biochemical interactions between the 26 M proteins and 
key host proteins 
III. Examine the interaction of M protein and host proteins in the presence of SV1 
IV. Examine how the different glycosylation profiles of human plasminogen affect the 
acquisition and activation by select GAS receptors. 
V. Conduct preliminary analysis to appraise the role of M proteins in GAS-glycan 
binding. 
The accumulation of sequence and binding data pertaining to these virulent strains may 
provide insight into the mechanisms that facilitate disease within the host, in turn, allowing 
potential therapies to be developed which can be used to treat GAS infection and reduce 
mortality on a global scale.  
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2. General Materials and Methods 
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2.1 General Materials 
Details of general buffer compositions are listed in Appendix A. 
2.2 Bacterial strains and culture methods 
2.2.1 Escherichia coli 
Escherichia coli (E.coli) containing plasmid DNA for DNA sequence analysis or protein 
expression were grown on Luria-Bertani (LB)-agar plates containing either 100 µg/mL 
ampicillin (Ap100) or 50 µg/mL kanamycin (Km50). LB-Agar plates were incubated at 37°C 
for 16 h. Liquid E. coli cultures were grown using a single colony of each strain in LB media 
containing either Ap100 or Km50 at 37°C overnight with shaking at 200 rpm. E.coli strains 
and plasmids used in this study are outlined in table 2.1. 
2.2.2 Streptococcus pyogenes 
GAS strains used in this study were grown on horse blood agar (HBA) plates (Oxoid, UK) or 
Todd-Hewitt agar supplemented with 1% (w/v) yeast (THYA) (Difco, Australia). Static GAS 
cultures were grown overnight in Todd-Hewitt broth supplemented with 1 % (w/v) yeast 
(THY) at 37°C. GAS containing pDCerm were cultured in THY containing 2 µg/mL 
erythromycin. GAS strains and plasmids used in this study are outlined in table 2.1.  
2.3 DNA manipulations 
2.3.1 Plasmid extraction from E.coli. 
Plasmid DNA was extracted and purified using the Wizard
®
 Plus SV Minipreps DNA 
purification systems kit (Promega, USA). Bacterial cells were grown overnight in a total 
volume of 10 mL as stated above. Cells were harvested via centrifugation (5000 × g, 5 min) 
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and resuspended in 250 µl cell resuspension solution. Following resuspension, 250 µl of cell 
lysis solution was added to bacterial samples and mixed by inversion four times. Once cell 
lysis was achieved, 10 µl of alkaline protease solution was added to the cell lysate and mixed 
by inverting the microfuge tube 4 times. Following a 5 min incubation at room temperature, 
350 µl of neutralisation solution was added to each sample and mixed by inversion. Bacterial 
lysates were then centrifuged (16 000 × g, 10 min) and supernatants transferred to a Wizard 
spin column. Spin columns were then washed with 750 µl Column wash solution via 
centrifugation (16 000 × g, 1 min). This was then repeated using 250 µl Column wash 
solution. Spin columns were then transferred to a sterile 1.5 mL Eppendorf microfuge tube 
and DNA was eluted in 60 µl dH2O via centrifugation (16 000 × g, 1 min).  
2.3.2 Chromosomal extraction from S. pyogenes 
Chromosomal DNA from all GAS strains was prepared using the DNeasy Tissue Extraction 
Kit (Qiagen, Germany). GAS cells were pelleted from stationary phase cultures by 
centrifugation (5000 × g, 10 min), resuspended in 180 μl of enzymatic lysis buffer and 
incubated for 30 min at 37°C. Proteinase k (25 μl) and buffer AL (200 μl)  were added and 
the cell suspension incubated at 70°C for 30 min before adding 200 μl of 100% ethanol and 
mixing thoroughly by vortexing. Mixtures were then transferred to a DNeasy mini column 
within a 2 ml collection tube and centrifuged (14000 × g, 1 min), with the flowthrough 
discarded. 500 μl of AW1 was then added to the DNeasy mini column and centrifuged 
(16000 × g for 1 min), with flow through discarded.  500 μl of AW2 was then added to the 
DNeasy mini column and centrifuged (16000 × g, 3 min), with flow through discarded. The 
DNeasy mini column was then transferred into a sterile 1.5 ml microfuge tube and 100 μl of 
dH2O was added directly to the column membrane. Following 1 min incubation at room 
temperature, DNA was eluted by re-centrifugation as above. 
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Table 2.1: Bacterial strains and plasmid constructs utilised in this study. Where specified, 
symbols denote plasmid constructs generously provided by Prof. Mark Walker (University of 
Queensland, Australia)
 ǂ
 and Dr. David McMillan (University of the Sunshine Coast, 
Australia) 
# 
or
 
constructed commercially (Sigma-Aldrich, USA)
¶
. 
Bacterial strain 
or plasmid 
Characteristics References/ 
Origin 
Escherichia coli   
Top10 F-mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 
recA1 araD139 Δ(ara-leu)7697 galU galK rps L (StrR) 
endA1 nupG  
Invitrogen 
BL21(DE3) fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B 
int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 
Lab stock 
   
Streptococcus 
pyogenes 
  
NS696 M1 serotype. emm-pattern A. Isolated from 
uncomplicated infection: Throat (pharyngitis) 
(McKay et al. 2004; 
Sanderson-Smith et al. 
2007) 
5448 (M1T1) M1 serotype. emm-pattern A-C. Isolated from invasive 
infection: Necrotizing fasciitis and toxic shock 
(Aziz et al. 2004; 
Anderson et al. 2014) 
NS13 M53 serotype. emm-pattern D. Isolated from invasive 
infection: Blood (bacteremia)  
(McKay et al. 2004; 
Sanderson-Smith et al. 
2006; Sanderson-
Smith et al. 2007) 
NS88.2 M98 serotype. emm-pattern D. Isolated from invasive 
infection: Blood (bacteremia). 
(McKay et al. 2004; 
Sanderson-Smith et al. 
2007) 
NS226 M4 serotype. emm-pattern E. Isolated from invasive 
infection: Wound (cellulitis). 
NT of Australia 
isolate 
NS730 M90 serotype. emm-pattern E. Isolated from invasive 
infection: Pus from left hip (necrotizing fasciitis) 
(McKay et al. 2004) 
NS192 M106 serotype. emm-pattern E. Isolated from Invasive 
infection: Blood (bacteremia) 
(McKay et al. 2004) 
NS179 M9 serotype. emm-pattern E. Isolated from invasive 
infection: Pustules on foot (bacteremia)  
(McKay et al. 2004) 
NS8 M85 serotype. emm-pattern D. Invasive status and 
clinical origin unknown. 
NT of Australia 
isolate 
NS414 M11 serotype. emm-pattern D. Isolated from invasive 
infection: Wound (cellulitis). 
(McKay et al. 2004) 
NS931 M69 serotype. emm-pattern D. Isolated from invasive 
infection: Blood (necrotizing fasciitis). 
(McKay et al. 2004) 
NS1140 M57 serotype. emm-pattern E. Isolated from invasive 
infection: patient disease status unknown.   
NT of Australia 
isolate 
NS178 M54 serotype. emm-pattern E. Invasive status and clinical 
origin unknown. 
NT of Australia 
isolate 
NS501 M14 serotype. emm-pattern C. Isolated from invasive 
infection: Blood (bacteremia) 
(McKay et al. 2004) 
NS80 M70 serotype. emm-pattern E. Invasive status and clinical 
origin unknown. 
NT of Australia 
isolate 
PRS66 M102 serotype. emm-pattern E. Invasive status and 
clinical origin unknown. 
Lab stock 
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PRS18 M58 serotype. emm-pattern E. Invasive status and clinical 
origin unknown.  
Lab stock 
PRS2 M2 serotype. emm-pattern E. Invasive status and clinical 
origin unknown. 
Lab stock 
ALAB49 M53 serotype. emm-pattern D. Isolated from impetigo 
lesion. 
(Svensson et al. 2002) 
ALAB49ΔPAM ALAB49 derivative with Pam replaced  with 
erythromycin resistance gene. 
(Svensson et al. 2002) 
5448 (M1T1) (eGFP) 5448 (M1T1) derivative expressing eGFP via pDCerm Lab stock 
5448ΔM1 (M1T1) 
(eGFP) 
5448 (M1T1) derivative with emm1 replaced  with 
chloramphenicol  resistance gene. Expresses eGFP via 
pDCerm 
Lab stock 
   
Plasmids   
pGEX2T Ap
r
, ColE1 origin, P tac promoter, GST tag, laclq 
repressor. 
GE Healthcare, UK 
pET41 Km
r
 f1 pBR322 origin, T7 promoter, GST tag, his-tag, 
lacl repressor 
Novagen, Australia 
pET-28b(+) Km
r
, pBR322 origin, T7promoter, his-tag, lacl repressor Novagen, Australia 
pQE-30 Ap
r
, ColE1 origin, his-tag, T5 promoter, t0 and T1 
transcriptional terminators 
Qiagen,USA 
pDCerm Erm
r
, phoZ, gram-positive origin of replication (Jeng et al. 2003) 
pGEX2T-emm 1 pGEX2T derivative containing emm coding sequence 
from GAS strain NS696 
(Sanderson-Smith et 
al. 2007) 
pGEX2T-emm 2 pGEX2T derivative containing emm coding sequence 
from GAS strain PRS2 
This study 
pGEX2T-emm 3 pGEX2T derivative containing emm coding sequence 
from GAS strain SSI-1 
This study 
ǂ
 
pGEX2T-emm 4.2 pGEX2T derivative containing emm coding sequence 
from GAS strain NS226 
This study 
pGEX2T-emm 9 pGEX2T derivative containing emm coding sequence 
from GAS strain NS179 
This study 
pET41-emm 9.1 pET41 derivative containing emm coding sequence from 
GAS strain PRS55 
This study 
#
 
pGEX2T-emm 11 pGEX2T derivative containing emm coding sequence 
from GAS strain NS414 
This study 
pET41-emm 12 pET41 derivative containing emm coding sequence from 
GAS strain PRS8 
This study 
#
 
pGEX2T-emm 14 pGEX2T derivative containing emm coding sequence 
from GAS strain NS501 
This study 
pET41-emm 19 pET41 derivative containing emm coding sequence from 
GAS strain PRS9 
This study
 #
 
pET41-emm 19 pET41 derivative containing emm coding sequence from 
GAS strain PRS9 
This study
 #
 
pET41-emm 48 pET41 derivative containing emm coding sequence from 
GAS strain PRS15 
This study 
#
 
pGEX2T-emm 53 pGEX2T derivative containing emm coding sequence 
from GAS strain NS13 
(Sanderson-Smith et 
al. 2006) 
pGEX2T-emm 54 pGEX2T derivative containing emm coding sequence 
from GAS strain NS178 
This study 
pET41-emm 54 pET41 derivative containing emm coding sequence from 
GAS strain TVU5 
This study 
#
 
pGEX2T-emm 57 pGEX2T derivative containing emm coding sequence 
from GAS strain NS1140 
This study 
pGEX2T-emm 58 pGEX2T derivative containing emm coding sequence 
from GAS strain PRS18 
This study 
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pET41-emm 60 pET41 derivative containing emm coding sequence from 
GAS strain PRS20 
This study 
#
 
pGEX2T-emm 69 pGEX2T derivative containing emm coding sequence 
from GAS strain NS931 
This study 
pGEX2T-emm 70 pGEX2T derivative containing emm coding sequence 
from GAS strain NS80 
This study 
pET41-emm 83 pET41 derivative containing emm coding sequence from 
GAS strain PRS30 
This study 
#
 
pGEX2T-emm 85 pGEX2T derivative containing emm coding sequence 
from GAS strain NS8 
This study 
pGEX2T-emm 90 pGEX2T derivative containing emm coding sequence 
from GAS strain NS730 
This study 
pET41-emm 97 pET41 derivative containing emm coding sequence from 
GAS strain 88/30 
This study 
#
 
pGEX2T-emm 98.1 pGEX2T derivative containing emm coding sequence 
from GAS strain NS88.2 
(Sanderson-Smith et 
al. 2007) 
pGEX2T-emm 102 pGEX2T derivative containing emm coding sequence 
from GAS strain PRS66 
This study 
pGEX2T-emm 106 pGEX2T derivative containing emm coding sequence 
from GAS strain NS192 
This study 
pET-28b(+)-emm 1-
AB 
pET-28b(+) derivative containing A and B repeat emm 
coding sequence from GAS strain NS696 
This study 
pET-28b(+)-emm 1-
AC1 
pET-28b(+) derivative containing A, B and C1 repeat 
emm coding sequence from GAS strain NS696 
This study 
pET-28b(+)-emm 1-
A92C1 
pET-28b(+) derivative containing emm coding sequence 
beginning from the first 92 nucleotides of the A repeat up 
to and including the C1 repeat from GAS strain NS696 
This study 
pET-28b(+)-emm 1-B pET-28b(+) derivative containing  B repeat emm coding 
sequence from GAS strain NS696 
This study 
pET-28b(+)-emm 1-
BC1 
pET-28b(+) derivative containing B repeat   emm coding 
sequence from GAS strain NS696 
This study 
pET-28b(+)-emm 1-C pET-28b(+) derivative containing C repeat   emm coding 
sequence from GAS strain NS696 
This study 
¶
 
pQE-30-SKALAB49 pQE-30 derivative containing ska coding sequence 
from GAS strain ALAB49 
(Cook et al. 2012) 
 
2.3.4 Polymerase chain reaction conditions 
Polymerase chain reaction (PCR) amplification of all emm genes was performed using an 
Eppendorf Mastercycler thermal cycler (Eppendorf, Germany). PCR reaction mixtures 
consisted of 1 × PfuUltra
TM
 II reaction buffer (Stratagene, USA), 1 U of PfuUltra
TM
 II Fusion 
HS DNA polymerase (Stratagene, USA), 0.25 mM deoxynucleoside triphosphates (dNTPs), 
50 pmol each of  forward and reverse primer, and 200 µg of GAS chromosomal DNA, made 
up to a final volume of 50 μl with sterile dH2O. The thermocycling conditions of PCR 
consisted of 35 cycles. Each cycle consisted of a 1 min denaturation step performed at 95°C, 
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a 15 sec annealing step performed at 55°C, and a 1 min extension step performed at 72°C. A 
final extension cycle of 4 min at 72°C was also performed. PCR screening of E. coli 
transformants for cloning was conducted with reaction mixtures consisting of 2 U of Mango 
Taq polymerase(Bioline, Australia), 1 × Mango Taq reaction buffer (Bioline, Australia), 0.25 
mM of each dNTP, 50 pmol of each forward and reverse primer, and 2 mM MgCl2 made up 
to a final volume of 50 μl with sterile dH2O. A single bacterial colony was used as the DNA 
template. PCR thermocycling conditions were carried out as above. Details of primer 
sequences used for all PCR’s are provided in appendix B. 
2.3.5 Agarose gel electrophoresis 
DNA amplicons were resolved by electrophoresis on a 1% agarose gel for 1 h at 90 V in 1× 
TAE electrophoresis buffer in a Bio-Rad Minisub
™ 
(Bio-Rad, USA). DNA bands were 
visualised by ethidium bromide staining and recorded using the Bioimaging UVP E3C 
system (Biostrategy, USA). Hyperladder I molecular size marker (Fermentas, Canada) was 
used to determine the approximate size of DNA bands. 
2.3.6 DNA extraction from agarose gels and PCR’s 
DNA amplified by PCR or subjected to agarose gel electrophoresis was extracted and 
purified using the Wizard
®
 SV Gel and PCR clean-Up system (Promega, USA). Following 
electrophoresis, DNA bands of interest were excised and placed in a 1.5 mL microfuge tube. 
An equal weight/volume of membrane binding solution was added and allowed to incubate at 
50-65˚C until the excised gel slice was completely dissolved. Following PCR, equal volumes 
of membrane binding solution were added to PCR mixtures and incubated at room 
temperature for 1 min. Dissolved gel and PCR mixtures were then transferred to an SV 
Minicolumn assembly and allowed to incubate for 1 min at room temperature. Following 
incubation, samples were centrifuged (16 000 × g, 1 min) and the flow through discarded. SV 
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Minicolumns were then washed with 700 µl Membrane wash solution and the flow through 
discarded. This was then repeated with 500 µl Membrane wash solution, and centrifuged as 
above. The SV Minicolumn was then transferred to a sterile 1.5 mL microfuge tube. To elute 
the DNA, 50 µl dH2O was added to the SV Minicolumn and incubated at room temperature 
for 1 min. DNA was eluted from the SV Minicolumn via centrifugation (16 000 × g, 1 min).   
2.3.7 DNA sequence analysis 
emm amplicons were directly sequenced from products of PCR amplification. Each 
sequencing reaction consisted of 1 pmol of a single strain/plasmid specific primer (appendix 
B), 200 μg of purified PCR product or plasmid, 1 U of BigDye v 3.1 ready reaction mix 
(ABI, Australia), 1 U of sequencing buffer (ABI, Australia) made up to a final volume of 10 
μl with sterile dH2O. 25 cycles of PCR were performed with an Eppendorf Master Cycler 
(Eppendorf, Germany), consisting of a 1 min denaturation step at 96°C, a 15 sec annealing 
step at 55°C, and a 1 min extension step at 60°C. Resulting PCR products were purified using 
the Wizard
®
 PCR clean-up kit (Promega, USA) as described above. Purified PCR products 
were sequenced by Margret Philips (University of Wollongong, Australia) using a 3130xl 
Genetic Analyser (Applied Biosystems, USA) as per manufacturer’s specifications. 
2.3.8 Nucleotide and protein sequence identity analysis 
In order determine the level of sequence identity between emm genes, and between M 
proteins, nucleotide and protein sequence analysis was undertaken using MUSCLE with 
default parameters applied by Geneious version 6.0 (Biomatters, USA). Prior to sequence 
analysis, emm gene sequences and translated M protein amino acid sequences were trimmed 
from the first codon/amino acid of the mature protein to the first codon/amino acid of the D 
repeat domain adjacent the LPXTG motif. Phylogenetic analysis between mature M proteins 
were inferred under a Blossum80 matrices using a Jukes-Cantor genetic distance model and a 
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neighbour joining tree method via Geneious version 6.0 (Biomatters, USA). Strain collection 
data along with GenBank locus description of each emm gene in study are provided in 
appendix C.  
2.4 emm gene cloning 
2.4.1 Restriction enzyme digestion 
Plasmid DNA and PCR amplicons were routinely digested to facilitate cloning and confirm 
the presence of insert DNA in to designated vectors: pGEX2T and pET-28b(+). Restriction 
enzyme digestion mixtures for cloning in to pGEX2T consisted of 2 × of Tango buffer
 TM 
(Fermentas, Canada), 1 U of BamHI (Fermentas, Canada), 0.5 U of EcoRI (Fermentas, 
Canada), and 300 ng of DNA made up to a total volume of 20 μl with dH2O. Restriction 
enzyme digestion mixtures for cloning in to pET-28b(+) were made up of 2 ×  Tango buffer
 
TM 
(Fermentas, Canada), 1 U of NcoI (Fermentas, Canada), 1 U of XhoI (Fermentas, Canada), 
and 300 ng of DNA made up to a total volume of 20 μl with dH2O.  Digestions were carried 
out at 37°C for 2 h. Following digestion, mixtures were incubated at 80°C for 15 min to 
inactivate restriction enzymes. 
2.4.2 Ligation 
The amount of vector to insert used in each ligation was kept at a ratio of 3:1. DNA quantities 
were calculated using the following formula: 
Amount of insert (ng) = 3/1 × [size of insert (kb)/size of vector (kb)] × 100 ng vector 
To facilitate ligation, digested vector and insert mixtures were made to a total volume of 30 
μl with dH2O. Ligation mixtures were incubated at 60°C for 5 min, 37°C for 10 min, room 
temperature for 10 min, and left on ice for 5 min. 3 × ligase buffer (Fermentas, Canada) and 1 
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U T4 DNA ligase (Fermentas, Canada) was then added to the ligation mixture and incubated 
over night at 10°C.  
2.4.3 Preparation of electro-competent E.coli  
Single colonies of E.coli were cultured in 10 mL LB media and grown overnight at 37°C with 
shaking at 200 rpm. Overnight 10 mL cultures were inoculated into 100 mL cultures, and 
were allowed to grow at 37°C with shaking until an optical density (OD600nm) 1.0 was 
reached. Bacterial cells were harvested via centrifugation (5000 × g, 10 min) and washed 
twice in 80 mL of cold sterile dH2O. Cell resuspensions were then pelleted as above (5000 × 
g, 10 min) and washed once more in 80 mL of cold sterile 10% glycerol. After washing, cell 
pellets were resuspended in 2 mL of cold sterile 10% glycerol, remaining on ice until 
transformation.       
2.4.4 Transformation of electro-competent E. coli 
Electro-competent E.coli were transformed using a Bio-Rad Gene Pulser (Bio-Rad, USA) 
according to the manufactures instructions. Transformation mixtures consisted of 3.3 μl of 
ligation mixture, 80 μl of electro-competent E. coli (Top10 or BL21(DE3)cells) and 8 μl of 
dH2O in an ice cold cuvette. The Gene Pulser 
TM 
electroporator (Bio-Rad, USA) was set to 
2.5 kV, 25 μ FD, and 200 Ω. After electroporation, cells were then transferred to preheated 
(37°C) LB broth and incubated at 37°C for 1 h. Aliquots of 50 μl, 150 μl, and 300 μl of 
transformation mixture were plated out on LB agar plates containing Ap100 or Km50 and 
grown overnight at 37°C. Single colonies were then screened via PCR, using cloning primers 
and DNA sequence analysis of the resulting amplicons as previously described.  
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2.5 M protein expression 
2.5.1 Full length M protein expression 
The fundamental aspects of M protein purification were carried out as previously described 
(Smith et al. 1988) with minor modifications. Initial 100 mL starter cultures of LB media 
containing Ap100 were inoculated with a single colony of emm-pGEX2T E. coli 
transformants and grown overnight at 37°C with shaking (200 rpm). LB supplemented with 
Ap100 made to a total volume of 900 ml was then inoculated with 100 mL stationary phase 
E. coli and incubated at 37°C with shaking until OD600nm reached 0.6. At OD600nm 0.6, 
phenylmethylsulfonyl fluoride (PMSF) and isopropyl β-D-1-thiogalactopyranoside (IPTG) 
were added to final concentrations of 1 mM and 0.1 mM respectively. PMSF was again 
added 2 h after induction. After a total of 4 hours post induction, bacterial cells were pelleted 
by centrifugation (4000 × g, 20 min) and resuspended in 50 ml of ice cold cell lysis buffer. 
Samples were then incubated on ice for 10 min and lysed by applying the bacterial cell 
suspension 3 times to an Avestin EmulsiFlex-C5-Homogeniser (ATA Scientific, Australia) at 
120 000 kPa. The resulting lysate was then rotated end over end for 30 min at 4˚C. The lysate 
was then centrifuged (12 000 × g, 10 min) to remove cellular debris and the supernatant 
filtered using a 0.45 μm filter (Millipore, USA). Filtered lysate was then applied to a 
glutathione-agarose column (Sigma-Aldrich, USA) with a bed volume of 2 ml. The column 
was then washed with 50 ml of PBS at 4°C and 100 U of thrombin (Sigma-Aldrich, USA) 
was then run into the column and incubated overnight at 4°C. Cleaved protein was eluted 
from the column by washing the bed with 3 volumes of PBS. A 2 ml Ni-NTA column was 
then equilibrated in PBS, and each sample containing cleaved protein was re-applied to the 
column a total of 4 times.  The Ni-NTA column was then washed with 20 ml of PBS and 
recombinant protein was eluted using 4 column volumes of native elution buffer. Samples of 
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the recombinant protein purification process were analysed via 12% SDS-PAGE analysis 
(described below: section 2.5.3). 
2.5.2 Fragmented M-protein expression 
M1 protein fragments were expressed and purified as previously described (Macheboeuf et 
al. 2011). Initial 100 mL starter cultures of LB media containing Km50 were inoculated with 
a single colony of emm1AB; A92C1; AC1; B; BC1; C-pET28b(+) E. coli transformants and 
grown, cultured and lysed as described above. The filtered lysate was then incubated with 2 
mL of Ni-NTA resin equilibrated in PBS for 1 h at 4˚C with end-over-end rotation. Following 
incubation, lysate containing Ni-NTA resin was applied to a 15 mL column and washed with 
20 mL PBS. Recombinant M1-fragments were eluted using 4 column volumes of native 
elution buffer. Samples of the recombinant protein purification process were analysed via 
12% SDS-PAGE analysis (described below: section 2.5.3). 
2.5.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS- PAGE)  
SDS-PAGE analysis was routinely used to analyse/confirm protein expression and 
purification. Acrylamide gel ranging from 7-12% was poured into a MINI PROTEAN
®
2 Cell 
system (Bio-Rad, USA) and overlayed with 100% ethanol. The gel was allowed to set for 30 
min. Following rinsing with dH
2
O, gels were overlayed with 4% stacking gel, and a 0.75 mm 
wide comb was inserted to enable well formation. The gel was allowed to set for 30 min. 
Protein samples were then mixed with an equal volume of reducing cracking buffer, and 
boiled for 10 min. Samples were loaded into wells and the gel was run at 160 V for 1 h in 1 × 
SDS-PAGE running buffer. Visualisation of protein bands was conducted after staining with 
Coomassie rapid stain solution overnight with slight agitation. Protein bands were resolved 
upon addition of rapid de-stain solution. PageRuler Prestained Protein Ladder (Fermentas, 
44 
 
USA) and Broad Range Protein Marker (Bio-Rad, USA) were used as molecular weight 
markers to assess protein size and concentration. 
2.5.4 Protein quantification 
For proteins such as the M protein which typically lack aromatic amino acid residues, protein 
concentration was determined using BCA protein assay (Sigma-Aldrich, USA). A 25 μl 
sample of each protein dialysed in PBS was added, in triplicate, to a 96-well microtitre plate. 
BSA standards of known concentration (0 – 1 mg/ml) dialysed in PBS, were also added to the 
microtitre plate in triplicate. Colorimetric determination of protein concentration was initiated 
upon addition of 196 μl of reagent A, and 4 μl of reagent B to each sample. Microtitre plates 
were then incubated at 37°C for 30 min to allow the reaction to proceed. Individual samples 
were then read at 560 nm in a Spectramax 250 plate reader (Molecular Devices, USA). 
Protein concentrations were extrapolated from a BSA standard curve using Softpromax 
software (Molecular Devices, USA). Quantification of all proteins other than M protein was 
undertaken using a NanoDrop 2000c (Thermofisher, Australia). Following automated 
calibration, 2 µl of each protein sample was loaded on to the pedestal and absorbance was 
read at 280 nm. 
2.6 Western transfer analysis  
Using a Mini Trans-Blot apparatus (Bio-Rad, USA), Western transfer analysis was routinely 
conducted to confirm the presence of M protein and human plasminogen following SDS-
PAGE analysis. Cassettes were set up so that protein would travel from the negatively 
charged anode to the positively charged cathode. Once loaded in to the gel tank, and filled 
with Western transfer buffer, proteins were transferred at 100 V for 1 h at 4˚C with constant 
stirring to ensure even buffer temperature and ion distribution. Post-transfer, polyvinylidene 
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fluoride (PVDF) membranes were blocked in PBST with 10% (w/v) skim milk powder 
(Difco, Australia) overnight at 4˚C. PVDF membranes were then washed twice for 5 min in 
PBST and probed using either rabbit α-human plasminogen antibody (Calbiochem, USA) or 
rabbit polyclonal α-PAM
NS13 
antisera diluted 1:3000 and 1:30000 in PBST with 1% skim 
milk powder (Difco, Australia) respectively. Previous studies have shown that rabbit 
polyclonal α-PAM
NS13 
antisera antibody can recognise multiple M proteins, rather than PAM 
specifically, and does not detect proteins other than M proteins (Sanderson-Smith et al. 
2008). After incubation for 1.5 h with agitation at room temperature, membranes were then 
washed three times in PBST. Both M protein and human plasminogen recognising primary 
antibodies were detected using goat α-rabbit IgG horseradish peroxidase conjugate 
(Invitrogen, USA) diluted 1:3000 in PBST containing 1% skim milk powder (Difco, 
Australia) for 1 h at room temperature with agitation. Unbound secondary antibody was 
washed from the membrane with three 5min washes of PBST, followed by one 5 min wash in 
PBS. Enhanced chemiluminescence detection (Pierce, Biotechnology, Ill, USA) was used to 
visualise protein bands of interest. Exposed X-ray films were scanned using a GS-800 
calibrated densitometer (Bio-Rad, USA). 
2.7 Circular dichroism 
To identify potential secondary structure variation in all M proteins and M protein fragments, 
far UV circular dichroism (CD) spectroscopy was carried out. CD spectra were acquired 
using a Jasco J-810 Spectropolarimeter (Jasco, Canada). Analysis was undertaken at room 
temperature from 180 - 250 nm in a 0.1 cm pathlength cell containing 300 µl of protein 
solution in 10 mM sodium phosphate buffer (pH 7.4). Scanning mode was set to continuous, 
with a response time of 2 sec and a band width of 1 nm. Data pitch was set to 1, with 
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recorded data representing the average of 6 scans, corrected for buffer baseline. Molar 
residue ellipticity ([θ]) was calculated using the following formula: 
[θ] = (θ × mean residue weight) / (pathlength in millimetres × concentration in mg/mL) 
(Greenfield 2006). 
The percentage of α-helix for each protein was estimated from ellipticity at 222 nm using the 
following formula:  
% α-helix = - (θ222 nm – 4,800) / 45,400 (Phillips et al. 1981). 
2.8 Functional characterisation of recombinant M protein 
Functional analysis of clustered M proteins was undertaken to assess binding to key host 
proteins which have been previously shown to interact with multiple distinctive M proteins. 
Binding interactions were analysed using surface plasmon resonance on a BIAcore T200 (GE 
Healthcare, Sweden). 
2.8.1 Surface plasmon resonance – Plasminogen  
Purified histidine-tagged M protein was analysed for binding affinity to human glu-
plasminogen (Haemotologic Technologies Inc., USA) via single cycle kinetics, using a 
Biacore T200 (GE Healthcare, Sweden) at 20°C. α-histidine monoclonal antibody (Abcam, 
Australia) was immobilised to a series S CM5 sensor chip (Biacore AB) using an amine 
coupling kit as per the manufactures instructions (Biacore AB). Briefly, the chip was 
activated with a 1:1 mixture of 0.2 M N-ethyl-N’-(3-dimethylaminopropyl) carbodiimide and 
0.05 M N-hydroxysuccimide. To capture M protein at the surface, α-histidine monoclonal 
antibody was coated onto the chip at 100 µg/ml in 10 mM sodium acetate (pH 4) to a level of 
10000 response units (RU). Unoccupied binding sites were blocked using 1 M ethanolamine 
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(pH 8.5). Histidine-tagged M protein was captured at the surface of flow cells 2, 3 and 4 until 
a total of 80-100 RU was reached. Flow cell 1 was left blank to serve as a control. Analytes 
were diluted into running buffer (PBS, 0.05% Tween-20, pH 7.4), and kinetic assays were 
performed using human glu-plasminogen at varying concentrations (0-120 nM), over a series 
of five 60 s injections at a flow rate of 30 µl/min with a 900 s dissociation period. 
Regeneration of the surface was achieved with 10 mM glycine-HCl (pH 1.5) for 30 s at 30 
µl/min. M protein-glu-plasminogen interactions were analysed by non-linear fitting of the 
single cycle kinetic sensograms according to a 1:1 Langmuir binding model using Biacore 
T200 evaluation software (Biacore AB). 
2.8.2 Surface plasmon resonance – Fibrinogen, IgG, IgA, albumin and C4BP 
Purified histidine-tagged M protein was analysed for binding affinity to human fibrinogen 
(Sigma-Aldrich, Australia) IgG (Life Technologies, Australia), IgA (Abcam, Australia), 
albumin (Sigma-Aldrich, Australia) and C4BP (Athens Research and Technology, USA) via 
single cycle kinetics, on a series S Ni-NTA chip (BIAcore AB), using a Biacore T200 at 20 
°C. All four flow cells were activated with 0.5 mM NiCl2 for 60 s at 5 µl/min and washed 
with 3 mM EDTA for 60 s at 5 µl/min. M protein was captured at the surface of flow cells 2, 
3 and 4 until 100-200 RU was reached. Flow cell 1 remained as a blank control. Analytes 
were diluted into running buffer (PBS, 0.05% Tween-20, 50 µM EDTA, pH 7.4), and kinetic 
assays were performed using analyte at varying concentrations (0-200 nM) over a series of 
five 60 s injections at a flow rate of 30 µl/min with a 900 s dissociation period. Regeneration 
of the flow cell surface was achieved with two separate injections consisting of 50 mM 
NaOH and 350 mM EDTA (pH 8.3) for 50 s at 30 µL/min. M protein-host interactions were 
analysed as described above.  
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2.9 α-SV1-M protein binding interactions 
The ability of rabbit-α-SV1 IgG (α-SV1 IgG) to bind phylogenetically distinct M proteins in 
the absence and presence of host protein was analysed using surface plasmon resonance on a 
BIAcore T200 (GE Healthcare, Sweden). α-SV1 IgG was produced and graciously provided 
by Dr. David McMillan (University of the Sunshine Coast, Australia). 
2.9.1 Competitive binding analysis 
Binding affinity interactions between individual M proteins and α-SV1 IgG was carried out 
as stated above. Competitive binding analysis between M protein and α-SV1 IgG was 
assessed using host proteins plasminogen, fibrinogen, albumin, IgG and IgA. Respective host 
proteins were selected to enable coverage of all potential binding motifs across each repeat 
domain within selected M proteins. Analysis was carried out via single cycle kinetics, on a 
series S Ni-NTA chip (BIAcore AB), using a Biacore T200 at 20 °C. All four flow cells were 
activated with 0.5 mM NiCl2 for 60 s at 5 µl/min and washed with 3 mM EDTA for 60 s at 5 
µl/min. M protein was captured at the surface of flow cells 2, 3 and 4 until 100-200 RU was 
reached. Flow cell 1 remained as a blank control. For competitive binding analysis, either 
host proteins or α-SV1 IgG was captured on flow cells 2, 3 and 4 until saturation of M protein 
occurred. Host proteins and α-SV1 were diluted into running buffer (PBS, 0.05% Tween-20, 
50 µM EDTA, pH 7.4), and competitive kinetic assays were performed using analytes at 
varying concentrations (0-1000 nM) over a series of five 60 s injections at a flow rate of 30 
µl/min with a 900 s dissociation period. Regeneration of the flow cell surface was achieved 
as previously described. Affinity interactions were analysed as described above.  
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2.10 Plasminogen glycoform interactions with PAM expressing GAS 
Examination of how the varying glycosylation profiles of human plasminogen affect 
acquisition and activation by respective GAS plasminogen receptors, PAM and type-2b SK 
was analysed using host proteins, GI-plasminogen, GII-plasminogen and GII-angiostatin 
which were kindly provided by Prof. James Whisstock and Dr. Ruby Law (Monash 
University, Australia). 
2.10.1 Surface plasmon resonance - PAM binding analysis   
Recombinant histidine-tagged PAM was analysed for binding affinity to purified human GI-
plasminogen, GII-plasminogen and GII-angiostatin via single cycle kinetics, on a series S Ni-
NTA chip (GE Healthcare, Sweden), using a Biacore T200 (GE Healthcare, Sweden) at 20˚C 
as previously described. For competitive binding analysis, GI-plasminogen or GII-
plasminogen was captured on flow cells 2, 3 and 4 until saturation of immobilised PAM 
occurred. Analytes were diluted in running buffer (PBS, 0.05% Tween-20, 50 µM EDTA, pH 
7.4) or in running buffer containing varying concentrations (0-100 mM) of the lysine 
analogue εACA and/or benzamidine (Sigma-Aldrich, Australia). Kinetic assays were 
performed using varying concentrations of analyte (GI-plasminogen and GII-plasminogen, 0-
200 nM; GII-angiostatin, 0-100 nM) over a series of five 120 s injections at a flow rate of 30 
µL/min with a 600 s dissociation period. Regeneration of the flow cell surface was achieved 
as previously described. Affinity interactions were analysed as described above. Differences 
in binding affinity were determined by a one-way analysis of variance with Tukey’s multiple 
comparison test. 
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2.10.2 Detecting conformational change in plasminogen glycoforms I and II 
Plasminogen glycoforms were diluted to 1.5 µM in HEPES buffer (10 mM HEPES, 150 mM 
NaCl, pH 7.4). Methods were appended from Biggar et al (2012). Briefly, 5 µL of each 
plasminogen glycoform at a concentration of 1.5 µM was added to a thin walled 96-well 
unskirted polymerase chain reaction (PCR) microplate containing 2.5 µL of 40 × SYPRO
®
 
orange (Invitrogen, Carlsbad, CA, USA) and 12.5 µL of HEPES buffer with varying 
concentrations (0-100 mM) of εACA. Plates were read on a LightCycler® 480 II Real Time 
PCR system (Hoffman-La Roche, Basel, Switzerland) with excitation and emission set at 425 
nm and 625 nm respectively. Fluorescent measurements were expressed as change in the 
initial fluorescence (Fabs-Fo)/Fo=ΔF/Fo. As εACA was found to induce an immediate 
conformational change in plasminogen, intervals represent the end points of conformational 
change in relation to εACA concentration. 
2.10.3 Cell surface plasminogen glycoform acquisition 
To establish whether GAS preferentially captures GI-plasminogen or GII-plasminogen at the 
bacterial cell surface, PAM expressing GAS isolate NS13 was harvested at mid-log phase 
(OD600nm 0.5), washed in PBS and incubated in citrated normal human plasma  as a source of 
plasminogen for 1 h at 37 ˚C. Following two washes in PBS, bound plasminogen was eluted 
from the GAS cell surface using 100 mM glycine-HCl (pH 2.0) for 15 min at 25˚C. Eluted 
plasminogen was then probed using rabbit α-human plasminogen antibody (Calbiochem, 
USA), followed by goat α-rabbit IgG horseradish peroxidase conjugate (Invitrogen, USA). 
Enhanced chemiluminescence detection (Pierce, Biotechnology, USA) was used to visualise 
plasminogen protein bands. Purified GI-plasminogen and GII-plasminogen samples were 
used as positive controls to enable identification of bound plasminogen glycoforms from 
plasma by GAS based on electrophoretic mobility.  
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2.10.4 Cell surface plasminogen activation time-course 
To assess the ability of GAS to accumulate plasmin at the bacterial cell surface in the 
presence of each glycoform variant, a time-course assay was performed. GAS strains NS13 
and ALAB49 were harvested at mid-log phase (OD600nm 0.5) and pre-incubated with 100 nM 
of either GI-plasminogen or GII-plasminogen at 37°C for either 5 min or 10 min. Following 
two washes in PBS, bacterial cells were resuspended in PBS containing 500 µM of 
chromogenic substrate S-2251 and incubated overnight. GAS cell surface plasmin activity 
was measured at A405 using a SpectraMax Plus 384 spectrophotometer (Molecular Devices, 
Sunnyvale, CA, USA). Differences in plasmin acquisition were determined by a one-way 
analysis of variance with Tukey’s multiple comparison test. 
2.10.5 Non-proteolytic active site generation in plasminogen 
Non-proteolytic active site generation in GI-plasminogen and GII-plasminogen by type-2b 
SK was examined using the fluorescent active site titrant 4-methylumbelliferyl p-
guanidinobenzoate (MUGB) (Marker Gene Technologies Inc., USA) in a POLARstar Omega 
fluorescence spectrophotometer (BMG LABTECH, Germany). plasminogen glycoforms (200 
nM) were added to a black 96-well microtitre plate containing 1 μM MUGB in assay buffer 
(50 mM Tris-HCl, 100 mM NaCl, pH 7.4) and pre-incubated with PAM (200 nM) for 10 
mins at 37°C. To initiate the reaction, SK was added to a final concentration of 400 nM in a 
total volume of 100 μL and the development of fluorescence was monitored continuously 
with excitation at 355 nm and emission at 460 nm. Data was normalised by subtracting a 
control reaction of both plasminogen glycoforms without the addition of SK and 1 μM 
MUGB. Fluorescence measurements were expressed as the fractional change in the initial 
fluorescence (Fabs-Fo)/Fo=ΔF/Fo. Values for rates of active site generation were calculated 
using the initial linear portion of the reactions as (ΔF/Fo
-1
).min
-1
. Initial rates of non-
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proteolytic activation of GI-plasminogen and GII-plasminogen were compared using a two-
tailed unpaired students t-test. Data sets were considered statistically significant at p < 0.05. 
All analysis including data transformation and linear regression was performed using 
GraphPad Prism version 5 (GraphPad Software, La Jolla, CA, USA).  
2.10.6 GI-plasminogen and GII-plasminogen activation by type-2b SK variant 
plasminogen complexes 
The ability of type-2b SK variant plasminogen complexes to activate substrate plasminogen 
was studied by the addition of type 2b-SK (final concentration 5 nM) to assay buffer (10 mM 
HEPES, 150 mM NaCl, 0.01% Tween-20, pH 7.4) containing an excess of GI-plasminogen 
or GII-plasminogen (500 nM) and chromogenic substrate S-2251 (500 μM) in a total volume 
of 100 μL. As type-2b SK does not possess the ability to activate plasminogen without the 
presence of PAM (Cook et al. 2013), recombinant PAM was also added to each experiment 
at 500 nM. The parabolic generation of plasmin was monitored by change in absorbance at 
A405 nm and measured over 30 min at 37°C as described above. For quantitative comparison 
of plasminogen variant effect, change in A405 nm, which is a function of S-2251 substrate 
cleavage by plasmin generated during the activation of plasminogen by SK, was plotted 
against t
2
. The velocities of these reactions were then calculated from the gradient of A405 
nm vs t
2
. Initial rates of proteolytic activation of GI-plasminogen and GII-plasminogen were 
compared using a two-tailed unpaired students t-test. Data sets were considered statistically 
significant at p < 0.05. All analysis including data transformation and linear regression was 
performed using GraphPad Prism version 5 (GraphPad Software, La Jolla, CA, USA).  
53 
 
2.10.7 GI-plasminogen and GII-plasminogen activation at the GAS cell surface 
Differences in GAS cell surface activation of GI-plasminogen and GII-plasminogen was 
carried out using type-2b expressing GAS strains ALAB49 and isogenic mutant 
ALAB49ΔPAM (Cook et al. 2013). GAS strains were cultured to mid-log phase (OD600nm = 
0.5) and collected by centrifugation (5000 × g, 10 min) and washed twice in sterile PBS. 
Following washing, 1 × 10
8
 CFU of each GAS strain was resuspended in assay buffer (10 
mM HEPES, 150 mM NaCl, 0.01 % Tween-20, pH 7.4) containing either GI-plasminogen or 
GII-plasminogen (500 nM). Protein mixtures were incubated for 10 min at 37˚C in a 96-well 
plate to allow binding of each plasminogen glycoform to the GAS cell surface. To initiate 
activation, SKALAB49 and S-2251 were added to the wells at 5 nM and 500 µM respectively, in 
a final volume of 100 µl. The exponential generation of plasmin, monitored by change in 
absorbance at 405 nm was measured over 60 min at 37˚C using a SpectraMax Plus 384 
spectrophotometer (Molecular Devices, USA). Initial rates of proteolytic activation of GI-
plasminogen and GII-plasminogen at the cell surface were compared using a two-tailed 
unpaired students t-test. Data sets were considered statistically significant at p < 0.05. All 
analysis including data transformation and linear regression was performed using GraphPad 
Prism version 5 (GraphPad Software, La Jolla, CA, USA).  
2.10.8 Ethics statement 
Collection of blood was performed with the approval of the University of Wollongong 
Human Ethics Committee (HE08/250). Volunteers provided informed consent before 
donating blood samples. 
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2.11.0 Glycan interactions with S. pyogenes 
2.11.1 Glycan microarray analysis – M protein 
Glycan microarray analysis was undertaken at the Institute for Glycomics, Griffith 
University, Australia. Pre-printed glycan microarray slides were produced and generously 
donated by Dr. Lauren Hartley-Tassell and Prof. Michael Jennings (Institute for Glycomics, 
Griffith University, Australia). Glycan microarray techniques employed to identify novel M 
protein-glycan interactions were adapted from Day et al (2009). Purified recombinant M 
protein (0.5-1µg) was pre-incubated with mouse-α-histidine antibody (Abcam, Australia), 
rabbit-α-mouse Alexafluor488 antibody conjugate (Abcam, Australia) and goat α-rabbit 
Alexafluor488 conjugate, at a ratio of 4:2:1. For competitive binding analysis, M protein-
antibody complexes were incubated with glycans of interest (60 pM-60 µM) purchased from 
Dextra Laboratories (UK). Protein mixtures were made up to a final volume of 75 µL in 
Dullbecos PBS (DPBS) and incubated at room temperature for 10 min to allow protein 
complex formation.  Glycan microarray slides were blocked in DBPS with 1% (w/v) bovine 
serum albumin (Sigma-Aldrich, Australia) for 10 min at room temperature and dried by 
centrifugation (200 × g, 5 min). Following centrifugation, gene frames (Abgene, Australia) 
were bonded on to each glycan microarray slide, and 75 µL of pre-complexed protein mixture 
was applied. Protein mixtures were secured with the addition of a plastic cover, and samples 
were allowed to hybridise in the dark for 10 min at room temperature. Proceeding incubation, 
glycan microarray slides were washed in DPBS for 5 min with agitation, followed by a 
secondary wash in DPBS, 0.01% Tween-20 for 2 min with agitation. After washing, glycan 
microarray slides were dried by centrifugation (200 × g, 5 min). Fluorescence intensities of 
array spots were measured using the ProScanArray Microarray 4-Laser Scanner (Perkin 
Elmer, USA) using the Blue argon 488 nm excitation laser set to the FITC setting (494 nm 
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excitation and 518 nm emission), and gain set to 40-60 %. Image analysis was carried out 
using the ProScanArray imaging software ScanArray Express (Perkin Elmer, USA). 
Statistical analysis of the data was carried out using an independent sample T-test. 
2.11.2 Glycan microarray analysis – S. pyogenes 
Whole cell GAS glycan array analysis was undertaken using M1 serotype 5448 and isogenic 
mutant 5448ΔM1. GAS strains were harvested at OD600 nm = 0.5 by centrifugation (5000 × g, 
10 min) and 1 × 10
8 
CFU were resuspended in DPBS containing 1 mM Cell Trace BODIPY 
TR methyl ester (Thermo-Fisher Scientific, Australia) to a final volume of 250 µL. Staining 
of bacteria was allowed to proceed in the dark at room temperature for 15 min. Following 
staining, bacterial cells were applied to a 5 µM Millex-SV Syringe filter unit (Merk-
Millipore, Australia) to remove clumps of aggregated bacteria. Glycan microarray slides 
which were blocked and prepared as per above, were exposed to the stained filtered bacterial 
suspension for 10 min in the dark at room temperature. Glycan microarray slides were then 
washed, processed and analysed as previously described.  
2.11.3 Surface plasmon resonance – glycan 
Affinity interactions of M1 protein and M1-protein fragments with specific glycan subsets 
was undertaken via single cycle kinetics on a series S Ni-NTA chip (BIAcore AB) using a 
BIAcore T200 (GE Healthcare, Sweden) at 20˚C.  Recombinant proteins were captured on 
flow cells 2, 3 and 4 until saturation occurred. Glycan analytes were diluted in PBS and 
kinetic assays were performed using varying concentrations of analyte (0-100 µM) over a 
series of five 120 s injections at a flow rate of 30 µL/min.  Regeneration of the flow cell 
surface was achieved as previously described. M1/M1 fragment protein-glycan interactions 
were analysed via a steady-state affinity model using Biacore T200 evaluation software 
(Biacore AB).  
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It must be noted that increase in the RU of captured his-tagged lectin at the sensor surface 
increases the rate of dissociation of the lectin from the surface (Nieba et al. 1997). Due to 
unavoidable differences in lectin capture and dissociation across each of the three different 
flow cells relative to the negative control flow cell, binding affinity constants of each glycan 
binding interaction were shown to deviate. Furthermore, as the stoichiometry of each binding 
interaction was unknown, only steady state affinity binding analysis was able to be 
undertaken. Binding affinity constants were shown to have varying degrees of standard 
deviation, thus the binding data presented in this study provides a qualitative representation 
of the binding interaction between M1 protein/ M1 protein fragments and each respective 
glycan. 
2.11.4 Preparation of human Detroit-562 and HaCaT cell lines 
Human pharyngeal (Detroit-562) and keratinocyte (HaCaT) cells were cultured in DMEM-
F12 (Invitrogen, Australia), supplements with 2 mM L-glutamine and 10 % v/v heat 
inactivated foetal bovine serum (FBS) (Bovogen Biologicals, Australia). For association 
assays with GAS, adherent eukaryotic cells were washed once with sterile PBS and treated 
with 200 µL of 0.25% Trypsin, 0.02% EDTA (Sigma-Aldrich, Australia). Cells were pelleted 
via centrifugation (500 × g, 5 min) and resuspended in pre-warmed DMEM-F12 (Invitrogen, 
Australia), supplements with 2 mM L-glutamine and 10 % v/v FBS. Following washing, 24-
well plates were seeded with 1 × 10
5
 cells and were cultured 37˚C with 5% CO2 until 80-85% 
confluency (approximately 2 × 10
5
 cells).  
2.11.5 Pharyngeal cell association assays  
Assays measuring total association of GAS (5448 eGFP) to human pharyngeal (Detroit-562) 
and keratinocyte (HaCaT) cells was performed as previously described (Ryan et al. 2001; 
Hollands et al. 2010). To determine M1 protein specificity, GAS strains 5448ΔM1 and 
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NS730 were used as negative controls. Mid-logarithmic GAS (2 × 10
8
 CFU) were pre-
incubated with either lacto-N-tetraose (Dextra Laboratories, UK) or lacto-N-fucopentose type 
I (Dextra Laboratories, UK) in PBS made up to a volume of 200 µl for 30 min at room 
temperature. Following incubation, GAS were pelleted by centrifugation (5000 × g, 10 min), 
washed in sterile PBS and resuspended in 2 mL of DMEM F12 media (Invitrogen, Australia) 
supplemented with 2 mM L-glutamine. Bacteria (2 × 10 
6
 CFU) were then incubated with 
respective eukaryotic cells (2 × 10
5
) in a final volume of 200 µL for 2 h at 37˚C with 5% 
CO2. After the subsequent incubation, GAS were washed 6 times in sterile PBS, and adherent 
eukaryotic cells were released upon the addition of 200 µL of 0.25% Trypsin, 0.02% EDTA 
(Sigma-Aldrich, Australia). To enable lysing of eukaryotic cells, 800 µL of dH2O containing 
0.025% Triton-X 100 (Sigma-Aldrich, Australia) was added to each sample. Released 
bacteria were serially diluted on THYA for enumeration. Bacterial association was calculated 
as a percentage of the original inoculum. Statistical significance was determined using a one-
way ANOVA with the Tukey post-hoc test.     
2.11.6 Collection of saliva and human buccal epithelial cells 
Human buccal epithelial cells and human saliva were collected from 20 healthy individual 
donors of unknown blood type and secretor status. Buccal epithelial cells were collected via 
exfoliation of the buccal mucosa using flocked swabs (Micro Rheologics, Italy). Harvested 
cells were resuspended in sterile PBS, and sorted using a 70 µM cell strainer (Pacific 
Laboratories, Australia).  Buccal cells were then pelleted via centrifugation (500 × g, 5 min) 
and resuspended in ice cold PBS. Along with buccal cells, 2 mL of human unstimulated 
saliva was also collected. After collection, saliva was immediately frozen down and stored at 
– 80˚C. 
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2.11.7 N- and O-linked glycan release for mass spectrometry 
Release of N- and O-linked glycans was undertaken on salivary membrane glycoproteins 
according to Wilson et al (2002). Proteins were immobilised by dot-blotting on to a methanol 
activated PVDF membrane (Millipore, Australia). Once dry, PVDF membrane sections 
containing immobilised protein were excised and transferred to 1.5 mL Eppendorf tubes. N-
linked glycans were released from immobilised proteins by incubation with 3 U of PNGase F 
(Flavobacterium meningosepticum, Roche Diagnostics, Australia) overnight at 37°C. 
Released N-linked glycans were further treated with 15 mM NH4COOH, for 60 min at room 
temperature, and subsequently dried in a vacuum centrifuge (Eppendorf, Germany). Samples 
were then reduced with 20 µL of 1 M NaBH4 in 50 mM KOH for 3 h at 50°C. Reduction 
reactions were quenched with 1 µL glacial acetic acid. O-linked glycans were released from 
the same excised PVDF membrane spots via β-elimination via overnight incubation with 20 
µL of 0.5 M NaBH4 in 50 mM KOH at 50°C. Reduction was quenched with 1 µL glacial 
acetic acid. Both released N- and O-linked glycans were desalted using custom made 
exchange columns containing 30 µL AG50W-X8 cation-exchange resin (BioRad, Australia) 
packed in to µC18 ZipTips. Glycan samples were washed three times with 200 µL methanol 
to remove residual borate and dried via vacuum centrifugation. Purified glycans were 
resuspended in 10 µL dH2O and subjected to porous graphitised carbon liquid 
chromatography electrospray ionisation mass spectrometry (PGC-LC-ESI MS/MS).  
2.11.8 Human buccal epithelial association assays 
To measure the association of GAS to HBE cells, 2 × 10
5 
HBE cells were incubated with 2 × 
10
6 
eGFP expressing GAS (5448 and 5448ΔM1) in 250 µL DPBS for 2 h at 37°C with 5% 
CO2. Post-incubation, samples were transferred to FACS tubes, resuspended in 750 µL 
DPBS, pelleted (500 × g, 10 min) and resuspended in a further 500 µL DPBS. Association of 
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GAS to HBE cells was measured using a LSR II (BD Bioscience, USA) flow cytometer. 
Gated HBE cells were analysed with a 575/26 nm filter with data being recorded for 10000 
events. Fluorescent intensity of uninfected HBE cells was also measured to allow for 
compensation of auto-fluorescence. The relative quantity of GAS associated with HBE cells 
was estimated by the mean fluorescence intensity (MFI) of eGFP positive HBE cells. Data 
was analysed and processed using Flowjo (Treestar, USA). 
2.11.10 Mass spectrometry   
ESI-MS of N- and O-glycans was carried out as previously described (Everest-Dass et al. 
2012). Released N- and O-glycans were separated by PGC (5 µm Hypercarb, 180 µm ID × 
100 mm, Thermo Scientific, USA). Separation of N-glycans was performed over an 85 min 
gradient of 0-45% (w/v) CH3CN in 10 mM NH4HCO3. The flow rate set for N- and O-
glycans was set to 3 µL/min, using a Agilent 1100 HPLC system (Agilent Technologies, 
USA) which was connected directly to an Aglient 6330 ESI source. Capillary voltage was set 
to 3 kV, and the dry gas maintained at 300°C. MS spectra was obtained in the negative-ion 
mode with scan range between m/z 200 and m/z 2200. MS data analysis was carried out in 
ESI-Compass 1.3 (Bruker Daltonics, Germany).     
2.11.11 Ethics for human tissue collection 
Collection of HBE cells and saliva was performed with the approval of the University of 
Wollongong Human Ethics Committee (HE08/250). Volunteers provided informed consent 
before donating tissue samples. 
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3. Phylogenetic and functional characterisation of 
M protein from invasive GAS isolates 
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A section of this work has been published in The Journal of Infectious Diseases. 
Reference:  
Martina L. Sanderson-Smith, David M. P. De Oliveira, Julien Guglielmini, David D. J  
McMillan, Therese Vu, Jessica K. Holien, Anna Henningham, Andrew C. Steer, Debra E. 
Bessen, James B. Dale, Nigel Curtis, Bernard W Beall, Mark J. Walker, Michael W. Parker, 
Jonathan R. Carapetis, Laurence Van Melderen, Sri K. Sriprakash, Pierre R. Smeesters; M 
protein study group. (2014). A systematic and functional classification of Streptococcus 
pyogenes that serves as a new tool for molecular typing and vaccine development. The 
Journal of Infectious Diseases. 210: 1325-38.    
3.1 Introduction 
S. pyogenes is a major cause of global morbidity and mortality, accounting for approximately 
19.9 million cases of severe infection and over 500 000 deaths per year (WHO 2005). The 
global burden of GAS, exemplified by current rates of rheumatic fever and rheumatic heart 
disease, has prompted the urgent development of a global vaccine (Steer et al. 2013). The 
GAS surface protein, the M protein, has been the most pursued GAS vaccine target to date. 
Despite numerous initiatives, a global GAS vaccine still remains commercially unavailable, 
principally due to the antigenic diversity displayed between M protein serotypes.    
Antigenic variation between M proteins forms the basis of nucleotide based M-typing, a 
classification system utilising 10-15% of the mature protein. The representation of GAS 
isolates in developed settings is restricted to several predominant M-types, most notably M-
types 1, 3, 12 and 28 which are frequently isolated from asymptomatic carriers (Ekelund et 
al. 2005). However, to date more than 220 M-types have been reported, with the majority 
circulating in low-income settings (McMillan et al. 2013). Within areas such as the NT of 
Australia, the diversity of M-types is significantly greater. Selective pressures influencing 
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these genetic disparities remain unclear. Potential factors such as climate, socio-economic 
status, population immunity and genetic susceptibilities have been proposed to play a role in 
explaining the high number of circulating M-types (Smeesters et al. 2008). 
Few studies provide a detailed characterisation of M-types in poor-income regions, although 
preliminary analysis of M proteins from a subset of 51 Brazilian and Belgian GAS serotypes 
suggests that the majority of circulating M-types in low-socioeconomic countries and 
territories share a high level of sequence identity (Smeesters et al. 2006). Defined on the 
basis of whole surface-exposed M protein sequence, prior work analysing the distribution and 
diversity of Belgian and Brazilian isolates discovered that M-types could be categorised into 
9 and 13 clusters respectively (Smeesters et al. 2008). These findings have questioned the 
concept of type-specific immunity and whether highly homologous M proteins are 
susceptible to cross-reactive immunity. A framework which enables the development of an 
immunologic cross-protective vaccine may also provide insight into the function of diverse M 
proteins in specific disease states.  
A major function of the M protein is to initiate interactions between GAS and the host. As 
such, M proteins interact with a diverse range of host proteins. A small but diverse range of 
these interactions have been characterised, particularly binding of select host proteins which 
serve to mediate bacterial virulence and evade host immunity (Walker et al. 2014). A novel 
M protein based classification system based on full length amino acid sequence, 
encompassing both sequence diversity and function may help to explain anomalies observed 
in M-type cross-protection, while further enhancing our understanding of antibody mediated 
recognition and bacterial opsonisation. By using the sequences of 175 M-types from 1086 
invasive GAS isolates, a phylogenetic classification system was developed. To evaluate the 
utility of this novel functional classification system, 26 M proteins from 24 distinct M-types, 
representative of each of the major emm-cluster groups were systematically characterised.  
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3.2 Results 
3.2.1 DNA sequence analysis  
PCR amplification of emm genes from 13 of the 26 GAS isolates used in this study was 
undertaken using serotype specific primers. The remaining emm gene sequences were kindly 
provided by Dr. Pierre Smeesters. PCR amplification of the 13 emm genes resulted in the 
production of amplicons ranging from 0.8-1.5 kb (Fig 3.1).  
 
 
 
 
 
Figure 3.1: PCR amplification of emm genes from 13 GAS strains. Lane 1, NS226 emm4; lane 2, 
NS730 emm90; lane 3, NS192, emm106; lane 4, NS179, emm9; lane 5, PRS66, emm102; lane 6, 
PRS2, emm2; lane 7, NS8, emm85; lane 8, NS414, emm11; lane 9, NS931, emm69; lane 10, NS1140, 
emm57; lane 11, NS178, emm54; lane 12, NS501, emm14; lane 13, NS80, emm70. PCR amplicons 
were electrophoresed on a 1% agarose gel. Molecular weight markers are shown on the left in kilo 
base pairs. 
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In order to determine the extent of homology between M proteins, DNA sequence analysis 
was undertaken on emm genes from 26 GAS isolates and aligned via a Pairwise MUSCLE 
alignment using default settings. All emm sequences were trimmed from the first codon of the 
translated mature protein to the last codon expressing the first amino acid of the D-repeat 
domain. At the nucleotide level emm genes were found to be highly variable and 
demonstrated low sequence identity at the 5’ regions which code A and B repeat domains. 
Alignment of N-terminal emm sequences starting from the first nucleotide codon of the 
mature protein up to the first nucleotide codon corresponding to the start of the C-repeat 
domain identified that emm genes had an average sequence identity of 29.7 % (Fig 3.2A). 
Unlike the N-terminal region, the 3’ end which codes the C-repeat domains was found to be 
highly conserved among emm genes (Fig 3.2B). MUSCLE alignment starting from the first 
codon on the C-repeat domain up to the first codon of the D-repeat domain showed an 80.0% 
average in sequence identity among emm genes at the C-terminal region. 
3.2.2 M protein sequence analysis 
At the amino acid level, translated emm sequences from 26 GAS isolates were aligned using 
MUSCLE pairwise alignment as previously mentioned (Appendix E). Sequence identity 
between full length M proteins was found to be approximately 44%. N-terminal regions that 
encode A and B repeat domains and form the basis of M-serotyping were found to be highly 
variable. With the exception of M9, M9.1, M11 and M85 which displayed highly conserved 
sequences, sequence identities were found to range from 6% to 55% (Fig 3.3A). Sequence 
identity between M proteins at the C-terminal end which encodes C and D repeat domains 
was considerably more conserved with amino acid sequence identity ranging from 44% to 
100%. 
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Using a Jukes-Cantor distance model, phylogenetic analysis identified that the 26 full length 
M proteins could be categorised into two major clades; clade X and clade Y. Clade X could 
be further sub-divided into 6 cluster groups whereas clade Y could be separated in to 3 minor 
cluster groups with the exception of M57, which was deemed an outlier (Fig 3.4). Within 
clade X, cluster groups E1-4 was exclusively comprised of M-serotypes originating from 
emm-pattern E GAS isolates. Cluster E5 consists of M proteins belonging to emm-pattern D 
and E whereas E6 comprised solely of A-C pattern isolates. Within clade Y, cluster D1 
consisted of D-pattern isolates whereas clusters AC-1, AC-2 and outlier M57 were all made 
up of sequences originating from A-C pattern isolates. 
The subset of 26 M proteins representing 24 M-types were included in a phylogenetic and 
functional classification study analysing 174 M-types derived from 1086 GAS isolates 
(Sanderson-Smith et al. 2014). Phylogentic analysis of all 174 M-types identified that M 
proteins could be arranged into two major clades, clade X and clade Y. Clade X was 
composed of 5 main M-pattern E clusters (E1 to E4 and E6), whereas clade Y was divided 
into two sub-clusters (Y1 and Y2) which contained 10 main M protein clusters (Y1: D1 to 
D5; Y2: A-C1 to A-C5). Major cluster groups within clade X and clade Y accounted for 145 
of the 175 M-types in study (Fig 3.5). 
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Figure 3.2: Pairwise identity analysis of emm N-terminal (A) and C-terminal (B) gene sequences. Sequence alignments were carried out via the 
pairwise MUSCLE alignment tool using default settings on Geneious version 6.0, Biomatters. Sequence identity is presented as a heat map, 
whereby darker shades of grey correspond to an increase in percentage of identical bases between distinct emm gene sequences.
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Figure 3.3: Pairwise identity analysis of M protein N-terminal (A) and C-terminal (B) gene sequences. Sequence alignments were carried out via the 
pairwise MUSCLE alignment tool using default settings on Geneious version 6.0, Biomatters. Sequence identity is presented as a heat map, 
whereby darker shades of grey correspond to an increase in percentage of identical amino acids between distinct M protein sequences.
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Figure 3.4: Phylogentic assembly based on M protein amino acid sequences from 25 M-types. 
The tree is drawn to scale, with branch length in the same units (number of amino acid substitutions 
per site) to those of the evolutionary distances used for the phylogenetic tree. For phylogenetic 
analysis M protein sequences were trimmed from the first amino acid of the mature protein to the first 
amino acid preceding the anchor LPxTG motif. The phylogenetic tree was constructed using 
Geneious version 6.0 (Biomatters, USA) with default settings. M54 is represented twice through two 
different GAS strains. 
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Figure 3.5: Systematic cluster classification via phylogenetic analysis of M proteins from 175 M-
types. The tree is drawn to scale, with branch length in the same units (number of amino acid 
substitutions per site) to those of the evolutionary distances used for the phylogenetic tree. 
Phylogenetic inferences of M protein sequences were drawn by PhyML. For phylogenetic analysis, M 
protein sequences were trimmed from the first amino acid of the mature protein to the first amino acid 
preceding the anchor LPxTG motif. Test values >80% are indicated at the tree nodes. The tree has two 
major clades: Clade X is comprised of six main clades whereas clade Y is divided into two sub-clades 
that are then divided into 10 main clusters. Six main outliers are indicated via dashed lines. The (*) 
mark indicates recombinant M protein representatives expressed in E. coli. 
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3.2.3 Functional M protein classification 
Functional analysis of 26 M proteins derived from each of the major cluster groups was 
undertaken to assess binding to key host proteins known to interact with M proteins. 
Following expression in E. coli, purified recombinant M proteins were found to range from 
36-58 kDa (Fig 3.6). Some M proteins appeared as doublet bands following SDS-PAGE 
analysis, which is characteristic of certain M proteins (Cunningham 2000). To further 
confirm that purified proteins represented M protein, proteins were subjected to Western blot 
analysis using rabbit polyclonal α-M53NS13 antisera. This antisera has been shown to 
recognise multiple M proteins due to cross-reactivity with the C repeat domain (Sanderson-
Smith et al. 2006). All 26 recombinant M proteins were detected using this method at the 
same molecular weight as observed in SDS-PAGE analysis. High and low molecular weight 
proteins visible in some samples may be indicative of protein dimerisation or protein 
breakdown.    
 
 
 
 
 
 
 
 
 
 
Figure 3.6: SDS-PAGE and Western blot analyses of purified recombinant M proteins. Proteins 
were electrophoresed under non-reducing conditions on a 12% acrylamide gel. Molecular weight 
markers are shown on the left and are given in kilodaltons (kDA) (above). All M proteins were shown 
to react with rabbit polyclonal α-M53NS13 antisera (below).    
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The secondary structure characteristics of all 26 recombinant M proteins were analysed using 
far UV CD spectroscopy. All M protein were found to have a CD emission spectrum 
characteristic of an α-helical coiled-coil protein (Freifelder 1982), displaying two distinctive 
minima at 210 nm and 220 nm, and a maximum peak at 190 nm (Fig. 3.7A-L). These 
emission spectra were similar to that of previously characterised M proteins (Nilson et al. 
1995).  Percent α-helicity was found to range from 77% to 99%. emm-cluster D1 M protein 
representatives and M19 situated just outside of emm-cluster D1 demonstrated the lowest 
level of α-helicity ranging from 76-81%. No significant differences in percent α-helicity were 
observed between remaining emm-cluster groups.   
To assess whether the phylogenetic classification system serves as a synergistic functional 
classification system, M protein cluster representatives were examined for binding to select 
host proteins; specifically, IgG, IgA, C4BP, plasminogen, fibrinogen and albumin. M 
proteins were expressed with C-terminal (His)6 tags. The positioning of the C-terminal tag 
ensured that for SPR experiments, M proteins were captured and presented in an orientation 
which allowed the N-terminal portion of the protein to extend away from the BIAcore sensor 
surface. By capturing the C-terminal region of each M protein, we were able to closely model 
the presentation of M protein at the GAS cell surface, thus allowing for a more 
physiologically relevant comparison of each binding interaction. Sequence alignments with 
annotation and binding profiles of all truncated M protein can be found in Appendix E. 
The binding of IgG was found to be restricted primarily to clade X with affinity constants 
ranging from 2.06 nM to 82.69 nM. IgG binding was specifically observed for clusters E1-E6 
as well as clade Y representatives, M57 (non-clustered A-C) and M1 (A-C3) (Fig 3.8A & C). 
As previously identified in M2 (E4 representative), IgG3 binding is dependent on the 
presence of conserved glutamic acid (E) and glutamine (Q) rich amino acid sequences, a 
common property of IgG binding proteins (Pack et al. 1996). The 35 amino acid EQ-rich 
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sequence characterised in M2 was found to be highly conserved in clusters E1-4 with 
sequence identity ranging from 69% to 100% (Fig 3.8B). M1 has been previously shown to 
bind IgG, via the 38 amino acid S-domain (Akesson et al. 1994). M48 (E6 representative), 
did not express an EQ rich motif, but was shown to share a small level of sequence 
conservation (41%) with the S-region of M1. 
No other M protein sequence in this study exhibited sequence conservation consistent with 
the previously characterised M1 S-domain (Fig 3.8D). With the exception of M48, sequence 
conservation between the EQ rich IgG binding motif present in clusters E1-E4 and the S-
domain of M1 were absent in E6 clustered M proteins as well as in M57 and M14, suggesting 
the existence of an additional IgG binding site (Fig 3.8A-D).  
As with IgG, IgA binding was limited to clade X. The IgA binding motif ‘ALxGENxDLR’ 
has been previously characterised in M4 protein (Bessen 1994). MUSCLE pairwise 
alignment analysis of M protein sequences with this IgA binding motif revealed that M 
protein representatives from cluster E4 demonstrated 50% sequence identity whereas M 
proteins from clusters E1, and E6 shared 64-100% sequence identity with the previously 
characterised IgA binding motif. High affinity IgA binding was demonstrated by cluster E1 
and E6 M protein representatives with affinity constants ranging from 0.66 nM to 5.36 nM. 
Although M proteins from both cluster E1 and E6 contained the previously characterised IgA 
binding motif, all except M65 bound IgA (Fig 3.8E-F).  
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Figure 3.7: Circular dichroism spectra of phylogenetically clustered recombinant M protein. A, 
E1; B, E2; C, E3; D, E4; E, E6; F, non-clustered A-C M proteins; G, D1; H, D4; I, D5; J, A-C3; K, A-
C4; L, A-C5. All M protein cluster representatives exhibit CD emission spectra characteristic of α-
helical coiled-coil proteins, displaying two minima at approximately 210 nm and 220 nm and a 
maximum peak at 190 nm.   
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C4BP, a ligand that confers phagocytosis resistance, is known to bind the N-terminal, 
hypervariable region of M22 (Persson et al. 2006). C4BP was observed to bind exclusively to 
M protein from clade X. Clusters E1, E3, E4 and E6 bound C4BP with extremely tight 
affinity (KD = 5.10 pM – 119.93 pM) (Fig 3.9A). M102 from cluster E4 demonstrated no 
binding to C4BP. No significant conservation in sequence identity was observed between the 
previously published N-terminal domain of M22 and the M proteins in this study. Since 
binding of C4BP has been previously localised to the hypervariable N-terminal section of the 
M protein, it may explain why a defined binding motif has yet to be identified. 
The capacity to bind fibrinogen was only demonstrated by clade Y M protein representatives. 
M protein-fibrinogen binding interactions were restricted to cluster D1, AC3-5 and M 
proteins from subclade Y1 (M57, M54, M19 and M14) with affinity constants of 0.09 nM - 
0.64 nM (Fig 3.9B). To date, a conserved fibrinogen binding motif has not been identified. 
Previous studies analysing the capacity of M1 and M5 to bind fibrinogen identified that 
binding was dependant on the B1 and B2 repeats within M1 and M5 protein even though they 
were shown to not share homologous B1 and B2 sequences (Ringdahl et al. 2000; 
Waldemarsson et al. 2009). Furthermore, for M1, fibrinogen binding was suggested to be 
dependent on irregularities within the coil-coiled structure of B1 and B2 domains (McNamara 
et al. 2008). Sequence alignment of M proteins from each cluster group identified limited 
sequence homology with the B repeat domains of M1 supporting the suggestion of a 
structural non-linear binding motif.  
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Figure 3.8: Binding of IgG and IgA by clustered M protein representatives. All M proteins from 
clusters E1-4, E6 and AC-3 bound IgG (A & C). Unclustered M57 and M14 were also shown to bind 
IgG (Data not shown. See appendix E). Sequence alignments identified that clusters E1-4 share EQ-
rich IgG binding motifs where as M48 was shown to have considerable sequence conservation with 
the S-domain of M1 (B & D). IgA binding was restricted to cluster E1 and E6 M proteins which 
contained the previously characteriesed IgA binding motif (E & F). All kinetic assays were performed 
using analytes at varying concentrations (0-200 nM) over a series of five 60 s injections at a flow rate 
of 30 μl/min with a 900 s dissociation period. Affinity interactions were determined via surface 
plasmon resonance and were analysed by non-linear fitting of the single cycle kinetic sensograms 
according to a 1:1 Langmuir binding model. 
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As with fibrinogen, plasminogen binding was specific to clade Y. Conservation of lysine, 
arginine, and histidine residues in the N-terminal A1 and A2 repeats of M53 and M98 have 
been shown to be critical in the binding of plasminogen (Ringdahl et al. 2000; Sanderson-
Smith et al. 2006; Sanderson-Smith et al. 2007). SPR analysis identified that plasminogen 
binding was a restricted to cluster D4 with affinity constants ranging from 1.33 nM to 3.06 
nM (Fig 3.10A). The highly-conserved plasminogen binding motif (EAELERLKSERHD) 
was present only in D4 M proteins, as well as in M140 protein, situated directly adjacent to 
the D4 cluster with sequence conservation ranging from 62-100% (Fig 3.10B). This motif can 
therefore be considered predictive of plasminogen binding M proteins.  
All cluster groups examined with the exception of E4, contained representative M proteins 
that bound albumin (Fig 3.10C), which is in agreement with prior studies (Sandin et al. 
2006). Within cluster D4 only M53 and M98 were shown not to bind albumin. M protein-
albumin interactions exhibited affinity constants ranging from 2.17 nM to 18.14 nM. The 
binding of albumin by M proteins has been attributed to a 14 amino acid motif 
(RDLDASREAKKQVE) localised in the C-repeat domain  (Retnoningrum et al. 1994). This 
motif was present in all M proteins, including those which did not bind albumin whereby 
sequence identity ranged from 79-100 % (Fig 3.10D).  
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Figure 3.9: Binding of C4BP and fibrinogen by clustered M protein representatives. C4BP 
binding was restricted to clade-X M proteins from clusters E1, E3, E4 and E6 (A). Fibrinogen binding 
was only observed by M proteins from clade Y, specifically D1, D5 and A-C3-5 clusters. M proteins 
from subclade Y1 (M57, M54, M19 and M14) were also shown to bind fibrinogen (M57 and M19 
data not shown. See appendix E) (B). Representative single cycle kinetic SPR sensograms are shown 
for M proteins originating from each major cluster group. All kinetic assays were performed using 
analytes at varying concentrations (0-200 nM) over a series of five 60 s injections at a flow rate of 30 
μl/min with a 900 s dissociation period. Affinity interactions were analysed by non-linear fitting of the 
single cycle kinetic sensograms according to a 1:1 Langmuir binding model. 
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Figure 3.10: Binding of plasminogen and albumin by clustered M protein representatives. 
Plasminogen binding was restricted to cluster D4 M proteins (A) which contained the highly 
conserved plasminogen binding motif (B). Albumin was shown to bind all M proteins except protein 
representative from cluster E4, and M53 and M98 from cluster D4 (Only M19 and M9 shown. See 
appendix E for remaining data) (C). All M proteins, including those which did not bind albumin, 
possesed the previously characterised albumin binding motif (D). All kinetic assays were performed 
using analytes at varying concentrations (0-200 nM) over a series of five 60 s injections at a flow rate 
of 30 μl/min with a 900 s dissociation period. Affinity interactions were determined via surface 
plasmon resonance and were analysed by non-linear fitting of the single cycle kinetic sensograms 
according to a 1:1 Langmuir binding model. 
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3.2.4 SV1 competitive binding analysis 
Recently, a J-14 variant encompassing sequences from 77 different M-types, termed SV1, 
was described (Bauer et al. 2012). Despite emphasis on its ability to elicit an effective 
immunogenic response, the ability of SV1 to effectively opsonise GAS via M protein directed 
antigens in the presence of host proteins has not been examined. This is of interest as 
blocking of host proteins could constrain the candidature of this novel GAS vaccine 
candidate. Alternatively, it has been hypothesised that the generation of antibodies which 
block M-protein – host protein interactions may further contribute to a reduction in GAS 
virulence following vaccination (Sandin et al. 2006).   
To assess the recognition of α-SV1 IgG against M protein, and examine the associated 
downstream effects on M protein-host protein binding interactions, competitive binding 
analysis was performed using M protein and α-SV1 IgG in the presence of various host 
proteins (IgG, IgA, plasminogen, fibrinogen and albumin) (Appendix E). Host proteins were 
selected based on their known capacity to interact with different repeat domains of different 
M protein serotypes, ensuring complete coverage of ligand binding sites along the M protein, 
which may affect α-SV1 IgG-M protein interactions. 
All M proteins in this study displayed high affinity for α-SV1 IgG, with affinity constants 
ranging from 6.82 nM to 108.75 nM. Known IgG binding motifs such as the EQ rich domain 
and the S-domain of M1 are situated within the central region of the M protein, 
approximately 20-25 residues upstream of the α-SV1 IgG target motif. Competitive binding 
assays indicated that the presence of IgG binding motif did not significantly reduce M protein 
recognition by SV1. When saturated with either IgG or α-SV1, IgG binding M protein 
representatives from clusters E1, E3, E4, E6, A-C3 along with M proteins M14 and M57 
were able to bind α-SV1 IgG and IgG with slightly reduced affinity (IgG affinity: KD = 6.29 
nM – 102.63 nM; α-SV1 IgG affinity: KD = 10.29 nM – 71.18 nM) (Fig 3.11A-B). The IgA 
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binding motif has been previously localised to the N-terminal portion of M protein, distal 
from the α-SV1 IgG binding motif (Johnsson et al. 1999). IgA binding by E1 cluster M 
proteins was shown to outcompete interactions with α-SV1 IgG, whereas M proteins from 
cluster E6 were able to bind α-SV1 IgG in the presence of IgA (KD = 18.65 nM to 48.76 nM). 
M proteins from both cluster E1 and E6 displayed high affinity for IgA in the presence of α-
SV1 IgG (KD = 0.35 nM to 2.22 nM) (Fig 3.11C-D). 
Plasminogen binding function has been attributed to the N-terminal A repeat domains of 
cluster D4 M proteins (Berge et al. 1993; Sanderson-Smith et al. 2006). As expected due to 
the proximity of both binding domains, saturation of D4 M protein with either plasminogen 
or α-SV1 IgG was unable to block the binding by respective ligands (plasminogen affinity: 
KD = 11.10 nM – 39.29 nM; α-SV1 IgG affinity: KD = 31.32 nM -106.95 nM) (Fig 3.12A-B). 
M protein-fibrinogen interactions have been shown to be dependent on a combination of 
sequence conservation and tertiary structure irregularities in the coiled-coil assembly of the 
B-repeat domain. Fibrinogen binding has been shown to be restricted to clusters D1, A-C3-5, 
and M proteins M57, M19 and M14. Neither α-SV1 IgG nor fibrinogen appeared to compete 
for binding to respective M protein (α-SV1 IgG affinity: KD = 64.84 nM - 129.15 nM; 
fibrinogen affinity: KD = 0.10 nM – 0.64 nM) (Fig 3.12C-D). Albumin binding by M proteins 
has been localised to the C-repeat domain which is highly conserved among M protein 
(Retnoningrum et al. 1994). The J-14 variant sequences which form the basis of SV1 are 
expressed within M protein C1 and C2 repeat domains which subsequently contains the 
previously characterised albumin binding motif (Bauer et al. 2012). Interestingly, M proteins 
from all cluster groups (except E4, M53 and M98) were able to bind α-SV1 and albumin in 
the presence of respective ligands (α-SV1 affinity: KD = 9.10 nM – 158.0 nM; albumin 
affinity: KD = 2.17 nM – 18.14 nM) (Fig 3.12E-F).     
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Figure 3.11: Saturation binding analysis of IgG, IgA and α-SV1-IgG to immobilised 
recombinant M protein. Recombinant poly-histidine tagged M protein was immobilised and 
saturated with IgG (A & B), IgA (C & D) and α-SV1 IgG (A-D). Competitive binding analysis 
between M proteins, IgG and IgA against α-SV1 IgG was measured and analysed by non-linear fitting 
of the single cycle sensograms according to a 1:1 Langmuir binding model using Biacore T200 
evaluation software (Biacore AB). Competitive binding data of the remaining M proteins can be 
found in Appendix E.  
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Figure 3.12: Saturation binding analysis of plasminogen, fibrinogen, albumin and α-SV1IgG to 
immobilised recombinant M protein. Recombinant poly-histidine tagged M protein was 
immobilised and saturated with plasminogen (A-B), fibrinogen (C-D), albumin (E-F) and α-SV1IgG 
(A-E). Competitive binding analysis between M proteins, plasminogen, fibrinogen and albumin 
against α-SV1-IgG was measured and analysed by non-linear fitting of the single cycle sensograms 
according to a 1:1 Langmuir binding model using Biacore T200 evaluation software (Biacore AB). 
Competitive binding data of the remaining M proteins can be found in Appendix E.  
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3.3 Discussion 
Until recently, GAS classification has been based on sequence variation within the initial N-
terminal section (10-15%). This has fostered concerns regarding type-specific immunity, and 
whether different M-types similar in sequence can exhibit cross-protection via M protein 
targeted GAS vaccines (Lancefield 1962; Bauer et al. 2012; McMillan et al. 2013). In this 
study, development of a novel GAS classification system that correlates full length M protein 
sequence with M protein function was undertaken using 1086 GAS isolates collected from 31 
countries representing 175 M-types. This study confirmed the utility of a system which 
encompasses phylogenetic cluster based classification of full length M protein sequence in 
conjunction with M protein function. 
At the amino acid level, phylogenetic analysis demonstrated that M proteins could be 
grouped into 2 clades, 2 sub-clades and 48 clusters, 16 of which encompass 82% of the M-
types in this study. Both at the nucleotide and amino acid level, the N-terminal portions of 
respective emm-genes and translated M protein sequences demonstrated high levels of 
sequence divergence. Through both sequence and phylogenetic analysis, it is evident that 
different M protein cluster groups are under different patterns of diversifying selection. The 
observed diversification, occurring predominately at A and B repeat domains has given rise 
to 16 homogenous cluster groups. If emm genes/M proteins within a cluster group are 
experiencing similar rates of non-synonymous mutation, than it could be assumed that 
different M-types alike in sequence are undergoing similar levels of diversification, brought 
about through common environmental and host-related immune factors. Highly variable A 
and B domains possess opsonic epitopes and generally determine the function of individual 
M-types, facilitating the binding of certain host proteins (Ringdahl et al. 2000; Sanderson-
Smith et al. 2006). It has been suggested that the functional domains expressed in A and B 
repeat domains may constrain the amount of sequence divergence exhibited by an M-type 
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(McNamara et al. 2008). Segregation of 32 single M protein cluster groups, divergent from 
the 16 main cluster groups, may have resulted through allelic variation within an M-type, 
giving rise to mutant populations with altered function and host immunity.  
The plasminogen and IgA binding regions of M proteins are examples of functional domains 
which restrict diversifying selective pressures in the N-terminal domains of select subsets of 
clustered M proteins. The restricted binding function of plasminogen and IgG binding M 
protein has been shown to be integral in eliciting pathogenesis and facilitating immune 
evasion (O'Toole et al. 1992; Sanderson-Smith et al. 2008; Ly et al. 2014). The highly 
predictive plasminogen binding motif was restricted to cluster D4 M protein, which displayed 
high affinity for the respective host protein. Previous studies analysing the plasminogen 
binding characteristics of M53 identified that plasminogen binding is mediated via conserved 
arginine, histidine, and lysine residues in the A1 and A2 repeat domains (Wistedt et al. 1995; 
Sanderson-Smith et al. 2006). Together, lysine, arginine, and histidine make up a highly 
hydrophilic domain in the A1/A2 repeat domains of D4 M protein representatives. Prior 
analysis of the plasminogen binding receptor, urokinase plasminogen activator identified that 
a hydrophilic ligand binding domain is essential for the recruitment of plasminogen 
(Behrendt et al. 1991). IgA binding has been observed to correlate with infection of the 
nasopharyngeal mucosa (Bessen et al. 1990). M protein representatives from clusters E1 and 
E6 were shown to exclusively express the previously characterised N-terminal IgA binding 
motif (Bessen 1994). Interestingly, of the proteins functionally assessed from cluster E6, M65 
was unable to bind IgA even though it expresses the IgA binding motif. If the IgA binding 
motif in M protein requires a particular conformation in order to bind IgA, then flanking 
sequences may be critical for maintaining this conformation.   
Comparison of M protein central regions revealed a high level of sequence variation between 
M proteins. Perhaps the most well characterised function of the central region is the ability of 
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the B repeat domain of M1 and M5 to mediate fibrinogen binding (Waldemarsson et al. 2009; 
Macheboeuf et al. 2011). The ability of M proteins to bind fibrinogen is thought to prevent 
opsonisation, and ultimately phagocytosis of GAS. Fibrinogen binding was found to be 
restricted to clusters D1, A-C3-5 and M proteins M57, M54, M19 and M14 which are 
situated in close proximity to cluster D1. Ringdahl et al (2000), suggested that different GAS 
strains may have evolved different fibrinogen binding sequence motifs within their M 
proteins while retaining the same function. This suggestion is supported by the finding that 
no sequence identity was observed between the B repeat domains of the fibrinogen binding 
proteins in this study. IgG binding has also been shown to be a function of the central 
domains of M protein. IgG binding by M protein has been associated with the prevention of 
complement activation at the GAS cell surface (Stenberg et al. 1992; Carlsson et al. 2003). 
IgG binding clusters E1-E4 were observed to contain the previously described EQ rich region 
reported for IgG3 binding by M2 protein (Pack et al. 1996). This motif was not shared among 
other IgG binding M protein in study such as cluster E6 M protein, M1 (A-C3) and M57 
(non-clustered A-C). Prior studies analysing M1 protein have suggested IgG-Fc regions bind 
M1 via the S-domain, directly upstream of the C repeats (Akesson et al. 1994). The lack of 
sequence conservation between the IgG binding motif of cluster E1-E4 M protein, the M1 S-
domain, and the M protein from E6, M57 and M14 suggest the existence of additional 
uncharacterised IgG binding sites. Furthermore, the binding interactions between M protein 
from cluster E1-E4 and IgG were found to be weaker in affinity than those observed by other 
IgG binding M protein in study. This could imply that the different clusters of M proteins 
function to bind different subclasses of IgG (Jefferis et al. 1990). 
Previous research has highlighted that the C-repeat domains of M protein are highly 
conserved (Fischetti 1989; Smeesters et al. 2008). Sequence analysis of C-repeat domains 
from the M proteins in this study identified that these regions share a high level of sequence 
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identity. The binding of albumin has been shown to be localised to the C-repeats domains. 
Although in this study albumin was not observed to block α-SV1 IgG binding, prior work has 
shown that albumin-M protein interaction is capable of blocking the recognition of C-repeat 
targeted antibodies (Akesson et al. 1994; Retnoningrum et al. 1994). The previously 
characterised albumin binding motif was present in nearly all sequences from this study, 
including those which did not bind albumin (M102, M2, M53 and M98). Prior work 
examining M23 (sub-clade Y) and M1 (A-C3 cluster) proteins suggested that regions 
adjacent to the C-repeat domains are involved in stabilising the coiled-coil conformation, 
essential for interaction with albumin (Gubbe et al. 1997; Hong 2007). These data clearly 
highlight the importance of a whole M protein sequence-based approach in examining 
interactions between different M protein regions, and the impact of these interactions on GAS 
pathogenesis.  
To further examine the effects of M protein binding interactions on adjacent binding motifs, 
functional binding analysis was undertaken using α-SV1 IgG in the presence and absence of 
select host proteins. Recent studies have shown the J-14 variant M protein epitope is 
accessible to α-SV1 IgG at the GAS cell surface (Bauer et al. 2012). The ability of α-SV1 
IgG to recognise a wider range of M protein targeted antigens was assessed in the presence of 
host proteins; IgG, IgA, plasminogen, fibrinogen and albumin. M protein representatives 
from every cluster group were observed to bind α-SV1 IgG with tight to moderate affinity. 
Variations in binding affinity between M proteins for α-SV1 IgG may be attributed to 
conformational differences in the C-repeat domain, resultant from upstream flanking residues 
(Hong 2007). Furthermore, IgG binding M protein representatives were generally observed to 
bind α-SV1 IgG with tighter affinity than non-IgG binding M proteins. This suggests that two 
binding sites such as the EQ rich domain of E1-E4 M protein or the S-domain of M1 may be 
co-operatively involved with the C-repeat α-SV1 IgG binding motif. The degree of 
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contribution each M protein IgG binding motif plays in binding α-SV1 is yet to be evaluated. 
The α-SV1 M protein epitope was found to be distinct from the M protein IgG binding 
domain in all characterised IgG binding M proteins. Thus, M protein-IgG interaction was not 
expected to block the α-SV1 binding site. Conversely, α-SV1 was hypothesised to bind both 
the IgG binding site and the α-SV1 epitope within the M protein. Based on the similar KD 
values each M protein displays for α-SV1 IgG in the presence and absence of IgG, it can 
assumed that α-SV1 IgG interaction with M protein is predominately restricted to the α-SV1 
epitope, and not the respective M protein IgG binding motifs.    
Only M-types M4 (E1) M11 and M48 (E6) were shown to have significantly reduced affinity 
for both α-SV1 IgG and IgG when in the presence of each respective protein, supporting the 
presence of a more heterogeneous multi-domain α-SV1 IgG binding motif. Differences in the 
binding affinity of IgG binding M protein for IgG and α-SV1 IgG could be the consequence 
of discrete binding sites on IgG. Previous studies have identified that in IgG deficient areas 
such as saliva, binding of IgG by M1 is mediated via the Fc region of IgG, where as in blood, 
binding occurs via the Fab domain (Nordenfelt et al. 2012). Observed differences in affinity 
observed between IgG binding M proteins for IgG and α-SV1 IgG may be due to differences 
in affinity for Fab and Fc domains of IgG.   
Functional analysis identified that M proteins from clusters E1 and E6 were able to bind IgA. 
IgA binding by E1 M proteins was shown to both inhibit and outcompete α-SV1 IgG binding 
interactions. Interestingly, IgA binding by E6 M proteins was not affected by or able to 
outcompete α-SV1 IgG binding. IgA binding motifs present in cluster E1 M proteins are 
situated closer in proximity to C-repeat domains than in cluster E6 M proteins. To explain the 
functional differences displayed by these two IgA cluster groups, two theories could be put 
forward. IgA is 320 kDA in size, thus steric hindrance may influence and mediate inhibition 
of E1 M protein function. Secondly, structural changes induced by IgA or α-SV1 IgG binding 
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may be more prominent in cluster E1 than cluster E6 M protein, which may subsequently 
alter the remaining protein binding sites.    
Competitive α-SV1 IgG binding studies analysing the effects of plasminogen and fibrinogen 
binding identified that, generally, binding of either host protein did not sterically obstruct α-
SV1 IgG C-repeat domain recognition. Both plasminogen and fibrinogen have been shown to 
bind to the N-terminal hypervariable region of M protein (Berge et al. 1993; Ringdahl et al. 
2000; Macheboeuf et al. 2011). It could be inferred that these respective binding motifs are 
positioned in a manner, distal enough to the C-repeat domain which does not allow for steric 
hindrance or induce conformational changes, inhibiting further M protein interactions. 
Previous studies analysing the effects of C-repeat directed antibodies against M5 protein, 
identified that binding was not inhibited in the presence of fibrinogen (Sandin et al. 2006). 
Two exceptions were observed within this study. α-SV1 IgG interaction with M1 protein was 
shown to obstruct but not inhibit binding of fibrinogen. The M1 exclusive S-domain is 
responsible for binding IgG, and is likely to be a viable low affinity secondary binding site 
for α-SV1 IgG. The structure of the B-repeat domain which resides just upstream of the S-
domain has been shown to be critical in the proteins ability to bind fibrinogen  (McNamara et 
al. 2008). Therefore it is possible that binding of α-SV1 IgG to the S-domain may affect the 
irregular coiled-coil arrangement of the B-repeat domain structure which is required for high 
affinity fibrinogen binding. The second exception was observed in M19 interaction with α-
SV1 IgG which was slightly inhibited in the presence of excess fibrinogen. Although this 
result was unexpected, it could be inferred that potential conformational rearrangement as a 
result of fibrinogen binding, in conjunction with a relatively weak affinity for α-SV1 IgG 
could account for the slight quantitative decrease in α-SV1 IgG binding. 
M protein C-repeat domains are responsible for binding albumin. The M protein albumin 
binding motif is situated in close proximity to the SV1 domain, with both regions sharing a 
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high level of sequence identity (Akesson et al. 1994; Retnoningrum et al. 1994; Bauer et al. 
2012). Binding of albumin did not prevent α-SV1 IgG-binding to M proteins in this study. 
Additionally α-SV1 IgG was unable to affect albumin-M protein interactions. SV1 
development is centred on J14 sequence variants found in all three C-repeat domains of M 
protein (Smeesters et al. 2008; Bauer et al. 2012). It was originally postulated that the high 
affinity interactions between albumin and M protein would inhibit α-SV1 IgG binding 
activity, especially since both proteins share analogous binding motifs which are in close 
proximity. Using GAS serotype M5, it has been previously shown that albumin is capable of 
blocking C-repeat directed antibody opsonisation (Sandin et al. 2006). Unlike N-terminal 
domains, C-terminal domains of M protein which are covalently linked to the GAS cell 
surface have been shown to be ridged in α-helical structure (Fischetti et al. 1988; McNamara 
et al. 2008). A possible explanation for the contradicting competitive binding data may lie in 
the fluidic structural nature of the M protein molecule where unlike M protein covalently 
bound at the GAS cell surface, recombinantly expressed M protein may be able to 
accommodate both ligands due to the reduction in conformational restriction.   
In this study, we have developed a unique M protein based classification system categorising 
a large subset of circulating M-types in to 16 major cluster groups. This classification system 
highlights the potential for cross-reactivity in GAS vaccine development but also serves as a 
tool for the identification of potential binding motifs and M protein function (Sanderson-
Smith et al. 2014). The results presented here clearly demonstrate the utility of a GAS 
classification system based on full length M protein sequence with the goal of facilitating 
future M protein functional studies, epidemiological surveillance and vaccine development.   
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A section of this work has been published in Biochemistry. 
Reference:  
David M. P. De Oliveira, Ruby H. P. Law, Diane Ly, Simon M. Cook, Adam J. Quek, Jason 
D. McArthur, James C. Whisstock, and Martina L. Sanderson-Smith. (2015). Preferential 
acquisition and activation of plasminogen glycoform II by PAM positive Group A 
streptococcal isolates. Biochemistry. In press.  
4.1 Introduction 
Multiple species of bacteria interact with the host protein plasminogen and increasing 
evidence suggests the ability to bind plasminogen is central to multiple stages of bacterial 
pathogenesis (Sanderson-Smith et al. 2008). Plasminogen is a single chain glycoprotein 
zymogen of the broad spectrum protease plasmin  that circulates in plasma and extracellular 
fluids at an approximate concentration of 2 µM (Ponting et al. 1992; Andreasen et al. 1997).  
Regulation of the plasminogen activation system is essential for the maintenance of 
homeostatic function and the conversion of plasminogen into plasmin is a major regulatory 
target. The conformation of the plasminogen molecule greatly influences the regulation of 
plasminogen activation. Intramolecular binding between lysine residues and the lysine 
binding sites (LBS) of kringle (KR)-4, KR5 and the N-terminal Pan-apple (PAp) domain 
maintains circulating plasminogen in a compact and internally rigid ‘closed’ conformation 
that is highly resistant to activation (Ponting et al. 1992). Upon binding to specific cell 
surface receptors or ligands, such as fibrin, plasminogen adopts an ‘open’ conformation that 
becomes more susceptible to activation (Law et al. 2012). It is now well recognised that these 
interactions play a central role in modulating key steps in plasminogen activation by host and 
bacterial plasminogen activators (Law et al. 2012; Sanderson-Smith et al. 2012).  
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Plasminogen receptors and activators are expressed by a range of bacterial species including 
Streptococcus pneumoniae, Staphylococcus aureus and GAS (Bergmann et al. 2003; 
Sanderson-Smith et al. 2006; Sanderson-Smith et al. 2006; Kwiecinski et al. 2010; 
Sanderson-Smith et al. 2012). The interaction of GAS with plasminogen has been well 
characterised. GAS has evolved numerous highly specialised interactions with 
plasminogen/plasmin which are critical for virulence. Central to this are the plasminogen 
binding group A streptococcal M-proteins (PAM), and the secreted plasminogen activator, 
streptokinase (SK). A distinct 43 kDa PAM protein (M-type 53) belonging to emm-cluster D4 
has been shown to bind plasminogen with high affinity (KD ~ 1 nM) (Berge et al. 1993). 
Plasminogen is known to interact with ligands via LBS within specific KR structures. KR1, 4 
and 5 demonstrate the highest affinity for lysine-containing ligands, with KR2 displaying the 
weakest affinity (Marti et al. 1997). The high affinity interaction between PAM and 
plasminogen is unique, in that PAM lacks a typical C-terminal lysine, a common feature of 
most but not all plasminogen receptors. Early reports suggest that Lys98 and Lys111 of PAM 
mediates binding to KR2 of plasminogen (Wistedt et al. 1995). More recent work has shown 
that binding of plasminogen to PAM is primarily mediated by positively charged Arg101, 
Arg114, His102 and His115 in the A1 and A2 repeat domains of PAM (Sanderson-Smith et al. 
2006). In addition to the expression of PAM, GAS also secrete SK, a potent plasminogen 
activating protein. SK mediates plasminogen activation by the formation of a 1:1 
(SK:plasminogen) complex, with substrate recognition occurring at KR5 of plasminogen 
(Tharp et al. 2009).  
SK produced by GAS displays considerable genetic and phenotypic diversity. Phylogenetic 
studies of ska sequences from GAS isolates have revealed two main sequence clusters 
(cluster type-1 and -2) with  cluster type-2 sequences being further subdivided (cluster type-
2a and -2b)  (Kalia et al. 2004; McArthur et al. 2008). Recent studies analysing these distinct 
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SK variants  from specific GAS isolates suggest that the phenotypic differences displayed by 
SK may directly affect GAS pathogenic outcomes (Cook et al. 2012). Epidemiological 
studies have shown the type-2b ska lineage to be largely restricted to PAM positive GAS 
strains. In these isolates PAM and SK play a co-operative role in the acquisition and 
activation of plasminogen/plasmin. Specific ligand-binding induced conformational changes 
in plasminogen mediated by PAM and other host proteins such as fibrinogen are required for 
type-2b SK to form a functional activator complex with plasminogen. Furthermore the 
combination of PAM and fibrinogen is required for these type-2b SK variants to display 
resistance to inhibition by circulating α2-antiplasmin, which is a hallmark of classical SK 
mediated activation process (Cook et al. 2013).  
Glycosylation of plasminogen gives rise to two major species of the zymogen; GI-
plasminogen and GII-plasminogen. GI-plasminogen possesses carbohydrate chains N-linked 
to Asn289 and O-linked to Thr346, while GII-plasminogen contains a sole O-linked 
carbohydrate at Thr346. GI-plasminogen and GII-plasminogen exist in humans at an 
approximate ratio of 2:3, respectively (Law et al. 2012). Differences in carbohydrate content 
between the two glycoforms of plasminogen lead to disparities in the kinetic and activation 
properties of the zymogen (Gonzalez-Grownow et al. 2002). The ability of highly specialised 
plasminogen-binding pathogens such as GAS to interact with different glycoforms of 
plasminogen and the downstream consequences of these interactions has not been 
investigated. Here, we examine the biochemical, structural and functional differences 
between the interaction of GI-plasminogen and GII-plasminogen with GAS proteins, PAM 
(M53 – cluster D4) and SK, with a view to resolve how binding and activation of these two 
different glycoforms may contribute to the interaction of GAS with the plasminogen 
activation system.  
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4.2 Results 
4.2.1 Conformational change analysis between plasminogen GI and GII  
To examine the effect of εACA on protein-domain unfolding in each plasminogen glycoform, 
GI-plasminogen and GII-plasminogen were monitored in the presence of εACA using the 
hydrophobic protein denaturation marker SYPRO
® 
orange as previously described (Biggar et 
al. 2012). εACA is a synthetic lysine analogue which at high concentrations can inhibit the 
plasminogen activation system by blocking high affinity LBS (Griffin et al. 1978; Sun et al. 
2002). At low concentrations, εACA has been shown to induce conformational changes in 
plasminogen, allowing the molecule to adopt an open, activation susceptible conformation 
(Law et al. 2012). Unfolding analysis identified that both GI-plasminogen and GII-
plasminogen undergo structural change in the presence εACA. Dramatic conformational 
change was observed with both plasminogen glycoforms at a εACA concentration of 2.5 mM, 
indicating potential exposure of the typically compact KR2-5 and serine protease domains 
(Fig 4.1A). In the presence of εACA concentrations of 5 mM and above, hydrophobic 
exposure was consistently greater in GI-plasminogen than GII-plasminogen. Higher levels of 
hydrophobicity displayed by GI-plasminogen over GII-plasminogen may be the result of the 
mobile KR3 domain in GI-plasminogen which has been implicated in allowing the molecule 
to more readily adopt an ‘open’ conformation than its GII-plasminogen counterpart (Law et 
al. 2012). Subsequently, these data may also suggest that GII-plasminogen undergoes a 
smaller degree of εACA induced conformational change than GI-plasminogen (Fig. 4.1A).    
4.2.2 Binding analysis of PAM for GI and GII plasminogen 
In order to analyse the biochemical interactions of PAM with GI-plasminogen and GII-
plasminogen, PAMNS13 was cloned and expressed as a truncated recombinant protein, lacking 
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the N-terminal signal sequence and C-terminal anchor domain (Sanderson-Smith et al. 2006). 
SPR analysis indicated that PAM has a comparative high affinity for closed forms of GI-
plasminogen and GII-plasminogen with KD of 27.4 ± 1.6 and 37.0 ± 6.6 nM respectively. 
Crystallisation studies of full length human plasminogen have revealed that only the LBS of 
KR1 is unprotected in closed plasminogen, however upon adopting an ‘open’ conformation 
KR5 moves away from the core of the plasminogen structure allowing it to be transiently 
exposed to interact with lysine-containing ligands (Law et al. 2012). To assess the impact of 
plasminogen conformation on the interaction with PAM, an open conformation was induced 
by the addition of lysine analogue εACA to the binding buffer. As shown in figure 4.1A, at 
εACA concentrations of 5 mM and above, plasminogen adopts a fully ‘open’ conformation, 
however large excesses of εACA will also block LBS and reduce interactions with ligands. In 
the presence of 5 mM εACA, both GI-plasminogen and GII-plasminogen maintained the 
ability to interact with PAM with a high affinity. However, binding of GI-plasminogen by 
PAM was completely inhibited in the presence of 100 mM εACA, whereas GII-plasminogen-
PAM was still able to form in 400 mM εACA, although with reduced affinity (Fig 4.1B-C). 
Unlike GI-plasminogen, the affinity of PAM for GII-plasminogen was increased 
approximately 10-fold in the presence of 5 mM εACA (GI-plasminogen KD = 33.2 ± 4.4 nM, 
p > 0.05; GII-Plasminogen KD = 2.8 ± 0.6 nM, p = 0.0001), suggesting the conformational 
change to an ‘open’ conformation: 1) promotes a significantly higher affinity interaction 
between PAM and LBS of GII-plasminogen than occurs between LBS and εACA or 2) 
exposes a secondary PAM binding site outside of the LBS of GII-plasminogen which cannot 
be outcompeted with εACA.  
To further investigate the higher affinity displayed by PAM for ‘open’ GII-plasminogen over 
GI-plasminogen, competitive binding analysis was undertaken via SPR, using both ‘closed’ 
and ‘open’ forms of each plasminogen glycoform. In the ‘closed’ conformation, neither 
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plasminogen glycoform was able to out-compete binding of the other to immobilised PAM. 
The low level binding displayed by each ‘closed’ plasminogen glycoform in the presence of 
immobilised PAM-GI-plasminogen or PAM-GII-plasminogen complex is likely to be 
attributed to the dissociation of respective PAM-plasminogen glycoforms, subsequently 
unmasking further binding sites. Interestingly, when in the ‘open’ conformation, induced by 
the addition of 5 mM εACA, GII-plasminogen was able to out-compete GI-plasminogen-
PAM binding interactions. Furthermore, once ‘open’ conformation GII-plasminogen was 
bound to immobilised PAM, this interaction was unable to be disrupted by ‘open’ form GI-
plasminogen (Fig. 1D). Collectively, these data suggest a higher affinity interaction between 
PAM and GII-plasminogen compared with GI-plasminogen when plasminogen is in the 
‘open’ conformation. 
4.2.3 Competitive binding analysis between PAM and GII-angiostatin in the presence 
of εACA  
The KR2 LBS has been reported to mediate the interaction between PAM and plasminogen, 
however, our finding that 400 mM εACA is unable to fully disrupt the interaction between 
PAM and GII-plasminogen suggests the possibility of a secondary binding site within the 
plasminogen molecule. The first three KR domains of plasminogen (angiostatin) have been 
previously shown to interact with PAM via LBS (Berge et al. 1993; Cnudde et al. 2006). To 
determine if a novel binding domain exists outside of KR1-3, GII-angiostatin-PAM binding-
kinetic analysis was undertaken with increasing concentrations of εACA (Fig. 2A). In 
contrast to our findings with full-length GII-plasminogen, the interaction of GII-angiostatin 
with immobilised PAM was completely inhibited in the presence of 5 mM εACA. This 
supports previous findings that LBS within KR1-3 are involved in the PAM-plasminogen 
interaction. However, as comparative concentrations of εACA were unable to inhibit 
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interactions of immobilised PAM with full length GI-plasminogen and GII-plasminogen, 
these data also suggests that a secondary site outside of KR1-3 may mediate the interaction of 
PAM with plasminogen. This interaction may represent a non-LBS mediated event, or 
alternatively a secondary higher affinity interaction within full-length plasminogen. 
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Figure 4.1: Effects of εACA on the structural conformation of GI/GII-plasminogen and 
associated affinity for PAM. (A) Conformational changes in GI-plasminogen and GII-plasminogen 
induced by the lysine analogue, εACA. Changes in structural conformation were undertaken using the 
conformational sensitive dye SYPRO orange. Analysis was undertaken at 37 ˚C using a LightCycler® 
480 II Real Time PCR system, with excitation and emission set at 425 nm and 625 nm respectively. 
Fluorescent measurements were expressed as change in the initial fluorescence (Fabs-Fo)/Fo=ΔF/Fo. 
Single cycle kinetic BIAcore sensograms analysing the affinity of immobilised PAM for plasminogen 
glycoform GI-plasminogen (B) and GII-plasminogen (C) in closed and open conformations. (D) 
Competitive binding analysis between GI-plasminogen and GII-plasminogen against immobilised 
PAM in the presence and absence of 5 mM εACA. Each run reflects five injections of plasminogen at 
12.5, 25, 50, 100 and 200 nM. A dissociation period of 600 s followed the last injection. PAM-
plasminogen interactions were analysed by non-linear fitting of the single cycle sensograms according 
to a 1:1 Langmuir binding model using Biacore T200 evaluation software (Biacore AB). 
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4.2.4 Competitive binding analysis between PAM-GI/GII-plasminogen in the presence 
of benzamadine 
Plasminogen is known to adopt three different conformational states; the compact ‘closed’ 
conformation, the partially extended intermediate conformation and the fully extended ‘open’ 
conformation (Ponting et al. 1992; Marshall et al. 1994). The PAp domain serves as an 
important factor in the precise arrangement of ‘closed’ plasminogen by interacting with KR5, 
preventing the reversible conformational change to intermediate state plasminogen and/or 
extended ‘open’ form plasminogen  (Ponting et al. 1992; Law et al. 2012). Prior studies 
analysing the interactions of PAM with the PAp-KR5 interface are limited (Wistedt et al. 
1995; Cnudde et al. 2006). To determine whether PAM is able to bind outside of KR1-3 in 
the PAp domain, SPR analysis using Lys-plasminogen which lacks the PAp domain and 
exists in the intermediate conformation was undertaken both in the presence and absence of 
10 mM εACA. εACA has been previously shown to result in Lys-plasminogen adopting the 
extended ‘open’ conformation (Marshall et al. 1994). In the absence of εACA, immobilised 
PAM was shown to bind Lys-plasminogen with high affinity (KD = 0.44 ± 0.03 nM) 
indicating the PAp domain is not required for high affinity PAM-plasminogen interactions. In 
the presence of εACA, binding affinity decreased 9-fold (KD = 3.83 ± 0.1 nM), but was still 
high affinity (Fig 4.2B). This decrease in affinity may be the result of blocking the PAM-K2 
interaction, as seen for angiostatin. To further dismiss the PAp-KR5 interface as a factor in 
PAM-plasminogen recognition, benzamidine, a KR5 binding site competitor able to induce 
an intermediate conformation in plasminogen was employed (Varadi et al. 1981; Marshall et 
al. 1994). The addition of 5 mM benzamidine with and without equimolar concentrations of 
εACA was unable to inhibit binding in either plasminogen glycoform, but was shown to 
significantly increase the affinity (p < 0.001) of PAM-GII-plasminogen complexes which is 
similar to the effect seen in the presence of low concentrations of εACA. This is most likely 
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due to the higher affinity interaction between GII-plasminogen vs GI-plasminogen in the 
potential open conformation as a result of the secondary glycosylation site in GI-plasminogen 
(Fig 4.2C). 
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Figure 4.2: Isolating a potentially novel non-lysine dependant PAM binding site in GI/GII-
plasminogen by SPR. (A) Affinity of immobilised PAM for GII-plasminogen angiostatin (KR1-3) in 
the presence of varying concentrations of εACA (0-5 mM). (B) Affinity of immobilised PAM for lys-
plasminogen with and without 10 mM εACA. (C) Affinity of immobilised PAM for GI/GII-
plasminogen in the presence of KR5 binding competitor, benzamidine (BZ), and εACA. Each run 
reflects five injections of analyte at 12.5, 25, 50, 100 and 200 nM. A dissociation period of 600 s 
followed the last injection. PAM-GI/GII-plasminogen interactions were analysed by non-linear fitting 
of the single cycle sensograms according to a 1:1 Langmuir binding model using Biacore T200 
evaluation software (Biacore AB). 
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4.2.5 Selective plasminogen glycoform recruitment at the GAS cell surface 
To determine if PAM preferentially sequesters a particular glycoform of plasminogen at the 
GAS cell surface, the PAM expressing GAS strain NS13 was incubated in human plasma. 
Eluted GAS cell surface bound protein (encompassing plasminogen) and positive control GI- 
and GII-plasminogen samples were then screened using α-human plasminogen Western blot 
analysis. The molecular weight of GI-plasminogen and GII-plasminogen correspond to 93 
KDa and 89 KDa respectively. Plasminogen acquisition at the GAS cell surface was found to 
be GII-plasminogen specific (Fig. 4.3A), corresponding to an approximate molecular weight 
of 89 KDa. The presence of a 93 kDa band consistent with GI-plasminogen was absent from 
the elution sample. 
4.2.6 Plasminogen activation at the GAS cell surface 
For each glycoform, recruitment and activation at the GAS cell surface was qualitatively 
measured using the chromogenic substrate S-2251. S-2251 hydrolysis in this assay is given as 
a function of activated plasmin bound to the GAS cell surface. SK expression during the 
course of the assay and subsequent formation of SK-plasminogen/plasmin complexes at the 
cell surface is assumed to have a minimal contribution to pNA generation and is equal 
between isolates. This is due to the large molar excess of exogenous plasminogen added to 
the experiment versus endogenous SK and evidenced by subsequent saturation of plasmin 
activity between pre-incubation time points. PAM and type-2b SK expressing GAS strains 
NS13 and ALAB49 were incubated in the presence of equimolar levels of either GI-
plasminogen or GII-plasminogen for 5 or 10 min periods. At both time points, plasminogen 
acquisition by GAS strains NS13 and ALAB49 was significantly higher in the presence of 
GII-plasminogen compared to GI-plasminogen (p < 0.05; Fig. 4.3B). This suggests that PAM 
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expressing GAS isolates preferentially recruit GII-plasminogen/plasmin over GI-
plasminogen/plasmin at the cell surface. 
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Figure 4.3: Selective plasminogen glycoform variant recruitment and plasmin glycoform 
acquisition at the GAS cell surface. (A) GAS isolate NS13 was incubated in human plasma and 
bound plasminogen was eluted using 100 mM Glycine-HCl (pH 2.0). Purified controls GI-
plasminogen (lane 1) and, GII-plasminogen (lane 2) and eluted GAS cell surface plasminogen 
samples (lane 3) were visualized via an α-human plasminogen Western blot. (B) GAS isolates NS13 
and ALAB49 were incubated with GI-plasminogen, GII-plasminogen (100 nM) or PBS for 5 or 10 
min intervals at 37˚C. GAS cell surface plasmin acquisition was measured by the addition of S-2251 
and change in absorbance was monitored at 405 nm at 37˚C.  
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4.2.7 SK mediated non-proteolytic active site generation and plasminogen activation 
SK from the type-2b expressing GAS strain ALAB49 was examined for its ability to generate 
an active site in GI-plasminogen and GII-plasminogen. Non-proteolytic active site generation 
was examined using the fluorescent active site titrant MUGB as previously described (Cook 
et al. 2012). The rate of active site generation by type-2b SK was significantly higher for GII-
plasminogen (21.0 × 10
-3
 ΔF.Fo
-1
.min
-1
) compared to GI-plasminogen (5.4 × 10
-3
 ΔF.Fo
-1
.min
-
1
) (p = 0.01) (Fig. 4.4A). Type-2b SK mediated plasminogen activation in the presence of 
PAM was monitored using the chromogenic substrate, S-2251. Type-2b SK was able to 
generate plasmin activity in both GI-plasminogen/GII-plasminogen-PAM complexes. 
Plasmin activity generated by type-2b SK was observed to be significantly higher for GII-
plasminogen (3.0 mAbs405nm.min
-2
) than GI-plasminogen containing samples (0.90 
mAbs405nm.min
-2
) (p < 0.001) (Fig. 4.4B). Using GAS strain ALAB49, cell surface, type-2b 
SK dependant activation of plasminogen glycoform variants was shown to be significantly 
higher in GII-plasminogen (0.70 mAbs405nm.min
-2
) than GI-plasminogen (0.49 
mAbs405nm.min
-2
) (p < 0.01). GAS strain ALABΔpam was unable to activate either 
plasminogen glycoform confirming the importance of PAM in type-2b SK mediated 
plasminogen activation (Fig. 4.4C). Differences in the lag-time of plasmin generation 
displayed by both plasminogen glycoforms may be attributed to delay in active site 
generation, but could also be influenced by the differing affinities of PAM for each 
plasminogen glycoform. 
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Figure 4.4: Non-proteolytic active site generation in plasminogen glycoforms by type-2b SK and 
the influence of variant plasminogen conformation on SK mediated plasminogen activation. (A) 
GI/GII-plasminogen (200 nM) and PAM (200 nM) were added to 1 µM MUGB in assay buffer (50 
mM Tris-HCl, 100 mM NaCl, pH 7.4) and pre-incubated at 37 °C for 10 min. To initiate the reaction, 
SK was added to a final concentration of 400 nM in a total volume of 100 µL and the development of 
fluorescence was monitored continuously with excitation at 355 nm and emission at 460 nm. (B) SK 
(5 nM final concentration) was added to assay buffer (10 mM HEPES, 150 mM NaCl, 0.01% Tween-
20, pH 7.4) containing variant GI/GII-plasminogen (500 nM), PAM (500 nM) and S-2251 (500 µM). 
(C) GAS cell surface plasminogen activation using GAS strains ALAB49 and ALABΔpam containing 
GI/GII-plasminogen (200 nM) and exogenous SK (5 nM) carried out in assay buffer (10 mM HEPES, 
150 mM NaCl, 0.01% Tween-20, pH 7.4). The generation of plasminogen activation activity was 
monitored at an absorbance of 405 nm at 37 °C. Insets show transformed plot of absorbance at 405 
nm vs. t
2 
with linear regression of the linearised region. 
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4.3 Discussion 
The interaction of PAM and plasminogen combined with SK plays an important role in the 
pathogenicity of GAS. A key virulence mechanism of GAS is the bacterium’s ability to 
sequester and activate plasminogen both extracellularly and at the GAS cell surface, aiding in 
the migration of the bacterium from cutaneous and mucosal surfaces to deeper tissue sites, 
resulting in severe invasive infection (Walker et al. 2005). Plasminogen has been previously 
shown to typically bind receptors via C-terminal lysine residues (Broder et al. 1991; Pancholi 
et al. 1998). In contrast, plasminogen binding to PAM has been attributed to a combination of 
internal lysine residues, and a series of positively charged arginine and histidine residues 
present within a1 and a2 repeat domains of PAM (Sanderson-Smith et al. 2006). In this study, 
we have shown that PAM preferentially binds GII-plasminogen over GI-plasminogen and 
propose that both plasminogen glycoforms contain secondary PAM binding sites outside of 
KR2 which are impacted by glycosylation at Asn289. Furthermore, GII-plasminogen was also 
shown to have a higher rate of activation than GI-plasminogen by type-2b SK.   
GI-plasminogen and GII-plasminogen circulate in plasma at an approximate ratio of 2:3. 
Biochemical and affinity analysis presented in this study demonstrated that GAS 
preferentially recruits and activates GII-plasminogen over GI-plasminogen. Analysis of the 
interaction between PAM and GI-plasminogen or GII-plasminogen, in combination with 
plasminogen recruitment at the cell surface, demonstrated that PAM preferentially binds GII-
plasminogen, the most abundant glycoform. Earlier work investigating the dynamics of 
interaction between GI-plasminogen and GII-plasminogen at the site of injury in the thoracic 
aorta of rabbits found that GII-plasminogen accumulates approximately five times faster than 
GI-plasminogen (Hatton et al. 1999). This result is consistent with an earlier report 
identifying that GII-plasminogen is synthesized and released by the liver five times faster 
than GI-plasminogen in eukaryotes (Hatton et al. 1994). The differences in the abundance 
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between the two glycoforms of plasminogen in both serum and at the site of cutaneous injury 
may have served as a selective pressure for preferential recruitment of GII-plasminogen by 
PAM. 
PAM is one of the few plasminogen receptors able to bind plasminogen via residues other 
than lysine (Sanderson-Smith et al. 2006). Crystallography studies of the first three KR 
domains of plasminogen (angiostatin) bound to VEK-30, a peptide derived from PAM, 
suggest that interactions between PAM and plasminogen occur exclusively at KR2 (Cnudde 
et al. 2006). Using GII-angiostatin, we have shown that binding of PAM to KR1-3 can be 
inhibited with the lysine analogue εACA, supporting the role of the KR2 LBS in the 
interaction between PAM and GII-plasminogen (Rios-Steiner et al. 2001). In contrast, whole 
molecule binding data using full length GI-plasminogen and GII-plasminogen demonstrated 
that interactions with PAM in α-helical coiled coil conformation could not be inhibited with 
comparative concentrations of εACA (Sanderson-Smith et al. 2006). Berge and Sjöbring 
(1993) previously identified that interaction between PAM and radiolabeled plasminogen 
could be outcompeted with 100 mM εACA. Although we cannot explain the discrepancies 
between these two data sets, observed differences may be a direct result of differences in 
binding methodology. Within this study, SPR experiments captured and presented PAM in an 
orientation which allows the N-terminal portion of the protein to extend away from the 
BIAcore sensor surface. By capturing the C-terminal of PAM, we were able to closely model 
the presentation of PAM at the GAS cell surface, thus allowing for a more physiologically 
relevant comparison of binding with each plasminogen glycoform.     
The affinity between PAM and GII-plasminogen was significantly increased in the presence 
of εACA, an inducer of ‘open’ conformation plasminogen. Unlike GII-plasminogen, GI-
plasminogen is glycosylated at Asn289 on KR3. Previous studies have shown that 
glycosylation at Asn289 results in reduced affinity of KR1 for fibrin and α2-antiplasmin 
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(Lijnen et al. 1981; Thorsen et al. 1981). Conformational change to full extended ‘open’ form 
plasminogen has been suggested to be dependent on co-operative binding interactions 
between two ligands and plasminogen (Christensen et al. 1992). Christensen and Molgard 
proposed that co-operative binding involving two separate LBS where an initial low-affinity 
ligand interaction induces a rate-determining conformational change in plasminogen allowing 
subsequent interaction with a secondary ligand of significantly higher affinity (Christensen et 
al. 1992). The presence of this additional glycosylation site at the KR3/SP interface which 
also lies in the vicinity of KR2 in GI-plasminogen may act to sterically hinder but not inhibit 
a secondary PAM interaction, potentially limiting the degree of conformational change 
undertaken by GI-plasminogen. Although glycosylation at Asn289 lies in the vicinity of KR2, 
we cannot discern if KR2 function of GI-plasminogen is impaired by glycosylation at Asn289 
in GI-plasminogen. PAM has been previously shown to bind KR1-3, but not truncated KR4 
and KR5 fragments of plasminogen (Wistedt et al. 1998). Taken together with SPR data 
discounting the role of the PAp and KR5 LBS in PAM-plasminogen binding interactions, we 
suggest a secondary binding interaction may be occurring between PAM and the SP domain 
of plasminogen, or via a cryptic binding site which is more accessible when GII-plasminogen 
is in the open conformation. Recent superposition experiments have revealed that SK can 
bind to the SP domain of plasminogen in a way which avoids the KR domains (Law et al. 
2012). Therefore, we cannot rule out that at the SP domain in both glycoforms of 
plasminogen, two independent binding sites may exist where both PAM and SK are able to 
co-operatively interact. 
Epidemiological studies have associated type-2b SK with skin tropic, PAM positive GAS 
isolates (Kalia et al. 2004). Type-2b SK variants have been previously shown not to induce 
the formation of an active site in plasminogen, and have 25 fold less affinity for plasminogen 
compared to other SK polymorphic variants (Cook et al. 2012). Unlike GII-plasminogen, GI-
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plasminogen contains a glycosylation site at Asn289 which does not allow for the formation of 
a hydrogen bond between KR3 and the Gly714 residue from the SP domain (Law et al. 2012). 
The absence of a hydrogen bond at the KR3-SP interface allows GI-plasminogen to more 
readily adopt an ‘open’ conformation (Molgaard et al. 1997; Law et al. 2012). Consequently, 
this has been shown to be responsible for higher rates of activation of GI-plasminogen by 
select host and bacterial plasminogen activators where by only in the presence of a lysine 
analogue, is the activation rate of GII-plasminogen enhanced to the same extent of GI-
plasminogen (Takada et al. 1983). Only in the presence of either fibrinogen and/or PAM has 
type-2b SK been shown to create an active site in plasminogen (McArthur et al. 2008; Cook 
et al. 2013). In the presence of PAM, our results indicate that type-2b SK can form both an 
active site and mediate plasminogen activation significantly faster in GII-plasminogen than 
GI-plasminogen. This suggests that differences in glycosylation profile between the two 
glycoforms, particularly at Asn289 in GI-plasminogen, affect the potential of type-2b SK to 
generate active plasmin. It is well established that PAM and type-2b SK play a co-operative 
role in plasminogen activation, dependent on ligand-binding induced conformational change 
in plasminogen. As stipulated above, differences in binding interaction between each 
plasminogen glycoform and PAM may prompt significant disparities in conformational 
change between GI-plasminogen and GII-plasminogen, ultimately influencing activation in a 
manner which is unique to type-2b SK.  
The acquisition of plasminogen/plasmin by PAM and SK is a fundamental step in GAS 
virulence. In this study we demonstrate for the first time that PAM expressing GAS 
selectively bind GII-plasminogen over GI-plasminogen with an affinity that is significantly 
higher than the affinity of GII-plasminogen for εACA. This suggests a role for either a non-
LBS secondary interaction or the induction of a high affinity LBS dependent interaction in 
the open form of GII-plasminogen. Furthermore, we have identified significant differences in 
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type-2b SK mediated activation of plasminogen glycoforms. Due to similarities in M protein 
structure, and conservation of the highly predictive plasminogen binding motif, it can be 
suggested that emm-cluster D4 GAS isolates preferentially recruit GII-plasminogen. Type-2b 
SK is restricted to emm-cluster D4 GAS isolates and thus activation of plasminogen in other 
emm-cluster D4 GAS strains is expected to parallel the results shown in this study. 
Recognising the molecular mechanisms of how GAS sequesters plasminogen and how it is 
influenced by the distinct glycosylation profiles of plasminogen may significantly contribute 
to our understanding of GAS pathogenesis.  
 
 
 
 
 
 
 
 
 
 
 
111 
 
 
 
 
 
 
 
 
5. Characterisation of M protein mediated 
interactions with host glycan structures 
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5.1 Introduction 
Glycans (or carbohydrates) are the most abundant and diverse biopolymers in nature, playing 
key roles in numerous cell recognition events, including those involved in the recognition of 
the immune system, and in the attachment of pathogenic organisms to host tissue (Sharon 
1996; Crocker et al. 2007). The use of glycan array technology is becoming widely employed 
as a tool to efficiently identify carbohydrate binding proteins expressed both on human 
mammalian cells and select species of pathogenic bacteria (Tao et al. 2008; Day et al. 2009; 
Arndt et al. 2011). Several pathogenic bacterial species such as Pseudomonas aeruginosa, 
Helicobacter pylori (H. pylori), and Campylobacter jejuni have been shown to mediate 
adherence to host tissue via cell surface exposed glycan residues (Ilver et al. 1998; Mitchell 
et al. 2002; Day et al. 2009). To date, only a select subset of M protein-glycan interactions 
have been characterised. Glycosaminoglycans (GAG’s) such as dermatan sulphate, highly 
sulphated fractions of heparin sulphate and heparin have been observed to facilitate M protein 
dependant binding of a diverse range of GAS serotypes to human epithelial cells (Frick et al. 
2003). Specific surface glycosylation patterns are indicative features of certain cell types such 
as pharyngeal, skin and  kidney as well as forming the basis of ABO blood group antigens 
(Arndt et al. 2011).  
To date, M protein-glycan interactions and their potential role in GAS virulence have not 
been adequately explored. Glycan binding analysis of M protein representatives from the 
newly developed cluster based classification system outlined in chapter 3 may further reveal 
the importance of glycan interactions in different stages of GAS pathogenesis. 
Epidemiological studies have identified the existence of distinct tissue tropic GAS strains, 
which subsequently attach to cell types with markedly different glycosylation profile (Bessen 
et al. 2010; Arndt et al. 2011). The, identification of novel M protein-glycan interactions may 
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provide insight in to the selective pressures which drive GAS tissue tropic pathogenesis. Our 
interest into better understanding the role of M protein-glycan interactions may help identify 
which glycans and/or glycosylated cell surface proteins are involved in contributing to the 
spectrum of diseases caused by GAS. 
5.2 Results 
5.2.1 Glycan microarray analysis  
To further assess the application of the novel cluster based GAS classification system, M 
protein representatives from the 11 major cluster groups were screened for glycan binding 
using newly developed microarray technology (Day et al. 2009). From the 26 M proteins 
expressed in this study, 20 were chosen for glycan microarray analysis representing 20 
different M-types from 11 major cluster groups. Positive binding was determined when 
binding fluorescence was above the mean background fluorescence (defined as greater than 
one fold increase of the mean background plus 3 standard deviations). Statistical analysis of 
the data was performed by a Student’s t-test with a confidence level of 99.99% (p ≤ 0.0001) 
and only glycans that met these criteria for three biologically independent samples (n = 12 
glycans spot replicates) were interpreted as positive binding interactions. Complete M 
protein-glycan binding profiles are shown in Figure 5.1 and describe each respective glycan 
structure with designated glycan index number. 
Carbohydrates carrying terminal galactose residues have been shown to be common adhesion 
receptors for an array of bacterial pathogens such as Streptococcus suis, Shigella dysenteriae 
and Neisseria gonorrhoeae (Lindberg et al. 1987; Calander et al. 1988; Haataja et al. 1993). 
Binding of terminating-galactose containing glycan structures was an observed characteristic 
of all emm clusters. Galactose covalently attached via α-linkage (1, Galα) was shown to bind 
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clusters E2-E6, A-C3, A-C4 and M proteins M57 and M19. Binding of mono-galactose 
moieties covalently attached via β-linkage (2, Galβ) were observed to exclusively bind 
clusters E2, E6, A-C4 and M protein M14 suggesting the importance of residue presentation 
in lectin recognition. Galactose structures Galβ1-3GlcNaAcβ (11) Galβ1-4Glcβ (16) were 
collectively bound by M protein representatives from clusters E1-E6, D1, A-C3 and non-
clustered M proteins M14 and M57. Of particular note, binding to blood group antigen 
precursor lacto-N-tetraose (53, Galβ1-3GlcNAcβ1-3Galβ1-4Glc) was found to be an 
exclusive property of M proteins from clusters E3, A-C3, A-C4 and M proteins M57 and 
M19 suggesting a potential role in blood group antigen recognition. Cluster D4 was shown to 
exhibit little, to no conservation in binding of galactose-terminating structures between 
representative M proteins. From the glycans screened D4 M protein representatives were 
universally able to bind only GalNAcα1-3GalNAcβ (16), Galβ1-4GlcNAcβ1-6(Galβ1-
3GlcNAcβ1-3)Galβ1-4Glc (56), GalNAcβ1-3Gal (65) and Galα1-4Galβ1-4GlcNAc (67) 
suggesting D4 M proteins are selectively restricted in function. M proteins which 
demonstrated the ability to bind a diverse range of galactose-terminating structures included 
non-clustered M proteins M57, M19 and A-C3 clustered M1.  
Glucose terminating glycan structures are present in human secretions such as saliva and 
have been previously shown to be a fundamental source of carbon, involved in bacterial 
metabolism (Fuhrer et al. 2005; Wiesen et al. 2012). Recognition of glucose terminating 
glycan structures was shown to vary between M protein cluster groups. Unlike most clustered 
M protein, non-clustered M19 was observed to uniquely bind a wide range of terminal 
glucose glycan structures. M protein binding profiles of maltose (76, Glcα1-4Glcβ), 
maltotriose (82, (Glcα1-4)3β), isomaltotriose (83, (Glcα1-6)3β), maltotetraose (84, (Glcα1-
4)4β), isomaltotetraose (85, (Glcα1-6)4β), isomaltopentaose (86, (Glcα1-6)5β), and 
maltohexaose (87, (Glcα1-6)6β) were shown to vary between cluster groups suggesting the 
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binding of maltose containing glycans by M protein is dependent on the number of repeat Glc 
residues and linkage.  
N´acetyl glucosamine, a derivative of glucose, is an important biopolymer in bacterial cell 
wall structure, which when cross-linked with various oligopeptides, forms the bacterial 
peptidoglycan layer (Mesnage et al. 2014). Terminal N´acetyl glucosamine glycan binding 
patterns exhibited by clustered M protein were found to differ between M protein cluster 
groups. Of the glycans assessed, M protein cluster groups E4 and D1 were unable to bind any 
terminal N´acetyl glucosamine glycan structure. Conversely, M protein representative from 
clusters E6, A-C3, and non-clustered and M19 were observed to bind a wide range of 
N´acetyl glucosamine glycan structures, including common binding structures GlcNAcβ1-
6(GlcNAcβ1-3)Galβ1-4GlcNAcβ (103), (GlcNAcβ1-4)5β (104), and GlcNAcβ1-4MurNAc 
(110).  
Mannose residues presented on the surface of bacteria are an important marker in host innate 
immunity, mediating non-opsonic phagocytic uptake by macrophages (Stahl et al. 1998). 
Prior studies analysing the pathogenic S. pneumoniae have suggested that association of the 
bacterium to Schwann cells is mediated via mannose specific lectins on the bacterial cell 
surface (Macedo-Ramos et al. 2014). With the exception of clade-X representative, cluster 
E6, binding of mannose containing glycan structures was over-represented by clade-Y M 
protein. Cluster groups E1-E4 were observed to bind little, to no mannose containing glycan 
structures. Clusters E6, D5, A-C3, A-C4 and M proteins M57 and M19 demonstrated an 
ability to bind a broad range of mannose containing structures including manβ (112), 
ManNAcβ (13) and Manα1-6(Manα1-3)Manα1-6(Manα1-3)Man (124) (124 did not bind 
D5). GlcNAcβ1-3Manβ was also observed to bind all M protein representatives belonging to 
clade-Y clusters D4, D5, A-C3, A-C4, A-C5 and M19 suggesting a conserved function 
among these M proteins. 
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Fucosylation of terminating galactose structures is an important step in blood group antigen 
synthesis (Yang et al. 1991). Prior studies have shown that fucose containing structures are 
utilised by a subset of bacterial species for host colonisation and metabolism (Stahl et al. 
2011; Pacheco et al. 2012). Glycan array analysis of M proteins in this study identified 
binding to fucosylated structures by the majority of M protein clusters groups. Only M 
protein representatives from cluster E2 lacked conserved binding function to fucosylated 
glycans. Of particular note, the ability to bind lacto-N-fucopentaose I, (150,  Fucα1-2Galβ1-
3GlcNAcβ1-3Galβ1-4Glc; LNFP I, H antigen I), the most commonly expressed blood group 
antigen was displayed by M protein clusters E3, D4, A-C3 and M proteins M57 and M19. 
With the exception of clusters D2, D4 and A-C4, binding of one or more complex multi-
residue blood group related Lewis antigen containing structures (538-543) was observed 
between all major cluster groups and non-clustered M protein. For bacterial species such as 
H. pylori, phenotypic differences in host blood group antigen expression have been shown to 
be correlated with disease status (Jaff 2011). Here in this study, the varying patterns of A, B, 
O(H) and Lewis blood group antigen binding profiles displayed between all emm-cluster 
groups may provide avenues for future research investigating host blood group expression 
and GAS disease status. 
N-acetylneuraminic acid (Neu5Ac) is the predominant sialic acid found in complex glycans 
attached to mammalian cell membranes. Prior studies analysing the ability of M6 protein to 
bind Neu5Ac identified that M protein interactions with Neu5Ac mediated association to host 
pharyngeal tissue (Ryan et al. 2001). M6 protein is situated in clade Y adjacent to non-
clustered M protein and M19. Glycan array analysis identified that both M19 and M1 are able 
to recognise a wide range of Neu5Ac structures. Little to no binding of Neu5Ac containing 
structures was observed for clusters E1-E4, D4, and D5. Neu5Ac linkage has been shown to 
play a major role in M protein recognition. Neu5Ac α2-6 linked with galactose was suggested 
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to be a key sialylated linkage for M6 protein recognition (Ryan et al. 2001). Glycan array 
data identified that all Neu5Ac binding cluster groups were able to recognise both α2-3 and 
α2-6 linked Neu5Ac, demonstrating little to no linkage specificity. Furthermore, siaylation of 
galactose containing structures shown to bind various M proteins did not affect binding 
function. Lacto-N-tetraose and Lewis
a 
binders, M1 (A-C3) and M19 (non-clustered), 
demonstrated siaylated lacto-N-tetraose (215, Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-4Glc) 
and siaylated Lewis
a
 (213, Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAc) binding function, 
highlighting the ability of select lectins to recognise conserved residues in distinct 
polysaccharides. 
Sulphated oligosaccharides are a known adherence mediating factor for bacterial pathogen 
Mycoplasma pneumoniae, while also serving as a biomarker for the characterisation of cystic 
fibrosis and bronchitis (Krivan et al. 1989; Degroote et al. 2003; Xia et al. 2005). Glycan 
array analysis identified that clusters E2-E4 and D4 have little to no affinity for sulphated 
structures. M proteins representative of cluster E6 along with non-cluster M57 and M19 
protein were shown to recognise a wide range of sulphated structures, irrespective of linkage 
or adjacent connecting oligosaccharides. Sulphation of galactose containing structures Galβ1-
3GlcNaAcβ (237, 3-O-Su-Galβ1-3GalNAcα; 238, 6-O-Su-Galβ1-3GalNAcα) and Galβ1-
4Glcβ (239, 3-O-Su-Galβ1-4Glcβ; 240, 6-O-Su-Galβ1-4Glcβ) was shown to inhibit binding 
to clusters E1-E4, D1, D5 and non-clustered M protein M14. 
Carrageenans a family of sulphate containing carbohydrates commonly found in various 
types of marine seaweed have been shown to have antibacterial properties against 
Enterobacter cloacae, S. aureus and Enterococcus faecalis (Briones et al. 2014). Of the 
carrageenans screened, E1 clustered M protein and non-clustered M57 protein were observed 
to bind 5 of 6 carrageenan structures (273, 274, 276, 277 and 278) whereas M1 (A-C3) was 
able to bind all 6 (273-278). Remaining M protein cluster groups exhibited varying patterns 
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of carrageenan recognition whereby only cluster E2 demonstrated no conserved carrageenan 
binding function. Glycosaminoglycans (GAGs) belong to an assemblage of glycan structures 
which are expressed both on host cell surfaces and within the ECM of connective tissue. 
GAGs such as chondroitin sulphate, dermatan sulphate and heparin sulphate are typically 
comprised of repeating disaccharide residues, forming linear sulphated polysaccharides 
(Kjellen et al. 1991). Glycan array analysis revealed that binding of heparin (298) and 
heparin digested fragments (279-285) was a shared function among most M protein cluster 
groups. Only M proteins representative of clusters E2 and D5 did not exhibit conserved 
heparin and digested heparin fragment binding function. Sulphation of heparin (314) was 
observed to inhibit binding in cluster E1, D4, A-C4 and A-C5 M protein. Hyaluronic acid and 
related hyaluronan fragments are a common component of host epithelial and connective 
tissue. All M protein cluster groups were shown to bind hyaluronic acid (271), or various 
hyaluronan fragments (294-297; 302-313) whereby the number of repeating hyaluronan core 
units (GlcAβ1-3GlcNAcβ1-4) was observed to be a key factor in M protein recognition. 
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Terminal galactose glycan structures 
Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
1 Galα 
              
2 Galβ 
              
3 Galα1-2Galβ 
              
4 Galα1-3Galβ 
              
5 Galα1-3GalNAcβ 
              
6 Galα1-3GalNAcα 
              
7 Galα1-3GlcNAcβ 
              
8 Galα1-4GlcNAcβ 
              
9 Galα1-6Glcβ 
              
10 Galβ1-2Galβ 
              
11 Galβ1-3GlcNaAcβ 
              
12 Galβ1-3Galβ 
              
13 Galβ1-3GalNAcβ 
              
14 Galβ1-3GalNAcα 
              
15 Galβ1-4Glcβ 
              
16 GalNAcα1-3GalNAcβ 
              
17 GalNAcα1-3Galβ 
              
18 GalNAcα1-3GalNAcα 
              
19 GalNAcβ1-4GlcNAcβ 
              
20 Galβ1-2Galα1-4GlcNAcβ 
              
21 Galβ1-3Galβ1-4GlcNAcβ 
              
22 Galβ1-4GlcNAcβ1-3GalNAcα 
              
23 Galβ1-4GlcNAcβ1-6GalNAcα 
              
24 GalNAcβ1-4Galβ1-4Glcβ 
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Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
25 Galβ1-3GalNAcβ1-3Gal 
              
26 Galβ1-4Galβ1-4GlcNAc 
              
27 Galα1-3Galβ1-4GlcNAcβ1-3Galβ 
              
28 Galα1-4GlcNAcβ1-3Galβ1-
4GlcNAcβ               
29 Galβ1-3GlcNAcβ1-3Galβ1-
3GlcNAcβ               
30 Galβ1-3GlcNAcα1-3Galβ1-
4GlcNAcβ               
31 Galβ1-3GlcNAcβ1-3Galβ1-
4GlcNAcβ               
32 Galβ1-3GlcNAcα1-6Galβ1-
4GlcNAcβ               
33 Galβ1-3GlcNAcβ1-6Galβ1-
4GlcNAcβ               
34 Galβ1-3GalNAcβ1-4Galβ1-4Glcβ 
              
35 Galβ1-4GlcNAcβ1-3Galβ1-
4GlcNAcβ               
36 Galβ1-4GlcNAcβ1-6Galβ1-
4GlcNAcβ               
37 Galβ1-4GlcNAcβ1-6(Galβ1-
3)GalNAcα               
38 GalNacβ1-3GalαGalβ1-4Glcβ 
              
39 Galβ1-3GlcNAcβ1-3Galβ1-
3GlcNAcβ               
40 Galα1-3Galβ1-4GlcNAcβ1-3Galβ1-
4Glcβ               
41 Galβ1-4GlcNAcβ1-6(Galβ1-
4GlcNAcβ1-3)GalNAcα               
42 Galβ1-4GlcNAcβ1-3(GlcNAcβ1-
6)Galβ1-4GlcNAcβ               
43 Galβ1-4GlcNAcβ1-6(GlcNAcβ1-
3)Galβ1-4GlcNAcβ               
44 (Galβ1-4GlcNAcβ1-3)3 
              
45 Galβ1-4GlcNAcβ1-6(Galβ1-
4GlcNAcβ1-3)Galβ1-4GlcNAc               
46 Galβ1-3GalNAcβ1-3Galα1-4Galβ1-
4Glcβ               
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Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
47 Galβ1-3GlcNAc 
              
48 Galβ1-4GlcNAc 
              
49 Galβ1-4Gal 
              
50 Galβ1-6GlcNAc 
              
51 Galβ1-3GlcNAc 
              
52 Galb1-3GalNAcβ1-4Galβ1-4Glc 
              
53 Galβ1-3GlcNAcβ1-3Galβ1-4Glc 
              
54 Galβ1-4GlcNAcβ1-3Galβ1-4Glc 
              
55 Galβ1-4GlcNAcβ1-6(Galβ1-
4GlcNAcβ1-3)Galβ1-4Glc               
56 Galβ1-4GlcNAcβ1-6(Galβ1-
3GlcNAcβ1-3)Galβ1-4Glc               
57 Galα1-4Galβ1-4Glc 
              
58 GalNAcα1-O-Ser 
              
59 Galβ1-3GalNAcα1-O-Ser 
              
60 Galα1-3Gal 
              
61 Galα1-3Galβ1-4GlcNAc 
              
62 Galα1-3Galβ1-4Glc 
              
63 Galα1-3Galβ1-4Galα1-3Gal 
              
64 Galβ1-6Gal 
              
65 GalNAcβ1-3Gal 
              
66 GalNAcβ1-4Gal 
              
67 Galα1-4Galβ1-4GlcNAc 
              
68 GalNAcα1-3Galβ1-4Glc 
              
69 Galβ1-3GlcNAcβ1-3Galβ1-
4GlcNAcβ1-6(Galβ1-3GlcNAcβ1-
3)Galβ1-4Glc 
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Terminal glucose glycan structures 
Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
70 Glcα 
              
71 Glcβ 
              
72 GlcN(Gc)β 
              
73 HOCH2(HOCH)4CH2NH2               
74 GlcAα 
              
75 GlcAβ 
              
76 Glcα1-4Glcβ 
              
77 Glcβ1-4Glcβ 
              
78 Glcβ1-6Glcβ 
              
79 GlcAβ1-3GlcNAcβ 
              
80 GlcAβ1-3Galβ 
              
81 GlcAβ1-6Galβ 
              
82 (Glcα1-4)3β               
83 (Glcα1-6)3β               
84 (Glcα1-4)4β 
              
85 (Glcα1-6)4β               
86 (Glcα1-6)5β               
87 (Glcα1-6)6β 
              
Terminal N´acetyl glucosamine structures 
88 GalNAcα 
    
  
   
  
   
  
 
89 GlcNAcβ 
 
  
     
    
 
  
   
90 GlcNAcβ1-3GalNAcα 
 
  
     
    
  
    
 
91 GlcNAcβ1-4GlcNAcβ 
    
  
   
  
 
  
  
  
92 GlcNAcβ1-6GalNAcα 
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Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
93 
GlcNAcβ1-4-[HOOC(CH3)CH]-3-
O-GlcNAcβ      
  
  
  
     
94 
GlcNAcβ1-[HOOC(CH3)CH]-3-O-
GlcNAcβ-L-alanyl-D-i-glutaminyl-
L-lysine 
  
   
  
  
    
    
  
95 GlcNAcβ1-2Galβ1-3GalNAcα 
        
  
     
96 GlcNAcβ1-3Galβ1-3GalNAcα 
        
  
     
97 GlcNAcβ1-3Galβ1-4Glcβ 
    
  
   
  
 
  
   
98 GlcNAcβ1-3Galβ1-4GlcNAcβ 
    
  
   
  
     
99 GlcNAcβ1-4Galβ1-4GlcNAcβ 
              
100 GlcNAcβ1-6Galβ1-4GlcNAcβ 
        
  
     
101 GlcNAcβ1-6(Galβ1-3)GalNAcα 
     
  
 
    
  
  
 
  
102 
GlcNAcβ1-6(GlcNAcβ1-
3)GalNAcα      
  
     
  
  
103 
GlcNAcβ1-6(GlcNAcβ1-3)Galβ1-
4GlcNAcβ   
  
 
    
 
    
  
  
 
  
104 (GlcNAcβ1-4)5β   
   
    
  
  
  
  
  
105 (GlcNAcβ1-4)6β      
  
     
  
  
106 GlcNAcβ1-4GlcNAc   
    
  
  
  
  
  
  
107 GlcNAcβ1-4GlcNAcβ1-4GlcNAc 
        
  
  
  
  
108 
GlcNAcβ1-4GlcNAcβ1-
4GlcNAcβ1-4GlcNAc   
  
 
  
      
  
  
109 (GlcNAcβ1-4GlcNAc)3 β1-4   
    
  
  
  
 
        
110 GlcNAcβ1-4MurNAc 
    
  
  
      
 
    
 
Mannose containing structures 
111 Manα 
 
  
      
  
 
      
 
112 Manβ 
    
    
  
  
 
    
 
  
113 ManNAcβ 
    
    
  
    
 
    
 
114 6-H2PO3Manα       
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Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
115 GlcNAcβ1-3Manβ 
 
  
   
  
  
            
116 Manβ1-4GlcNAcβ   
   
  
 
  
 
  
     
117 GlcNAcβ1-2Man 
  
  
     
  
  
  
  
118 
GlcNAcβ1-2Manα1-6(GlcNAcβ1-
2Manα1-3)Man     
    
    
    
  
119 Manα1-2Man 
    
  
   
  
  
    
 
120 Manα1-3Man 
    
  
   
  
  
  
  
121 Manα1-4Man 
     
  
     
  
  
122 Manα1-6Man 
         
  
  
  
 
123 Manα1-6(Manα1-3)Man   
       
    
 
    
 
124 
Manα1-6(Manα1-3)Manα1-
6(Manα1-3)Man     
    
  
  
  
    
 
Fucosylated structures 
125 Fucα 
    
  
  
    
 
  
   
126 Fucα1-3GlcNAcβ 
    
    
  
  
   
  
 
127 Fucα1-4GlcNAcβ 
     
  
  
  
   
    
128 Fucα1-2Galβ1-4GlcNAcβ 
    
    
  
  
     
129 Fucα1-2Galβ1-3GalNAcα 
     
  
 
  
  
  
   
130 Fucα1-2Galβ1-4Glcβ 
    
    
  
  
  
  
  
131 Galα1-3(Fucα1-2)Galβ 
        
  
  
  
 
  
132 Galα1-3(Fucα1-2)Galβ1-3GlcNAcβ 
       
    
     
133 Galα1-3(Fucα1-2)Galβ1-4GlcNAcβ 
  
  
 
          
  
  
 
  
134 Galα1-3(Fucα1-2)Galβ1-3GalNAcα 
     
  
    
  
  
  
135 Galα1-3(Fucα1-2)Galβ1-3GalNAcβ 
           
  
  
136 Galα1-3Galβ1-4(Fucα1-3)GlcNAcβ 
        
  
  
  
  
137 
GalNAcα1-3(Fucα1-2)Galβ1-
3GlcNAcβ   
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Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
138 
GalNAcα1-3(Fucα1-2)Galβ1-
4GlcNAcβ         
  
   
  
 
139 
GalNAcα1-6(Fucα1-2)Galβ1-
3GalNAcα     
    
    
    
 
  
140 
Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-
4GlcNAcβ 
  
    
  
  
  
  
  
  
141 
Galα1-3(Galβ1-4)Fucα1-2(Fucα1-3) 
GlcNAcβ                 
    
  
  
     
142 
Fucα1-4(Fucα1-2Galβ1-
3)GlcNAcβ1-3Galβ1-4Glcβ 
  
   
    
  
  
  
  
  
143 
Fucα1-2Galβ1-4(Fucα1-
3)GlcNAcβ1-3Galβ1-4Glcβ     
  
   
  
  
  
  
144 Lex1-6'(Lec1-3')Lac   
  
      
 
  
  
    
  
145 LacNAc1-6'(Led1-3')Lac 
  
    
 
      
  
    
  
146 Lex1-6'(6'SLN1-3')Lac   
  
            
  
  
 
  
147 Lex1-6'(Led1-3')Lac 
  
        
 
    
  
  
 
  
148 LecLex1-6'(Lec1-3')Lac   
  
            
 
    
  
149 Lex1-6'(Leb1-3')Lac   
   
    
  
  
  
  
 
  
150 
Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-
4Glc   
  
  
  
  
    
 
  
  
151 
Galβ1-3(Fucα1-4)GlcNAcβ1-
3Galβ1-4Glc     
  
   
    
 
    
 
152 
Galβ1-4(Fucα1-3)GlcNAcβ1-
3Galβ1-4Glc          
  
 
  
  
153 
Fucα1-2Galβ1-3(Fucα1-
4)GlcNAcβ1-3Galβ1-4Glc           
  
   
154 
Galβ1-3(Fucα1-4)GlcNAcβ1-
3Galβ1-4(Fucα1-3)Glc 
  
 
  
 
  
  
    
  
  
  
155 Fucα1-2Gal   
   
    
    
    
  
156 Fucα1-2Galβ1-4Glc 
  
  
 
  
   
  
  
    
 
157 Galβ1-4(Fucα1-3)Glc 
     
  
     
    
 
158 Galβ1-4(Fucα1-3)GlcNAc 
  
  
  
  
     
  
  
159 Galβ1-3(Fucα1-4)GlcNAc 
        
  
 
      
 
160 GalNAcα1-3(Fucα1-2)Gal 
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Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
161 Fucα1-2Galβ1-4(Fucα1-3)Glc 
     
    
 
  
  
  
 
  
162 Galβ1-3(Fucα1-2)Gal 
         
  
 
  
  
163 Fucα1-2Galβ1-4(Fucα1-3)GlcNAc 
    
  
 
  
 
    
 
      
164 Fucα1-2Galβ1-3GlcNAc 
  
  
  
  
   
  
 
    
 
165 Fucα1-2Galβ1-3(Fucα1-4)GlcNAc 
  
  
 
  
   
  
  
  
  
166 SO3-3Galβ1-3(Fucα1-4)GlcNAc   
  
 
  
   
  
  
    
 
167 SO3-3Galβ1-4(Fucα1-3)GlcNAc    
  
     
  
 
    
  
168 
Galβ1-3GlcNAcβ1-3Galβ1-
4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc     
    
  
          
 
169 
Galβ1-4(Fucα1-3)GlcNAcβ1-
6(Galβ1-3GlcNAcβ1-3)Galβ1-4Glc      
  
      
  
 
170 
Galβ1-4(Fucα1-3)GlcNAcβ1-
6(Fucα1-2Galβ1-3GlcNAcβ1-
3)Galβ1-4Glc 
  
 
          
    
  
  
171 
Galβ1-4(Fucα1-3)GlcNAcβ1-
6(Fucα1-2Galβ1-3(Fucα1-
4)GlcNAcβ1-3)Galβ1-4Glc 
    
  
     
      
 
Siaylated structures 
172 Neu5Acα 
              
173 Neu5Acα 
              
174 Neu5Gcα 
              
175 9-NAc-Neu5Acα 
              
176 Neu5Acα2-3Galβ 
              
177 Neu5Acα2-6Galβ 
              
178 Neu5Acα2-3GalNAcα 
              
179 Neu5Acα2-6GalNAcα 
              
180 Neu5Gcα2-6GalNAcα 
              
181 Neu5Acα2-8Neu5Acα2 
              
182 Neu5Acα2-6GalNAcβ 
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Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
183 Neu5Gcα2-3Gal 
              
184 Neu5Acα2-6(Galα1-3)GalNAcα 
              
185 Neu5Acα2-6(Galβ1-3)GalNAcα 
              
186 Neu5Acα2-3Galβ1-3GalNAcα 
              
187 Neu5Acα2-3Galβ1-3GlcNAcβ 
              
188 Neu5Gcα2-3Galβ1-4GlcNAcβ 
              
189 Neu5Gcα2-6Galβ1-4GlcNAcβ 
              
190 
9-NAc-Neu5Acα2-6Galβ1-
4GlcNAcβ               
191 
Neu5Acα2-3Galβ1-4-(6-O-
Su)GlcNAcβ               
192 
Neu5Acα2-3Galβ1-3-(6-O-
Su)GalNAcβ               
193 
Neu5Acα2-6Galβ1-4-(6-O-
Su)GlcNAcβ               
194 
Neu5Acα2-3-(6-O-Su)Galβ1-
4GlcNAcβ               
195 (Neu5Acα2-8)3-sp3               
196 Neu5Acα2-6Galβ1-3GlcNAc-sp3 
              
197 
Neu5Acα2-6Galβ1-3(6-O-
Su)GlcNAc               
198 Neu5Gcα2-3Galβ1-3GlcNAcβ-sp3 
              
199 
GalNAcβ1-4(Neu5Acα2-3)Galβ1-
4Glcβ               
200 
Neu5Acα2-3Galβ1-4GlcNAcβ1-
3Galβ               
201 
Neu5Acα2-3Galβ1-4(Fucα1-3)6-O-
Su-GlcNAcβ               
202 
Neu5Acα2-3(6-O-Su)Galβ1-
4(Fucα1-3)GlcNAcβ               
203 
Neu5Acα2-6(Neu5Acα2-3Galβ1-
3)GalNAcα               
204 
Neu5Acα2-8Neu5Acα2-3Galβ1-
4Glcβ               
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Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
205 
Neu5Acα2-3Galβ1-4GlcNAcβ1-
3Galβ1-4GlcNAcβ               
206 
Neu5Acα2-3 Galβ1-4(Fucα1-
3)GlcNAcβ1-3Galβ               
207 
Neu5Acα2-6(Galβ1-3)GlcNAcβ1-
3Galβ1-4Glcβ               
208 
GalNAcβ1-4(Neu5Acα2-
8Neu5Acα2-3)Galβ1-4Glc               
209 
Neu5Acα2-8Neu5Acα2-
8Neu5Acα2-3Galβ1-4Glc               
210 
GalNAcβ1-4(Neu5Acα2-
8)2Neu5Acα2-3Galβ1-4Glc               
211 
Neu5Acα2-3Galβ1-4GlcNAcβ1-
3Galβ1-4GlcNAcβ               
212 
Neu5Acα2-3Galβ1-4GlcNAcβ1-
3Galβ1-4Glcβ-sp4               
213 
Neu5Acα2-3Galβ1-3(Fucα1-
4)GlcNAc               
214 
Neu5Acα2-3Galβ1-4(Fucα1-
3)GlcNAc               
215 
Neu5Acα2-3Galβ1-3GlcNAcβ1-
3Galβ1-4Glc               
216 
Galβ1-4(Fucα1-3)GlcNAcβ1-
6(Neu5Acα2-6Galβ1-4GlcNAcβ1-
3)Galb1-4Glc 
              
217 
 Neu5Acα2-3Galβ1-3(Neu5Acα2-
6)GalNAc               
218 
 Neu5Acα2-6Galβ1-3GlcNAcβ1-
3Galβ1-4(Fucα1-3)Glc               
219 Neu5Acα2-3Galβ1-4GlcNAc 
              
220 Neu5Acα2-6Galβ1-4GlcNAc 
              
221 
 Neu5Acα2-3Galβ1-3GlcNAcβ1-
3Galβ1-4Glc               
222 
Galβ1-3(Neu5Acα2-6)GlcNAcβ1-
3Galβ1-4Glc               
223 
Neu5Acα2-6Galβ1-4GlcNAcβ1-
3Galβ1-4Glc                
224 
Neu5Acα2-3Galβ1-3(Neu5Acα2-
6)GlcNAcβ1-3Galβ1-4Glc               
225 Neu5Acα2-3Galβ1-4Glc 
              
129 
 
Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
226 Neu5Acα2-6Galβ1-4Glc 
              
227 (Neu5Acα2-8Neu5Ac)n (n<50) 
              
228 
Neu5Acα2-6Galβ1-4GlcNAcβ1-
2Manα1-6(Neu5Acα2-6Galβ1-
4GlcNAcβ1-2Manα1-6)Manβ1-
4GlcNAcβ1-4GlcNAc-Asn 
              
Sulphated structures 
229 3-O-Su-Galβ 
       
    
   
  
 
230 3-O-Su-GalNAcα 
    
  
       
  
 
231 6-O-Su-GlcNAcβ 
 
  
  
  
   
  
 
  
   
232 3-O-Su-GlcNAcβ 
    
  
   
  
  
  
  
233 Galβ1-3(6-O-Su)GlcNAcβ 
    
      
 
  
  
    
 
234 Galβ1-4(6-O-Su)Glcβ   
   
    
 
    
     
235 Galβ1-4(6-O-Su)GlcNAcβ 
    
    
        
236 GlcNAcβ1-4(6-O-Su)GlcNAcβ 
    
    
  
  
  
  
  
237 3-O-Su-Galβ1-3GalNAcα 
    
    
  
  
     
238 6-O-Su-Galβ1-3GalNAcα 
   
        
 
  
  
  
 
  
239 3-O-Su-Galβ1-4Glcβ   
   
    
 
    
  
  
  
240 6-O-Su-Galβ1-4Glcβ   
   
    
  
  
  
  
  
241 3-O-Su-Galβ1-3GlcNAcβ 
    
    
    
    
  
242 3-O-Su-Galβ1-4GlcNAcβ   
   
    
 
    
    
  
243 4-O-Su-Galβ1-4GlcNAcβ 
    
    
        
244 6-O-Su-Galβ1-3GlcNAcβ 
    
    
  
  
 
    
  
245 6-O-Su-Galβ1-4GlcNAcβ 
      
  
 
  
   
    
246 3-O-Su-Galβ1-4(6-O-Su)Glcβ 
    
    
  
  
  
    
 
247 3-O-Su-Galβ1-4(6-O-Su)GlcNAcβ   
   
          
     
248 6-O-Su-Galβ1-4(6-O-Su)Glcβ 
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Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
249 6-O-Su-Galβ1-3(6-O-Su)GlcNAcβ 
    
    
 
    
  
  
  
250 6-O-Su-Galβ1-4(6-O-Su)GlcNAcβ 
    
    
  
  
     
251 3,4-O-Su2-Galβ1-4GlcNAcβ     
    
 
    
     
252 3,6-O-Su2-Galβ1-4GlcNAcβ     
    
  
  
     
253 4,6-O-Su2-Galβ1-4GlcNAcβ       
    
 
  
     
254 4,6-O-Su2-Galβ1-4GlcNAcβ      
  
   
  
  
  
  
255 
3,6-O-Su2-Galβ1-4(6-O-
Su)GlcNAcβ     
    
  
  
  
    
 
256 GalNAcβ1-4(6-O-Su)GlcNAcβ 
     
  
 
  
      
257 3-O-Su-GalNAcβ1-4GlcNAcβ 
     
  
 
    
  
    
 
258 6-O-Su-GalNAcβ1-4GlcNAcβ 
     
  
 
    
     
259 
6-O-Su-GalNAcβ1-4-(3-O-
Su)GlcNAcβ     
      
 
  
    
  
260 
3-O-Su-GalNAcβ1-4(3-O-Su)-
GlcNAcβ 
  
     
  
 
  
     
261 3,6-O-Su2-GalNAcβ1-4GlcNAcβ      
  
  
    
  
  
 
  
262 4,6-O-Su2-GalNAcβ1-4GlcNAcβ     
    
  
  
  
  
 
  
263 
4,6-O-Su2-GalNAcβ1-4-(3-O-
Ac)GlcNAcβ     
    
  
  
 
      
 
264 4-O-Su-GalNAcβ1-4GlcNAcβ 
        
  
     
265 3,4-O-Su2-Galβ1-4GlcNAcβ     
      
   
        
266 
6-O-Su-GalNAcβ1-4(6-O-
Su)GlcNAcβ     
    
      
  
 
267 Galβ1-4(6-O-Su)GlcNAcβ 
     
  
     
  
  
268 4-O-Su-GalNAcβ1-4GlcNAcβ 
        
  
     
269 
3-O-SuGalβ1-4GlcNAcβ1-3Galβ1-
4GlcNAcβ 
  
    
        
    
  
270 
4-O-SuGalβ1-4GlcNAcβ1-3Galβ1-
4GlcNAcβ     
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Carrageen and glycosaminoglycan structures 
Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
271 (GlcAβ1-4GlcNAcβ1-3)8-NH2-ol               
272 
(Sia2-6A-GN-M)2-3,6-M-GN-GNβ-
sp4               
273 
Neocarratetraose-41, 3-di-O-
sulphate (Na+)                 
274 
Neocarratetraose-41-O-sulphate 
(Na+)                  
275 
Neocarrahexaose-24,41, 3, 5-tetra-
O-sulphate (Na+)                
276 
Neocarrahexaose-41, 3, 5-tri-O-
sulphate (Na+)                 
277 
Neocarraoctaose-41, 3, 5, 7-tetra-O-
sulphate (Na+)                
278 
Neocarradecaose-41, 3, 5, 7, 9-
penta-O-sulphate (Na+)                
279 ΔUA-2S  GlcNS-6S Na4 (I-S)   
              
280 ΔUA  GlucNS-6S Na3 (II-S)   
              
281 ΔUA  2S-GlcNS Na3 (III-S)   
              
282 ΔUA  2S-GlcNAc-6S Na3 (I-A)  
              
283 ΔUA  GlcNAc-6S Na2 (II-A)   
              
284 ΔUA  2S-GlcNAc Na2 (III-A)   
              
285 ΔUA  GlcNAc Na (IV-A)    
              
286 ΔUA  GalNAc-4S Na2 (Δ Di-4S)    
              
287 ΔUA  GalNAc-6S Na2 (Δ Di-6S)    
              
288 
ΔUA  GalNAc-4S,6S Na3 (Δ Di-
disE)                 
289 
ΔUA  2S-GalNAc-4S Na2 (Δ Di-
disB)                 
290 
ΔUA  2S-GalNAc-6S Na3 (Δ Di-
disD)                 
291 
ΔUA  2S-GalNAc-4S-6S Na4 (Δ 
Di-tisS)                
292 
ΔUA  2S-GalNAc-6S Na2  (ΔDi-
UA2S)                 
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Index Glycan structure E1 E2 E3 E4 E6 AC - M57 D1 AC - M14 AC - M19 D4 D5 A-C3 A-C4 A-C5 
293 ΔUA  GlcNAc Na (Δ Di-HA)     
              
294 (GlcAβ1-3GlcNAcβ1-4)n (n=4) 
              
295 (GlcAβ1-3GlcNAcβ1-4)n (n=8) 
              
296 (GlcAβ1-3GlcNAcβ1-4)n (n=10) 
              
297 (GlcAβ1-3GlcNAcβ1-4)n (n=12) 
              
298 
(GlcA/IdoAα/β1-4GlcNAcα1-4)n 
(n=200)               
299 
(GlcA/IdoAβ1-3(±4/6S)GalNAcβ1-
4)n (n<250)               
300 
 ((±2S)GlcA/IdoAα/b1-
3(±4S)GalNAcβ1-4)n (n<250)               
301 
(GlcA/IdoAβ1-3(±6S)GalNAcβ1-
4)n (n<250)               
302 (GlcAβ1-3GlcNAcβ1-4)n (n=4) 
              
303 (GlcAβ1-3GlcNAcβ1-4)n (n=6) 
              
304 (GlcAβ1-3GlcNAcβ1-4)n (n=8) 
              
305 (GlcAβ1-3GlcNAcβ1-4)n (n=10) 
              
306 (GlcAβ1-3GlcNAcβ1-4)n (n=12) 
              
307 (GlcAβ1-3GlcNAcβ1-4)n (n=14) 
              
308 (GlcAβ1-3GlcNAcβ1-4)n (n=16) 
              
309 (GlcAβ1-3GlcNAc β1-4)n 
              
310 (GlcAβ1-3GlcNAc β1-4)n 
              
311 (GlcAβ1-3GlcNAc β1-4)n 
              
312 (GlcAβ1-3GlcNAc β1-4)n 
              
313 (GlcAβ1-3GlcNAc β1-4)n 
              
314 
(GlcA/IdoAα/ IdoASα/β1-
4GlcNAc/GlcNS/GlcNAc6Sα1-4)n               
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Figure 5.1: Glycan binding profile of phylogenetically clustered M protein. M protein binding to a glycan was defined as a value > 1 fold increase 
above mean background RFU. The mean background was calculated from the average RFU of all empty spots on the array plus three standard 
deviations. Glycan binding was examined using ProScanArray imaging software, ScanArray Express (PerkinElmer, USA) before data was 
exported to Microsoft Excel for further analysis. Statistical analysis of the data was performed by a Student’s t-test with a confidence level of 
99.99% (p≤0.0001) and only glycans that met these criteria for three biologically independent samples (n = 12 glycans spot replicates) were 
interpreted as positive binding interactions. Green blocks, indicative of glycan binding, are only presented if all M protein representatives within 
a cluster group were able to bind a respective glycan structures.  
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5.3 Discussion 
Glycan array technology represents a powerful tool for the rapid identification and 
characterisation of novel lectin-glycoconjugate interactions. Microbial lectins, typically 
presented as elongated surface structures have been shown to interact with a wide range of 
glycan residues, subsequently defining the susceptibility of specific host tissue to bacterial 
pathogenesis. To date, the characterisation of M protein-glycan interactions have been 
restricted to large glycosaminoglycans such as heparin, heparin sulphate, and dermatan 
sulphate (Winters et al. 1993; Frick et al. 2003). Prior to the use of glycan array technology, 
characterisation of GAS-glycan interactions has served as a challenge. Here, we have 
systematically categorised conserved glycan binding function across 11 major emm-cluster 
groups, further evaluating the functionality of a full length M protein sequence based 
classification system. Coalesced with the emm-cluster system, glycan array technology serves 
as a predictive functional tool, with potential to aid in the development of future therapeutics 
for GAS disease.  
Bacterial pathogens express a range of galactose specific lectins which allows for the 
interaction with various host tissues (Calander et al. 1988; Sharon 1996; Day et al. 2009). 
One of the most well characterised bacterial lectins capable of binding galactose is the E. coli 
surface expressed receptor, PapG the tip adhesin of Pap pilus, which recognises Galα1-4Gal 
residues present in the core of glycosphingolipids (Sung et al. 2001). Other bacterial lectins 
have also been shown to possess broad substrate specificity for terminal galactose structures. 
C. jejuni, a common pathogen of the digestive system expresses both galactose specific 
receptors as well as broad range galactose receptors, capable of binding both Galα1-3/4Gal 
and Galβ- linked glycans (Day et al. 2009). M protein representatives from all 11 emm-
cluster groups displayed contrasting specificity for a range of terminal galactose glycan 
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structures, independent of linkage and sub-terminal carbohydrate class. Although the nature 
of each M protein galactose binding interaction awaits elucidation, binding data suggests that 
all M proteins in this study recognise galactose structures which form distinct sub-units 
within specific A, B, O and Lewis blood group antigen structures. It is well established that 
blood group antigen related structures are abundant on the surface of cells and within 
extracellular matrices. (Arndt et al. 2011; Everest-Dass et al. 2012). It is conceivable that 
blood group antigen recognition by GAS may contribute to M protein mediated GAS 
adhesion. 
Glucose containing structures are a primary nutritional source for bacteria persisting within 
the host, specifically within secretions such as saliva and those pertaining to the human 
digestive system (Fuhrer et al. 2005; Eilam et al. 2014). With the exception of emm-cluster 
D4, all remaining clusters exhibited binding to several terminal glucose glycan structures. 
Derivatives of maltose (maltose, maltotriose,  isomaltotriose, maltotetraose, isomaltotetraose, 
isomaltopentaose and maltohexaose) were observed to bind every M protein representative, 
except those from cluster E6. The varying patterns of recognition displayed by each M 
protein for maltose containing structures was shown to be influenced by the number of 
repeating glucose residues and corresponding linkage. The observed differences in specificity 
for various analogues of maltose may be indicative of certain selective pressures brought 
about through host tissue localisation and specificity. Glucose derivative, N´acetyl 
glucosamine, is a common constituent of the bacterial peptidoglycan layer (Mesnage et al. 
2014). Binding recognition of N´acetyl glucosamine related structures was shown to vary 
between each emm-cluster whereby clusters E4 and D1 exhibited no conserved binding 
function. Apart from being an important biopolymer in the bacterial peptidoglycan layer, 
N´acetyl glucosamine has also been a target receptor for select bacterial N´acetyl glucosamine 
specific lectins. Gram negative Eikenella corrodens has been previously shown to mediate 
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adhesion to human oral epithelial cells via surface expressed N´acetyl glucosamine structures 
(Yamada et al. 2002). The capacity of each M protein representative within each emm-cluster 
group to bind various N´acetyl glucosamine structures may confer a broad function in 
mediating GAS adherence.  
With the exception of clade-X representative, emm-cluster E6, binding of mannose related 
structures was highly conserved within clade-Y. Mannose binding lectin (MBL), a soluble 
host serum protein, is a well-established constituent of the innate immune response, 
functioning to recognise select mannose structures on the bacterial cell surface. MBL has 
been previously shown to exhibit high levels of binding to GAS regardless of clinical origin 
(Neth et al. 2000). The expansive recognition of mannose structures displayed primarily by 
clade-Y M protein may act to enhance MBL binding function, facilitating macrophage 
mediated phagocytic uptake subsequently inducing a pro-inflammatory cascade. Bacterial 
mannose binding lectins have also been shown to play a role in adherence to host tissue. The 
vast majority of bacterial mannose lectins are able to recognise a wide range of mannose 
structures and have been suggested to be critical in the initial adherence to host tissue 
(Thomas et al. 2002; Thomas et al. 2004; Day et al. 2009). The broad range mannose binding 
specificity displayed by the different M-types in this study may be reflective of the general 
mannose-specificity observed in other bacterial species, ultimately facilitating the initial 
adherence of bacteria to host tissue. 
The acquisition of sialic acid based structures has been previously shown to be a fundamental 
element in bacterial metabolism and resistance of the host innate immune response (Severi et 
al. 2007). Bacterial species Haemophilus influenzae and E. coli K1 have been previously 
shown to utilise sialic acid as a carbon and nitrogen source via the enzymatic action of N-
acetylneuraminate aldolase (Vimr et al. 2000; Severi et al. 2005). Furthermore, the ability to 
sequester and/or express siaylated glycan structures at the bacterial cell surface has been 
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hypothesised to allow multiple bacterial pathogens to circumvent and counteract the host 
immune response through molecular mimicry (Ram et al. 1998; Harvey et al. 2001; Vimr et 
al. 2002). Glycan array binding data revealed that only emm-cluster E2 M protein was unable 
to bind to any siaylated glycan structures. Interestingly, clade-X representatives E1, E3 and 
E4 only demonstrated specificity for siaylated Lewis antigens and galactose-containing blood 
group antigen precursor structures. The specificity shown by clade-X representatives for 
these respective structures may infer that binding recognition is independent of sialylation, 
and instead, a function of galactose or fucose residue expression. The binding of sialic acid-
containing structures to clusters E6, D5, A-C3, A-C5 and non-clustered M protein, M57, M14 
and M19 was found to be independent of galactose or fucose sub-terminal sugars, suggesting 
these M protein are capable of binding directly to sialic acid residues. Although respective 
siaylated binding functions are yet to be determined, sialyation of select galactose containing 
glycans has been previously shown to block galactose-specific lectin recognition (Day et al. 
2009). Binding of lacto-N-biose (Galβ1-3GlcNAc) was found to be highly conserved across 
all clade-X emm-cluster groups. Terminal sialyation of lacto-N-biose (Neu5Acα2-3Galβ1-
3GlcNAc) was shown to abrogate binding to all clade-X M protein representatives. These 
results may suggest that GAS serotypes belonging to clade-X preferentially interact with 
niches within the host which express reduced levels of siaylated glycoconjugates. 
To date, investigation of M protein interaction with sulphated glycans have predominately 
focused on large sulphated glycosaminoglycans such as heparin sulphate and dermatan 
sulphate (Frick et al. 2003). Glycan array analysis of sulphated galactose and terminal N’ 
acetyl glucosamine structures demonstrated that sulphation could alter the binding properties 
of select emm-clusters for specific glycans. Sulphation of lacto-N-biose and lactose was 
shown to inhibit binding by M protein belonging to emm-clusters E1-E4, D1, D5 and non-
clustered M protein M14. Although the glycan binding domains of each M protein have not 
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yet been elucidated, the subsequent net negative change in charge upon addition of a sulphate 
group may prevent binding of lacto-N-biose or lactose to the respective binding domains of 
each M protein. Further analysis of sulphated glycans revealed that emm-cluster E6 along and 
non-cluster M57 and M19 protein can recognise a broad range of sulphate structures, 
irrespective of linkage and adjacent connecting oligosaccharides. The expansive specificity 
exhibited by these M proteins for sulphated structures suggest a defined function for 
sulphate-M protein binding interactions in GAS host-interaction. Such function has been 
demonstrated for M. pneumoniae, for which two distinct receptors have been reported to 
mediate binding of the bacterium to host cells: glycolipids containing sulphated galactose 
structures and glycoproteins containing sulphated forms of terminal N’ acetyl glucosamine 
(Krivan et al. 1989). The broad range binding specificity exhibited by M proteins may be 
akin to binding interactions in M. pneumoniae which are fundamental to the process of 
colonisation.   
GAS has been previously shown to mediate adhesion to cell surface and ECM connective 
tissue by M protein mediated interaction with glycosaminoglycans; heparin sulphate, 
dermatan sulphate and heparin (Bergey et al. 1988; Frick et al. 2003). Glycan array analysis 
identified that binding of heparin digested fragments, heparin sulphate, hyaluronic acid and 
hyaluronan fragments was a conserved function across multiple emm-cluster groups. Binding 
interactions between GAGs and M proteins, M1 and M5 have been previously attributed to 
electrostatic interactions between negatively charged sulphate group chains and positively 
charged N- and C-terminal regions of the M protein. (Frick et al. 2003). Since the C repeat 
domains are highly conserved among M protein, it is expected that binding of sulphated 
GAGs is a characteristic binding property of most if not all M protein. Furthermore, as GAG 
binding has also been partially attributed to the N-terminal domains of M1 and M5 protein, 
differences in binding affinities may be the result of amino acid sequence disparities in the A 
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and B repeat domains of respective emm-clustered M protein. Apart from being expressed on 
cell surfaces and within ECM connective tissue, soluble GAGs are abundant in wounds 
where dermatan sulphate is highly abundant (Penc et al. 1998). Therefore in such 
microenvironments, it could be assumed that GAS pathogenesis could be heightened via 
interaction with these GAG’s. Moreover, GAS is also known to express the broad range 
cysteine protease, SpeB, which can cleave fragments of M protein from the bacterial surface 
(Anderson et al. 2014). Once released from the GAS cell surface, M protein could potentially 
modulate interaction with GAGs known to be involved in the binding of select cytokines and 
mediators of inflammation (Iozzo et al. 1996).  
Fucosylated glycans and glycoproteins are frequently found in human saliva and are 
abundantly expressed on the surface of several types of cell epithelia (Arndt et al. 2011; 
Everest-Dass et al. 2012). Fucosylated glycans are also associated with A, B, H and Lewis 
blood group antigens which are commonly derived from the fucosylation of specific 
galactose containing precursors (Galβ1-3GlcNAcβ1-3Galβ1-4Glc; Galβ1-4GlcNAcβ1-
3Galβ1-4Glc). Interestingly, emm-clusters which demonstrated conserved binding to various 
blood group antigen precursor or precursor related structures, also exhibited binding to a wide 
range of A, B, H and Lewis antigen structures. Thus, it is likely that galactose residues play a 
central role in in blood group antigen recognition. The ability of bacteria to bind fucosylated 
glycan structures has been previously associated with pathogenesis, with P. aeruginosa 
representing a well characterised example. The fucose-specific lectin of P. aeruginosa (PA-
IIL) plays a central role in Pseudomonas infection by facilitating adherence and colonisation 
to heavily fucosylated mucosal layers (Rhim et al. 2001). M protein-mediated GAS 
interactions with fucosylated glycan structures may mediate two different outcomes in GAS 
colonisation, particularly in A-C pattern throat isolates. One potential function of binding 
fucosylated glycans is the promotion of GAS adherence to cell epithelia, possibly 
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contributing to non-invasive disease such as pharyngitis. Alternatively, binding interactions 
may serve as host protective measures against GAS adherence and colonisation. Since 
fucosylated glycoproteins are amply expressed in saliva, binding of fucosylated residues may 
result in the occlusion of other M domains utilised by GAS to adhere to host cells. In certain 
A-C pattern serotypes like M1 and M3 which do not express the major adherence protein 
Sfb1, the M protein serves as one of the primary adherence factors which may subsequently 
employ binding of fucose structures as a major means of adherence (Natanson et al. 1995). 
The finding that emm-clusters display unique patterns of binding to different blood group 
antigen structures may represent a selective pressure brought about through varying patterns 
of geographic serotype restriction. Different blood group antigens predominate in ethnically 
distinct populations which may subsequently reflect the divergent phenotypic binding 
capacity of M proteins from each emm-cluster (Farhud et al. 2013). Furthermore, these 
findings may also provide insight into niche adaptation between GAS isolates which typically 
colonise skin, versus those which colonise the throat, a site high in blood group antigen 
expression.  
To date, glycan interactions and their roles in GAS pathogenesis have not been 
comprehensively explored. The results presented here demonstrate the diverse binding 
profiles of each emm-cluster group for an array of diverse glycans. Furthermore, the newly 
implemented M protein classification system based on full length M protein sequence has 
provided a means by which conserved binding function can be identified across different M-
types sharing moderate levels of sequence identity. Although glycan array technology can be 
utilised to effectively identify novel bacterial glycan interactions, limitations exist in 
deciphering the role of each interaction. To determine the physiological relevance of these 
interactions, additional techniques must be employed. 
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6. Characterisation of M1 protein mediated 
interactions with blood group antigen related 
structures 
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6.1 Introduction 
Human blood group antigen expression has long been shown to play a key role in modulating 
bacterial colonisation for the host, while also inhibiting yeast colonisation of the oral cavity 
(Everest-Dass et al. 2012; Makivuokko et al. 2012). The typical human blood group antigen 
classification system is based on three glycan structures, A, B and O (H) with precursor lacto-
N-tetraose (LNT; Gal-β-1,3-GlcNAc-β-1,3-Gal-β-1,4-Glc) forming the backbone of all three 
antigens (Nishihara et al. 1999). Host gene expression of α-1,2-fuco-transferase enables 
synthesis of H antigen, which can be further processed by N-acetylgalactosaminyl-transferase 
or D-galactosyl-transferase to produce A and B antigens respectively (Yang et al. 1991; 
Persson et al. 2007) (Fig. 6.1). In addition to blood, A, B, H and related precursor structures 
are also expressed in other tissues and fluids such as saliva, tears, breast milk and oral 
epithelial cells (Slomiany et al. 1978; De Leoz et al. 2012; Everest-Dass et al. 2012). 
Expression of A, B, and H antigens on protein surfaces and secretion into extracellular fluid 
is dependent on expression of the Se(FUT2) gene encoding fucosyl-transferase-2 which 
enables secretion of the corresponding blood group antigens by mucin secreting goblet cells 
(Slomiany et al. 1978). Frequency population studies have shown that on average, 76% of 
people are blood group antigen secretors and 24% are non-secretors. Furthermore antigen H 
expressing individuals are found to have a significantly higher frequency of secretor status 
than non-antigen H expressing individuals (Jaff 2010).  
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Figure 6.1: Synthesis of A, B and O(H) blood group determinants in humans. Only the two 
main precursor oligosaccharides are depicted (type 1, lacto-N-tetraose; type 2: lacto-N-
neotetraose). Enzymes required for the synthesis of each blood group antigen are presented in 
italics. α1-2FT, α1-2 fucosyltransferase; α1-3GaT, α1-3 N-acetylgalactosyltransferase; α1-
3GT, α1-3 galactosyltransferase.  
 
 
 
 
α1-2FT 
1-4β 1-3β 1-3/4β 
1-4β 1-3β 1-3/4β 
H-type 1/2 
1-4β 1-3β 1-3/4β 
Type 1/2 precursor 
A-type 1/2 
α1-2 
α1-3 
α1-2 
1-4β 1-3β 1-3/4β 
B-type 1/2 
α1-2 
α1-3 
α1-3GT α1-3GaT 
Glucose 
Galactose 
N-acetylgalactosamine 
N-acetylglucosamine 
Fucose 
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Since the 1980’s, the M1T1 GAS clone has disseminated globally accounting for a significant 
proportion of clinical isolates in the developed world. Although the M1T1 clone is able to 
mediate invasive disease, it is classically a throat tropic isolate frequently associated with 
uncomplicated infection such as pharyngitis (Stevens 1992; Johnson et al. 2002). Previous 
studies analysing the ability of M1T1 clones to colonise glycan rich sites such as pharyngeal 
mucosa have been limited to the study of M-protein-host protein interactions, with little focus 
on the potential role of expressed glycan residues. Blood group antigens and their precursors 
are heavily represented on oral epithelia and in mucosal fluid, suggesting a potential role in 
pharyngeal associated infection. As such, the interaction between M1 and these glycan 
structures was explored in more detail. 
6.2 Results 
6.2.1 5448 whole cell glycan microarray  
The ability of M1 to bind glycan structures at the cell surface was assessed using M1T1 GAS 
strain 5448 and the previously described isogenic mutant, 5448ΔM1 (Walker et al. 2007). 
5448 was found to bind 19 different glycan structures including blood group antigen 
precursor lacto-N-tetraose (53) and blood group antigen H type I (150) in an M1 dependant 
fashion. With deletion of M1 at the cell surface, 5448 was no longer able to recognise these 
structures on the array (Fig. 6.2). Furthermore, 5448 and 5448ΔM1 were also shown to bind 
multiple blood group A (137-139) and B (131, 368 and 392) antigen species, suggesting the 
presence of additional blood group antigen/fucose receptors at the GAS cell surface 
(appendix G). Due to the expression of lacto-N-tetraose and blood group H antigen related 
structures on human tissue and in mucosal fluid, interaction of these structures with M1 were 
further investigated (Slomiany et al. 1978; Everest-Dass et al. 2012).  
145 
 
8 48 49 52 53 62 64 68 106 120 150 157 161 171 206 210 217 289 305
0
1
2
3
4
5
6
7
8
9
10
5448
5448M1
Glycan Index number
F
o
ld
 F
lu
o
re
s
c
e
n
e
 I
n
c
re
a
s
e
 A
b
o
v
e
 B
a
c
k
g
ro
u
n
d
 
 
Figure 6.2: Glycan binding profile of M1T1 clone GAS strains 5448 and 5448ΔM1. Glycan 
binding was analysed using ProScanArray imaging software, ScanArray Express 
(PerkinElmer, USA) before data was exported to Microsoft Excel for further analysis. 
Bacterial binding to a glycan was defined as a value > 1 fold increase above mean 
background RFU. The mean background was calculated from the average RFU of all empty 
spots on the array plus three standard deviations. Furthermore, statistical analysis of the data 
was performed by a Student’s t-test with a confidence level of 99.99% (p ≤ 0.0001) and only 
glycans that met these criteria for three biologically independent samples (n = 12 glycans 
spot replicates) were interpreted as positive binding interactions. Glycan index: 8, Galα1-
4GlcNAcβ; 48, Galβ1-4GlcNAc; 49, Galβ1-4Gal; 52, Galb1-3GalNAcb1-4Galb1-4Glc; 53, 
Galβ1-3GlcNAcβ1-3Galβ1-4Glc; 62, Galα1-3Galβ1-4Glc; 64, Galβ1-6Gal; 68, Galα1-
4Galβ1-4GlcNAc; 106, GlcNAcβ1-4GlcNAc; 120, Manα1-3Man; 150, Fucα1-2Galβ1-
3GlcNAcβ1-3Galβ1-4Glc; 157, Galβ1-4(Fucα1-3)Glc; 161, Fucα1-2Galβ1-4(Fucα1-3)Glc; 
171, Galβ1-4(Fucα1-3)GlcNAcβ1-6(Fucα1-2Galβ1-3(Fucα1-4)GlcNAcβ1-3)Galβ1-4Glc; 
206, Neu5Acα2-3 Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ; 210, GalNAcβ1-4(Neu5Acα2-
8)2Neu5Acα2-3Galβ1-4Glc; 217, Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAc; 289, ΔUA ® 
2S-GalNAc-4S Na2 (Δ Di-disB); 305, (GlcAβ1-3GlcNAcβ1-4)n (n=10). 
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6.2.2 M1-glycan affinity interactions via SPR 
To further characterise the interaction of M1 with lacto-N-tetraose (index number, 53) and 
lacto-N-fucopentaose type I (index number, 150; blood group antigen H type I), single cycle 
kinetic SPR analysis was undertaken using a BIAcore T200 (GE Healthcare, Sweden). Data 
were fitted with a steady state affinity model. SPR binding analysis revealed that M1 was 
able to bind lacto-N-tetraose (Galβ1-3GlcNAcβ1-3Galβ1-4Glc) with an affinity of 127.3 ± 
26.2 µM (Fig 6.3A). The binding of M1 to lacto-N-fucopentaose type I (Fucα1-2Galβ1-
3GlcNAcβ1-3Galβ1-4Glc) was observed to be > 400 fold higher (307.2 ± 168.9 nM) than 
exhibited by M1-lacto-N-tetraose suggesting a role of fucose residues in high affinity M1 
glycan interactions (Fig. 6.3B).     
6.2.3 Characterisation of glycan binding sites in M1 
In order to assess whether a common glycan binding site exists within M1, competitive 
glycan array analysis was undertaken using both structurally related and structurally distinct 
glycan species known to interact with GAS strain 5448 in an M1 dependant manner. Lacto-
N-tetraose, lacto-N-fucopentaose type I and β1-4galactosyl-galactose (Galβ1-4Gal) were 
selected due to Galβ1-4Gal residue conservation among these three glycan structures. α1-3-
mannobiose (Manα1-3Man) was also included as it is structurally distinct from the 
aforementioned glycan structures. Competition binding analysis was undertaken by pre-
incubating M1 protein with varying concentrations of either lacto-N-tetraose or lacto-N-
fucopentaose type I (60 – 0.6 µM) and binding was assessed against the aforementioned set 
of glycans immobilised at molar amounts of 5 mmol and 500 nmol. Pre-incubation of M1 
with either lacto-N-tetraose or lacto-N-fucopentaose type I was shown to out-compete M1 
interaction with all 4 immobilised glycan structures (Fig. 6.4 A-D). Furthermore, when 
immobilised at a molar amount of 5 mmol, lacto-N-fucopentaose I binding to M1 was unable 
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to be inhibited by pre-incubation with lacto-N-tetraose confirming M1 has a higher affinity 
for lacto-N-fucopentaose type I compared with lacto-N-tetraose.   
To better resolve which repeat domains of M1 are involved in the binding of lacto-N-tetraose 
and related blood group antigen structures, truncated M1 protein fragments with overlapping 
repeat domains were constructed as previously described (McNamara et al. 2008; 
Macheboeuf et al. 2011). The observed molecular weight of respective M1-fragments were 
shown to range from 27 kDa to 9 kDa and exhibited a far UV CD spectra characteristic of α-
helical coiled coil protein (Fig. 6.5A & B). The ability of each respective glycan to bind 
fragmented M1 protein constructs was measured using SPR and modelled using steady state 
affinity fitting of the single cycle kinetic sensograms. Binding analysis revealed that with the 
exception of fragment M1-C, all M1 protein fragments were able to bind lacto-N-tetraose (KD 
= 35.6 – 11.0 µM) and lacto-N-fucopentaose type I (KD = 238.3 – 609.6 nM) (Table 6.1). 
These data in conjunction with aforementioned competition glycan array analysis suggests 
the existence of a multifunctional glycan binding motif, localised to the B repeat domains of 
M1. 
To ascertain whether individual B repeat domains of M1 are capable of binding blood group 
related glycan structures, SPR binding analysis was undertaken using peptide amino acid 
sequences corresponding to the B1 and B2 repeat domains of M1. Binding analysis revealed 
that both B1 and B2 peptides were able to bind lacto-N-tetraose (M1-B1: KD = 989 ± 153 
nM; M1-B2: KD = 1.49 ± 0.16 µM) and lacto-N-fucopentaose type I (M1-B1: KD = 30.3 ± 3.6 
nM; M1-B2: KD = 50.0 ± 1.7 nM) with varying affinity (Fig 6.6A-B). 
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Figure 6.3: M1 binding of blood group antigen related structures. M1 binding to (A) lacto-N-
tetraose (LNT; Galβ1-3GlcNAcβ1-3Galβ1-4Glc) and (B) lacto-N-fucopentaose type I (LNFP I; 
Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc) was determined via surface plasmon resonance and were 
modelled using steady state affinity fitting of the single cycle kinetic sensograms.  
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Figure 6.4: Competitive binding glycan array analysis. M1 binding to immobilised (A) lacto-N-
tetraose (LNT; Galβ1-3GlcNAcβ1-3Galβ1-4Glc), (B) lacto-N-fucopentaose type I (LNFP I; Fucα1-
2Galβ1-3GlcNAcβ1-3Galβ1-4Glc), (C) β1-4galactosyl-galactose (Galβ1-4Gal), and (D) α1-3-
mannobiose (Manα1-3Man) was assessed in the presence of varying  competing concentrations of 
LNT and LNFP I. Glycan binding was analysed using ProScanArray imaging software, ScanArray 
Express (PerkinElmer, USA) before data was exported to Microsoft Excel for further analysis. M1 
protein binding to a glycan was defined as a value > 1 fold increase above mean background RFU. 
The mean background was calculated from the average RFU of all empty spots on the array plus three 
standard deviations. Furthermore, statistical analysis of the data was performed by a Student’s t-test 
with a confidence level of 99.99% (p≤0.0001) and only glycans that met these criteria for three 
biologically independent samples (n = 12 glycans spot replicates) were interpreted as positive binding 
interactions. 
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Figure 6.5: Recombinant M1 fragment protein analysis. (A) SDS-PAGE analysis of M1 (lane 1), 
M1-AB (lane 2), M1-A92C1 (lane 3), M1-AC1 (lane 4), M1-BC1 (lane 5), M1-B (lane 6) and M1-C 
(lane 7). Proteins were electrophoresed under non-reducing conditions on a 12% SDS-PAGE gel. 
Molecular weight markers are shown on the left and are given in kilodaltons (kDA). (B) CD spectra 
of M1 fragment proteins. All M1 fragment proteins exhibited CD emission spectra characteristic of α-
helical coiled-coil proteins, displaying two minima at approximately 210 nm and 220 nm and a 
maximum peak at 190 nm. 
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Table 6.1: Summary glycan binding profile of recombinant M1 fragments. Interactions were 
analysed via SPR using single cycle kinetics fitted with a binding model of steady state affinity. *Nb, 
no binding.  
 
  Lacto-N-tetraose Lacto-N-fucopentaose type I 
M1 127.3 ± 26.2 µM 307.2 ± 168.9 nM 
M1-AB 21.3 ± 8.0 µM 238.3  ± 203.0 nM 
M1-A92C1 35.6 ± 9.7 µM 484.0 ± 127.4 nM 
M1-AC1 33.7 ± 22.9 µM 311.0 ± 223.1 nM 
M1-B 11.0 ± 4.4 µM 609.6 ± 176.2 nM 
M1-BC1 15.6 ± 11.5 µM 511.5 ± 84.2 nM 
M1-C Nb* Nb* 
 
 
To potentially refine a glycan binding motif within the B repeat domains of M1, the first 12 
amino acids of the B1 repeat domain (M1-B1 motif: LEKELEEKKEALHHHHHHHHHH), sharing 
92% sequence identity with B2 was constructed. Binding analysis via SPR demonstrated that 
the M1-B1 motif peptide exhibited binding to lacto-N-tetraose (KD = 3.8 ± 0.72 µM) and 
lacto-N-fucopentaose type I (KD = 81.5 ± 46.3 nM). To further validate the glycan binding 
function of the M1-B1 motif sequence, a negative control scrambled adaptation of the M1-B1 
motif sequence (M1-B1 motif
*
; KLLKEKEAELEEHHHHHHHHHH) was constructed. Binding 
analysis demonstrated that the M1-B1 motif
*
 was not able to recognise lacto-N-tetraose or 
lacto-N-fucopentaose type I. These data suggest the importance of this 12 amino acid 
sequence in the recognition of specific blood group related antigen structures (Fig. 6.6A-B). 
Secondary structure analysis via far UV CD showed that M1-B1, M1-B2, M1-B1 motif and 
M1-B1 motif
* 
peptides exhibited secondary structures consistent with a monomeric random 
coil (Ogawa et al. 2006) (Fig. 6.6C). Thus, binding of lacto-N-tetraose and lacto-N-
fucopentaose type I may not be dependent on the secondary coiled coil structure of M1, but 
instead dependant on the primary amino acid sequence of the B-repeat domain. Furthermore, 
the observed increase in binding affinity displayed by the M1-B repeat peptides for lacto-N-
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tetraose and lacto-N-fucopentaose type I may suggest that typical ‘core’ forming amino acids 
are able to interact with these respective glycan structures once exposed. 
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Figure 6.6: SPR analysis of M1 peptide glycan interactions. Binding analysis of M1 derived 
peptides M1-B1, M1-B2, M1-B1 motif, and M1-B1 motif scrambled were screened for binding 
against (A) lacto-N-tetraose (LNT; Galβ1-3GlcNAcβ1-3Galβ1-4Glc) and (B) lacto-N-fucopentaose 
type I (LNFP I; Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc). Binding was determined via surface 
plasmon resonance and were modelled using steady state affinity fitting of the single cycle kinetic 
sensograms. (C) CD spectra of M1 derived peptides. Peptides, M1-B1, M1-B2 and M1-B1 motif 
exhibited CD emission spectra consistent with that of a monomeric random coil (Ogawa et al. 2006). 
 
 
6.2.3 Functional characterisation of M1 mediated glycan interactions 
Pharyngitis is frequently attributed to a subset of M types including A-C3-5 clustered 
serotypes, M12, M3 and M1 (Walker et al. 2014). The oral mucosa and epithelium of 
pharyngeal tissue is a glycan rich environment expressing a vast multitude of O- and N-linked 
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carbohydrate structures (Ryan et al. 2001; Everest-Dass et al. 2012). To examine whether 
specific M1-dependant glycan interactions facilitate the association of M1 serotype 5448 to 
pharyngeal tissue, association assays were undertaken using Detroit 562 pharyngeal cells in 
the presence of exogenous lacto-N-tetraose and lacto-N-fucopentaose type I.  
Following pre-incubation with lacto-N-tetraose (900 µM), 5448 WT was shown to associate 
significantly more with Detroit-562 cells compared to the PBS control (P < 0.01). 
Association of 5448 WT with Detroit-562 cells was significantly attenuated in the absence of 
lacto-N-tetraose. No significant differences in pharyngeal epithelial cell association were 
observed by 5448ΔM1 when pre-incubated with either lacto-N-tetraose or PBS (Fig 6.7A). 
Furthermore, lacto-N-tetraose was shown to promote association of 5448 WT in a 
concentration dependant manner (Fig. 6.7B). M90, expressed on the surface of GAS strain 
NS730 was shown not to bind lacto-N-tetraose via glycan array analysis (see chapter 5). The 
ability of lacto-N-tetraose to mediate increased NS730 association to Detroit-562 cells was 
therefore assessed to confirm the specificity of the observed increase in M1 binding. No 
significant difference was observed in the association levels of NS730 to Detroit-562 in the 
presence and absence of lacto-N-tetraose (Fig 6.7C). Numerous studies support the existence 
of throat-tropic GAS isolates, restricted primarily to emm pattern A-C isolates (Bessen et al. 
2010; Walker et al. 2014). To investigate whether the interaction of M1 and lacto-N-tetraose 
plays a role in the association of GAS to other forms of host tissue, association assays 
examining the binding of 5448 to HaCaT keratinocyte cells were employed in the presence of 
lacto-N-tetraose. Pre-incubation with lacto-N-tetraose did not alter the binding of 5448 WT  
or 5448ΔM1 to HaCat cells (Fig. 6.7D). Due to the high affinity of M1 for lacto-N-
fucopentaose I, and the physiological significance of the blood group antigen, association of 
5448 WT to Detroit-562 cells was examined in the presence and absence of exogenous lacto-
N-fucopentaose type I. Upon pre-incubation of 5448 WT with 900 µM lacto-N-fucopentaose 
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type I, 5448 WT demonstrated a slight but non-significant increase in association to Detroit-
562 cells. Association of 5448ΔM1 exhibited no increase in the presence of lacto-N-
fucopentaose type I (Fig. 6.8).  
6.2.4 Glycosylation profiles of human buccal epithelial cells and their potential role in 
GAS colonisation 
Terminal glycan epitope A, B, and H antigen structures have previously been shown to be 
expressed in high abundance at the surface of buccal epithelial cells. These cells are part of 
the oral mucosal surface, and represent a physiologically relevant cell type for investigating 
GAS-host cell interaction (Everest-Dass et al. 2012). The current study demonstrates that 
GAS strain 5448 is able to bind a variety of blood group antigen structures (See above 6.2.1). 
Binding of M1 protein to A (type I and II; GalNAcα1-3(Fucα1-2)) and B (type I-IV; Galα1-
3(Fucα1-2)Gal) antigen trisaccharide was assessed using SPR via single cycle kinetics. 
Recombinant M1 was shown to bind both A and B trisaccharide structures with binding 
dissociation constants of 2.41 ± 1.14 µM and 527.5 ± 252.7 nM respectively (Fig. 6.9A & B). 
To assess the potential role of blood group antigen structures in upper respiratory tract 
colonisation by GAS, buccal epithelial cell and saliva samples from 20 individuals of 
unknown blood type and secretory status were collected. Blood group status and expression 
were assessed via LC-ESI MS analysis of donor saliva and differences in association of 
5448eGFP WT and 5448ΔM1eGFP to buccal cells from each donor were examined via flow 
cytometry.    
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Figure 6.7: Lacto-N-tetraose mediated GAS association to host tissue. (A) Association of 5448 
WT and 5448ΔM1 to Detroit-562 pharyngeal cells in the presence and absence of lacto-N-
tetraose. (B) Association of 5448 to Detroit-562 cells in the presence of varying concentration 
of lacto-N-tetraose. (C) Comparable association of 5448 WT and NS730 (M90) to Detroit-
562 cells in the presence and absence of lacto-N-tetraose. (D) Association of 5448 WT and 
5448ΔM1 to HaCaT keratinocyte cells in the presence and absence of lacto-N-tetraose. GAS 
strains 5448 WT, 5448ΔM1 and NS730 were pre-incubated with 900 µM lacto-N-tetraose 
(unless stated otherwise) for 30 min at room temp, washed and incubated with Detroit-562 or 
HaCaT cells for 2 h at 37˚C, 5 % CO2. Associated CFU was calculated against the initial 
inoculum.  
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Figure 6.8: Lacto-N-fucopentaose type I mediated GAS association to host tissue. Association 
of 5448 WT and 5448ΔM1 to Detroit-562 pharyngeal cells was measured in the presence and 
absence of lacto-N-fucopentaose type I. GAS strains 5448 WT and 5448ΔM1 were pre-
incubated with 900 µM lacto-N-fucopentaose type I for 30 min at room temp, washed and 
incubated with Detroit-562 cells for 2 h at 37˚C, 5 % CO2. Associated CFU was calculated 
against the initial inoculum. 
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Figure 6.9: M1 binding of blood group A and B antigen related structures. M1 binding to (A) 
blood group A trisaccharide (Atri; GalNAcα1-3(Fucα1-2)) and (B) blood group B trisaccharide (Btri; 
Galα1-3(Fucα1-2)Gal) was determined via SPR and were modelled using steady state affinity fitting 
of the single cycle kinetic sensorgrams. 
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LC-ESI MS analysis of released N- and O-linked glycans from salivary glycoproteins 
revealed that of the 20 subjects, only 2 were blood group antigen non-secretors. The 
remaining 18 donors were shown to express a range of A, B and H antigen structures. From 
the 18 samples which tested positive for blood group antigen expression, 8 expressed the A 
antigen, 5 expressed A and B antigens, 4 expressed lone H antigen structures and only 1 was 
shown to express the B antigen moiety. Fragmented ions generated in the negative-ion MS
2
 
fragmentation spectra were used for detailed structural analysis of several of the many blood 
group antigen determining structures. Signals at m/z 350, 553 and 2002.7 indicate the 
presence of core fucosylation in reduced glycan structures, typical of blood group antigen 
related glycans (Everest-Dass et al. 2012) (Appendix G).  
To explore the potential relationship between blood group antigen expression and GAS 
association to epithelial cells of the oral mucosa, human buccal epithelial cells were 
examined in the presence of GFP expressing 5448 WT and 5448ΔM1 via flow cytometry. 
Human buccal epithelial cells were identified by their characteristic forward and side scatter 
profile and a single gate was used to exclude debris and non-associated GAS (Everest-Dass et 
al. 2012). Observed human buccal epithelial cell auto-fluorescence was accounted for in the 
binding exhibited by 5448 WT and 5448ΔM1 (Fig 6.10A-C). Flow cytometry analysis 
demonstrated that 5448 WT was able to associate with buccal epithelial cells expressing H 
antigen structures at a significantly higher level than cells expressing A (P < 0.05) and AB (P 
< 0.01) antigen structures. As only 1 subject was shown to express the B antigen, no 
statistical inferences were able to be made (Fig. 6.11A). No statistical differences in 
5448ΔM1 association were observed between buccal epithelial cells expressing A, A and B, 
B or H antigens (Fig. 6.11B). 5448ΔM1 was able to associate with buccal cells at a 
significantly higher level that 5448 WT (P < 0.001) (Fig 6.11A-B). This is supports previous 
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findings that SpeB mediated cleavage of M1 protein from the GAS cell surface enhances 
binding of the bacterium to epithelial cells of the oral tract (Anderson et al. 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10: Flow cytometry assay of 5448 and 5448ΔM1 binding to human buccal epithelial 
cells. Dot plots at the top show the forward scatter (FSC-A) and the side scatter (SSC-A) distribution 
while the corresponding histograms of buccal epithelial cell count vs. fluorescence intensity at 515-
520 nm is shown below. (A) Auto-fluorescence of buccal epithelial cells alone. (B) 5448eGFP WT 
incubated with buccal epithelial cells. (C) 5448ΔM1eGFP incubated with buccal epithelial cells.    
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Figure 6.11: 5448 WT and 5448ΔM1 association to human buccal epithelial cells expressing 
different blood group antigen structures. Differences in association of 5448 WT (A) and 5448ΔM1 
(B) to human buccal epithelial cells expressing either A, B, A and B, or H blood group antigen 
structures. 
 
 
 
 
161 
 
6.3 Discussion 
Since the 1980’s, the increase in GAS disease has been paralleled by the emergence of the 
globally disseminated M1T1 clone (Johnson et al. 2002). Epidemiological studies have 
identified that M1 serotypes are frequently isolated from throat cultures, representing a 
common cause of pharyngitis (Kaplan et al. 2001). Previous research examining the role of 
M1 protein-glycan interactions in GAS disease have focused on a select range of ECM-
expressed GAG’s. In this study, we have characterised novel M1-dependant glycan 
interactions which may be involved in M1 serotype colonisation of the host upper-respiratory 
tract.  
Whole GAS cell glycan microarray analysis identified that GAS M1 serotype 5448 was able 
to bind 19 different glycan structures in an M1 dependant fashion. Differences in M1-glycan 
binding were noted between glycan microarray analysis using recombinant M1 protein and 
whole cell 5448. These variances in binding could be influenced by a series of factors 
including glycan presentation at the microarray epoxy surface along with M1 binding motif 
proximity to the presented glycans. M1 has been previously shown to be cleaved from the 
GAS cell surface via GAS secreted cysteine protease speB (Anderson et al. 2014). Cleavage 
of M1 from the cell surface may act to overcome restrictive factors encompassing glycan 
residue presentation required for binding. 
Blood group antigen structures have been shown to be expressed on a range of host cell and 
protein surfaces (De Leoz et al. 2012; Everest-Dass et al. 2012). Interestingly, M1 dependent 
5448 binding partners included blood group antigen precursor lacto-N-tetraose and lacto-N-
fucopentaose I (H type I antigen). Blood group A and B antigen structures were found to bind 
recombinant M1, 5448 and 5448ΔM1, suggesting that along with M1, another lectin with 
blood group antigen specificity may be present at the GAS cell surface. Competitive glycan 
microarray analysis identified that structurally related lacto-N-tetraose, blood group H-
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antigen type I and β1-4galactosyl-galactose share a homogenous binding domain whereby 
Galβ1-4Gal was the minimum carbohydrate residue required for recognition. Furthermore, 
binding by structurally distinct α1-3-mannobiose was also observed to be outcompeted by 
excess lacto-N-tetraose and blood group H-antigen type I, suggesting the existence of a broad 
range carbohydrate binding domain within M1. In the current study, lacto-N-tetraose and 
lacto-N-fucopentaose type I interactions were restricted to a 12 amino acid sequence 
(LEKELEEKKE/KAL) present at the start of both the B1 and B2 repeat domains of M1. The 
function of M1 is largely attributed to the ability of the protein to exchange between 
monomer and dimer states, a result of irregularities in B-repeat alpha-helicies (McNamara et 
al. 2008). This structurally distinct binding domain may represent a flexible region within M1 
which is able to recognise multiple carbohydrates that are distinct in structure.   
Fucosylation of lacto-N-tetraose, which results in blood group H-antigen type I was shown to 
significantly increase the affinity of M1 for lacto-N-tetraose. SPR analysis of blood group A 
and B trisaccharides which both contain α2-linked fucose residues demonstrated a 
significantly higher affinity for M1 than observed for precursor lacto-N-tetraose. Studies 
analysing the blood group recognition properties of rotavirus show that fucose moieties do 
not play a direct role in blood group antigen binding (Bohm et al. 2015). Alternatively, it has 
been hypothesised that fucose residues may play an indirect role by stabilising the blood 
group antigen via non-conventional hydrogen bonding, a reported binding property of Lewis
x
 
antigen by norovirus (Zierke et al. 2013). Although the lectin binding mechanisms of M1 are 
yet to be elucidated, we have established that fucose is not essential for recognition of blood 
group related structures, but instead mediates a higher affinity interaction with the B-repeats 
of M1 which may parallel the observed lectin properties of both rotavirus and norovirus 
(Zierke et al. 2013; Bohm et al. 2015).  
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M1 serotypes are typically isolated from the upper respiratory tract during the course of a 
pharyngeal infection (Kaplan et al. 2001). Examination of the M1-lacto-N-tetraose binding 
identified that exogenous lacto-N-tetraose and not lacto-N-fucopentaose type I, significantly 
promoted the association of M1 GAS serotype 5448 to Detroit-562 pharyngeal cells in a 
tissue specific manner. If already present at the Detroit-562 cell surface, it was expected that 
exogenous lacto-N-tetraose would abrogate binding to the eukaryotic cell surface. The 
observed differences in association may suggest that lacto-N-tetraose can act as a bridging 
molecule between M1 and a specific cell surface receptor. Alternatively, M1-bound lacto-N-
tetraose may be capable of homologously binding to various structurally related 
carbohydrates at the Detroit-562 cell surface. Homologous glycan-glycan interactions have 
been previously reported in marine eukaryotes, facilitating cell recognition and adhesion 
events (Bucior et al. 2004). As saliva is a source of lacto-N-tetraose related structures, the 
ability of lacto-N-tetraose to either act as a bridging molecule or mediate carbohydrate self-
recognition events both represent conceivable means of GAS interaction with pharyngeal 
tissue.  
To further examine the potential role of blood group antigen structures in GAS colonisation, 
buccal epithelial cells from 20 individuals of different blood group status were measured for 
binding against M1 serotype 5448 and 5448ΔM1. To our knowledge, this is the first study to 
investigate the potential link between GAS disease and host blood group status. The ability of 
5448 to associate at a significantly higher level to buccal epithelial cells expressing H antigen 
structures may underlie differences in individual susceptibility to GAS disease, particularly 
pharyngitis. Correlations between blood group status and disease susceptibility have been 
shown for H. pylori with blood group H expressing individuals more predisposed to infection 
and symptomatic gastrointestinal complication (Jaff 2011). Although differences in 
association of GAS to buccal epithelial cell donors was correlated with blood group antigen 
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status, potential contributing factors such as donor age, ethnicity, and gender must not be 
overlooked in prospective studies. Secretor status of individuals has been previously 
associated with disease susceptibility (Jaff 2010). Due to sample size constraints, no 
definitive trend or correlation was able to be determined between secretor and non-secretor 
donor samples in the current study. Future studies examining differences in secretor status in 
relation to GAS colonisation may aid in future therapeutics centred on anti-adhesives that act 
to mimic host glycan receptors.   
Globally disseminated M1T1 is a significant cause of GAS disease. Here, we have identified 
numerous novel M1 protein dependent glycan interactions while suggesting a role for lacto-
N-tetraose in GAS colonisation of the upper respiratory tract. Furthermore, we have for the 
first time, provided evidence to support a potential link between host blood group antigen 
expression and GAS disease status. This study exemplifies the diverse nature of lectin-glycan 
interactions as well as the complexity of GAS disease and highlights the need for further 
studies focused on GAS-glycan interaction.    
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7. Conclusions and Future Research 
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The capacity of S. pyogenes to cause a wide range of non-invasive and invasive diseases 
makes it responsible for some of the highest morbidity and mortality rates worldwide. It is 
currently estimated that invasive GAS disease and disease related to post infection sequelae 
account for over 500 000 deaths per year (Carapetis et al. 2005; WHO 2005). In urbanised 
Western populations, M-types associated with outbreaks are typically over represented by M1 
and M3 serotypes (Aziz et al. 2008). However, in regions such as the NT, Australia, the 
epidemiology of GAS infection is less defined, and is often linked to a variety of GAS 
serotypes (Stollerman 1997; McMillan et al. 2013). As M protein is still one of the most 
pursued GAS vaccine targets, there has been an increasing need to characterise diverse M 
proteins associated with GAS strains from regions which display the highest burden of 
infection. Mechanisms by which GAS initiate pathogenesis are yet to be fully understood, but 
it is thought that the interaction with host factors by M protein plays a pivotal role in 
triggering invasive disease. As such this study aimed to systematically characterise the 
function of a diverse sub-set of M proteins associated with invasive disease  
The diversity of circulating emm-types has made epidemiological and functional comparisons 
extremely complex to analyse, and has hindered the development of a global GAS vaccine. 
Recent studies have challenged the concept of M-type specific immunity, which underlies the 
development of current M protein based vaccine candidates (Smeesters et al. 2008; Smeesters 
et al. 2010; Baroux et al. 2014). Here, the development of a cluster classification system 
which correlates full length emm/M protein sequence with function was undertaken, 
providing a strong foundation for prospective GAS vaccine development. Our results 
demonstrate that the cluster system can serve as a functional classification system which can 
facilitate future M protein functional studies, epidemiological surveillance and vaccine 
development. The recent application of this emm-cluster classification system against a sub-
set of New Caledonia GAS isolates further exemplifies the value of the emm-cluster system 
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in analysing epidemiological trends and evaluating subsequent cross-protective vaccine 
strategies (Baroux et al. 2014).  
As previously stated, one of the most pursued antigens for a global GAS vaccine is the M 
protein. The binding of host plasma proteins plays an important role in M protein vaccine 
development. These interactions can greatly influence the efficacy of selected opsonic 
epitopes. In M-types such as M6, these binding interactions have been shown to inhibit 
binding of antibodies directed against the B- and C-repeat domains of the protein. 
Furthermore in the case of IgG binding M protein, M protein-directed antibodies may also 
recognise directed and non-directed epitopes. The ability of α-SV1 IgG to recognise a wide 
range of M-types was reduced in the presence of various host plasma proteins. However, 
none of the plasma proteins examined in this study were able to completely inhibit α-SV1 
IgG interaction with M protein. Similarly, the ability of M proteins to bind host plasma 
proteins was not fully blocked in the presence of α-SV1 IgG. The single exception to this 
finding was IgA binding by emm-cluster E1 M proteins, whereby IgA was found to inhibit α-
SV1 IgG binding. Although the data presented here highlights the biochemical capabilities of 
α-SV1 IgG in recognising a broad range of M-types, it is not an absolute reflection of the 
interactions which may occur in vivo. Expression of M protein at the GAS cell surface has 
been shown to vary in response to disease progression and host selective pressures (Anderson 
et al. 2014). Future studies which examine α-SV1 IgG directed GAS recognition in human 
plasma, taking into account the aforementioned factors will significantly strengthen the utility 
of SV1 as a global GAS vaccine candidate.  
The ability to bind host zymogen, plasminogen, was shown to be a restricted function of 
emm-cluster D4 M protein. The capacity of GAS to bind plasminogen has been previously 
shown to be central to multiple stages of pathogenesis (Sanderson-Smith et al. 2008; Ly et al. 
2014; Walker et al. 2014). Differences in the glycosylation profile between GI-plasminogen 
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and GII-plasminogen are known to contribute to conformational differences between both 
glycoforms, subsequently affecting the kinetic and activational properties of certain 
plasminogen receptors (Takada et al. 1983; Gonzalez-Grownow et al. 2002; Law et al. 2012). 
In the current study, D4 M protein representative, PAM was shown display significantly 
higher affinity for GII-plasminogen over GI-plasminogen when plasminogen was in the 
‘open’ conformation suggesting glycosylation at Asn289 in GI-plasminogen hinders 
interaction with PAM. The ability of PAM to bind plasminogen has been attributed to lysine 
dependant interactions with KR2 of plasminogen (Cnudde et al. 2006). Analysis of PAM 
binding interaction with GII-angiostatin in the presence of εACA confirmed the role of KR2 
LBS in PAM-GII-Plg binding interactions. In contrast, whole molecule binding analysis 
revealed that comparative concentrations of εACA were unable to inhibit the interaction of 
PAM with full length GI-plasminogen and GII-plasminogen. The findings presented here 
suggest either: 1) the presence of a non-LBS dependent PAM binding site outside of KR2 
which is more accessible in GII- plasminogen, or alternatively 2) a secondary higher-affinity 
LBS interaction in full-length plasminogen. Along with PAM, emm D-pattern GAS also 
express phenotypically distinct type-2b SK, which requires plasminogen ligands such as 
PAM to activate plasminogen (Cook et al. 2014). In the presence of PAM, type-2b SK was 
shown to generate an active site and activate GII-plasminogen at a significantly higher rate 
than GI-plasminogen. The accumulations of these findings clearly demonstrate the 
preferential acquisition and activation of GII-plasminogen over GI-plasminogen by PAM 
expressing GAS isolates. Additionally, these data highlight the impact of glycosylation on 
protein structure and function, representing a model for future research analysing the impact 
of glycan expression on host proteins known to be utilised in GAS pathogenesis.  
To date, the characterisation of direct glycan-GAS interaction has focused on M protein 
interaction with a small selection of host GAG’s. The development of the emm-cluster 
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classification system in conjunction with novel glycan array technology has enabled 
qualitative high throughput identification of novel M protein-glycan interactions, a large 
degree of which were shown to be emm-cluster specific. Glycan array analysis identified 
unique patters of binding function across each designated emm-cluster, further highlighting 
the utility of this novel cluster classification system based on full length M protein sequence. 
Although emm-clusters for the most part, demonstrated unique patters of binding, 
conservation in binding was observed across multiple emm-cluster groups, with multiple 
emm-clusters recognising similar terminal galactose, sialic acid, and GAG containing 
structures. The capacity of these emm-cluster groups to demonstrate conserved binding 
function suggests that these interactions may be important in mediating GAS disease. Future 
studies of the biochemical and physiological roles of these interactions may further contribute 
to our understanding of GAS pathogenesis which may subsequently aid in future therapeutic 
development. 
Recent findings suggest that glycan interaction is an important step in initiating bacterial 
pathogenesis (Day et al. 2009; Everest-Dass et al. 2012). Results presented here indicate the 
M1T1 clone 5448 interacts with 19 glycan structures in an M1 protein dependant manner. 
Binding site analysis identified the presence of a homogenous glycan binding domain 
localised to the flexible disordered α-helical B-repeats of M1 (McNamara et al. 2008). 
Globally disseminated M1 is commonly associated with infection of the upper respiratory 
tract, a region which expresses high levels of terminal galactose and related blood group 
antigen structures (Johnson et al. 1992; Kaplan et al. 2001; Everest-Dass et al. 2012). 
Interaction with blood group antigen precursor, lacto-N-tetraose was shown to significantly 
promote adherence to Detroit-562 pharyngeal cells in an M1 dependent manner. Furthermore 
expression of blood group H antigen at the surface of human buccal epithelial cells was 
shown to significantly increase association of GAS strain 5448 over cells expressing blood 
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group antigens A, A and B or B. Although preliminary, these findings suggest that blood 
group antigens and related structures may be involved in GAS colonisation. Prior population 
studies have identified that pharyngitis is highly prevalent in children aged 5-15 (Carapetis et 
al. 2005). To date, no investigation has analysed GAS infection in relation to phenotypic 
differences in blood group antigen expression. The results presented in this study provide a 
scope for future research into the quantitative assessment of blood antigen expression in 
adolescents with respect to GAS disease status. Prospective studies such as these may further 
aid our understanding pharyngitis with potential for therapeutic development.   
The results presented here clearly highlight the utility of the newly implemented GAS 
classification system. Furthermore, this study has identified novel M protein functions which 
may contribute to the different stages of GAS infection. Understanding the role of genetically 
diverse M protein in GAS pathogenesis has widespread implications for both the study and 
treatment of GAS disease.   
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Appendix A: Media and general buffer compositions 
Unless stated otherwise, all media and buffers were made up to volume with distilled H2O 
Media composition  
Luria-Bertani (LB) broth 
Tryptone   10 g/L 
Yeast extract   5 g/L  
NaCl    10 g/L  
 
LB agar 
 LB broth  
Agar    15 g/L  
 
Todd-Hewitt broth (THY) 
Todd-Hewitt   30 g/L 
Yeast extract   10 g/L 
 
THY agar (THYA) 
THY 
Agar    15g/L 
 
Buffer composition 
1 × Phosphate buffer saline (PBS) 
NaCl    8 g/L 
KCl    0.2 g/L 
Na2HPO4   1.44 g/L 
KH2PO4   0.24 g/L 
Make up to 800 mL volume with dH2O, adjust to pH 7.4 and expand to 1L with dH2O. 
 
 
1 × Dulbecco’s PBS 
NaCl    8 g/L 
KCl    0.2 g/L 
Na2HPO4   1.44 g/L 
KH2PO4   0.24 g/L 
CaCl2    99.88 mg/L 
MgCl2    46.65 mg/L 
 
1 × Tris-acetate-EDTA (TAE) buffer 
Tris base    4.84 g/L 
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Glacial acetic acid   1.14 ml/L  
EDTA    0.292 g/L  
 
TAE agarose gel 1% 
1 × TAE buffer   100 mL 
Agarose   1 g 
 
DNA loading buffer 
Bromophenol blue  5 mg/10 mL 
Glycerol   7.5 mL/10 mL 
Make up to 10 mL with TAE buffer 
 
Ethidium bromide staining solution 
Ethidium bromide  1 µg/100 mL 
 
5 × protein cracking buffer 
Tris-HCl (pH 6.8)  4.5 mL/ 10 mL 
Glycerol   5 mL/ 10 mL 
SDS    0.5 g/ 10 mL 
Bromophenol blue  5 mg/ 10 mL 
 
1 × SDS-PAGE running buffer 
Tris base   3.03 g/L 
Glycine    14.33 g/L 
SDS    1 g/L 
 
Coomassie blue rapid stain 
Coomassie blue R-250  2 g/L 
Methanol   400 mL 
Glacial acetic acid  100 mL 
Make up to 1 L with dH2O. 
 
Rapid destain 
Glacial acetic acid  100 mL 
Methanol   400 mL 
Make up to 1 L with dH2O. 
 
Western transfer buffer 
Glycine    14.4 g/L 
Tris base   3.02 g/L 
Methanol   200 m/L 
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Make up to 1 L with dH2O. 
 
Native cell lysis buffer 
Lysozyme    50 mg/50 ml 
DNase I    25 μg/50 ml 
PMSF     8.725 mg/ 50 ml 
MgCl2     476 μg/50 ml 
CaCl2     1.4 μg/50 ml 
Triton X-100    50 μl/50 ml 
NaCl     1.055 g/50 ml 
NaH2PO4    0.3 g/50 ml 
Imidazole    85 μg/50 ml 
 
Native wash buffer – nickel affinity chromatography 
PBS    1 L 
Imidazole   1.36 g/L 
 
Native elution buffer – nickel affinity chromatography  
NaCl    17.5 g/L 
NaH2PO4   6.9 g/L 
Imidazole   17 g/L 
 
Circular dichroism phosphate buffer 
Na2HPO4   0.336 g/L 
NaH2PO4   1.02 g/L 
 
BIAcore running buffer 
1× PBS    1 L 
EDTA    29.22 mg/L 
 
BIAcore regeneration solution 1 
Glycine-HCl (pH 1.5)  1.11 g/L   
 
BIAcore regeneration solution 2 
NaOH    2 g/L 
 
BIAcore regeneration solution 3 
HEPES   2.38 g/L 
EDTA   102.28 g/L 
NaCl   8.77 g/L 
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Appendix B: Primers used in this study 
 
Table B.1: List of primers used in this study 
Primer name Sequence(5’-3’) 
Sequencing  
M1noRE AGAAAATTAAAAACAGGTACGGCAT 
M2noRE TTACCATCAACAGGGGGAAACA  
  
Cloning/sequencing  
M4.2 pGEX2T F GGGGGATCCGCGGAGATTAAAAAGCCTCAG 
M4.2 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCGTTCTCTTTTGTTGCTTCAT 
M90 pGEX2T F GGGGGATCCGCGGAAGCGGTTAGTCGATCT 
M90 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCGTTCTCTTTTGTTGTGTCAT 
M106 pGEX2T F GGGGGATCCACTACGGGCTCCCAGAAACAG 
M106 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCGTTCTCTTTTGTTGCGTCAT 
M58 pGEX2T F GGGGGATCCGATTCTTCCAGAGAAGTAACC 
M58 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCGTTCTCTTTTGTTGTGTCAT 
M9.1 pGEX2T F GGGGGATCCGAAGGGGTTAAGAAGGCGGAA 
M9.1 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCGTTCTCTTTTGTTGCGTCAT 
M102 pGEX2T F GGGGGATCCGACAATCCGAGCTCTGTCCCT 
M102 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCGTTCTCTTTTGTTGTGTCAT 
M2 pGEX2T F GGGGGATCCAACAGTAAGAACCCTGTCCCT 
M2 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGTGTTCTCTTTTGTTGCGTCAT 
M85 pGEX2T F GGGGGATCCACTGAAGTTAAGGCTGCGGGG 
M85 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCTGTCTCTTAGTTTCCTTCAT 
M11 pGEX2T F GGGGGATCCACTGAAGTTAAGGCTGCGGGG 
M11 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCGTTCTCTTTTGTTGCGTCAT 
M65 pGEX2T F GGGGGATCCGATGGCCCCCAGAAAAGCGTT 
M65 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCTGTCTCTTAGTTTCCTTCAT 
M57 pGEX2T F GGGGGATCCAATGACGATATTACTTCGATG 
M57 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCTGTCTCTTAGTTTCCTTCAT 
M54 pGEX2T F GGGGGATCCGAAGTATTGACTAGGCGTCAG 
M54 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCTGTCTCTTAGTTTCCTTCAT 
M14 pGEX2T F GGGGGATCCAGAGTTAGTAGGTCTATGTCA 
M14 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCTGTCTCTTAGTTTCCTTCAT 
M70 pGEX2T F GGGGGATCCGAAGAGCATGAGAGCGTAACA 
M70 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCTGTCTCTTAGTTTCCTTCAT 
M53 pGEX2T F GGGGGATCCAATAGAGCAGACGACGCTAGA 
M53 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCTGTCTCTTAGTTTCCTTCAT 
M98 pGEX2T F GGGGGATCCGATAGATATACCGATGCTCAC 
M98 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCTGTCTCTTAGTTTCCTTCAT 
M1 pGEX2T F GGGGGATCCAACGGTGATGGTAATCCTAGG 
M1 pGEX2T R GGGGAATTCTCAGTGATGGTGATGGTGATGCTGTCTCTTAGTTTCCTTCAT 
M1 A-B pET-28b(+) F GGGCCATGGTTAACGGTGATGGTAATCCTAGG 
M1 A-B pET-28b(+) R GGGCTCGAGTTCTAACTCTTTTTCTAAGAC 
M1 A-C1 pET-28b(+) F GGGCCATGGTTAACGGTGATGGTAATCCTAGG 
M1 A-C1 pET-28b(+) R GGGCTCGAGTAAATCTTTTTCAACCTGTTT 
M1 A92-C1 pET-28b(+) F GGGCCATGGTTGAAGAACTTGAAAAAGCAAAA 
M1 A92-C1 pET-28b(+) R GGGCTCGAGTAAATCTTTTTCAACCTGTTT 
M1 B pET-28b(+) F GGGCCATGGTTTGGGATAGACAAAGACTTGAA 
M1 B pET-28b(+) R GGGCTCGAGTAAATCTTTTTCAACCTGTTT 
M1 B-C1 pET-28b(+) F GGGCCATGGTTTGGGATAGACAAAGACTTGA 
M1 B-C1 pET-28b(+) R GGGCTCGAGTTCTAACTCTTTTTCTAAGAC 
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Appendix C:  emm gene accession numbers and 
classification 
 
Table C.1:  emm genes used for phylogenetic analysis in this study along with respective 
accession numbers.  
M-type 
M-type (old 
nomenclature) 
emm 
pattern 
emm-cluster Locus Accession number 
1 1 A-C A-C3 JX028599 
2 2 E E4 KC978826 
3 3 A-C A-C5 KC978816 
4 4 E E1 KC978806 
5 5 A-C Single protein emm-cluster clade Y  KC978827 
6 6 A-C Single protein emm-cluster clade Y  KC978835 
8 8 E E4 KC978796 
9 9 E E3 KC978828 
11 11 E E6 KC978833 
12 12 A-C A-C4 KC978829 
13 13 E E2 JX028611 
14 14 A-C Single protein emm-cluster clade Y JX028612 
15 15 E E3  KC978775 
17 17 A-C Single protein emm-cluster clade Y  JX028614 
18 18 A-C Single protein emm-cluster clade Y  KC978771 
19 19 A-C Single protein emm-cluster clade Y  KC978837 
22 22 E E4  KC978795 
23 23 A-C Single protein emm-cluster clade Y JX028618 
24 24 A-C Single protein emm-cluster clade Y  JX028619 
25 25 E E3  JX028620 
26 26 A-C Single protein emm-cluster clade Y  JX028621 
27 27 E E2  JX028622  
28 28 E E4  KC978790 
29 29 A-C Single protein emm-cluster clade Y  KC978834 
30 30 A-C A-C2  KC978842 
31 31 nd A-C5  KC978840 
32 32 D D2 JX028627 
33 33 D D4  JX028628 
34 34 D E5 JX472406   
36 36 D D1 JX028629 
37 37 A-C Single protein emm-cluster clade Y  JX028630  
38 38/40 A-C Single protein emm-cluster clade Y  JX028631 
39 39 A-C A-C4  JX028632 
41 41 D D4  KC978805 
42 42 D E6  KC978792 
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43 43 D D4 KC978807 
44 44/61 E E3  KC978823 
46 46 A-C A-C1  JX028637  
47 47 A-C Single protein emm-cluster clade Y  JX028638  
48 48 E E6  KC978808 
49 49 E E3  KC978809 
50 50/62 E E2  JX028641 
51 51 A-C E5  JX028642  
52 52 D D4  JX028643 
53 53 D D4  KC978810 
54 54 D D1  JX028645 
55 55 A-C Single protein emm-cluster clade Y  KC978839 
56 56 D D4 JX028647  
56.2 st3850 D D4 JX028745 
57 57 A-C Single protein emm-cluster clade Y  JX028648 
58 58 E E3  KC978785 
59 59 D E6  KC978836 
60 60 E E1  KC978811 
63 63 E E6  KC978812 
64 64 D D4  KC978830 
65 65/69 D E6  KC978788 
66 66 E E2  KC978813 
67 67 D E6  KC978803 
68 68 E E2  KC978841 
70 70 D D4  JX028658 
71 71 D D2  KC978780 
72 72 D D4  JX028660 
73 73 E E4  KC978814 
74 74 D Single protein emm-cluster clade Y  KC978815 
75 75 E E6 KC978786 
76 76 E E2  KC978772 
77 77 E E4  KC978787 
78 78 E E1  KC978838 
79 79 E E3  JX028667 
80 80 D D4  JX028668  
81 81 D E6  KC978783 
82 82 E E3  KC978794 
83 83 D D4  KC978817 
84 84 E E4  JX028672 
85 85 D E6  JX028673  
86 86 D D4  JX028674  
87 87 E E3  KC978818 
88 88 E E4  JX028676 
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89 89 E E4  KC978831 
90 90 E E2  JX028678  
91 91 D D4  JX028679 
92 92 E E2  KC978819 
93 93 D D4  KC978804 
94 94 E E6  KC978832 
95 95 D Single protein emm-cluster clade Y  KC978820 
96 96 E E2  JX028684  
97 97 D D5  KC978797 
98 98 D D4  KC978821 
99 99 D E6  JX028687  
100 100 D D2  JX028688 
101 101 D D4  KC978798 
102 102 E E4  KC978781 
103 103 E E3  KC978799 
104 104 E E2  JX028692  
105 105 D Single protein emm-cluster clade Y  KC978800 
106 106 E E2  KC978801 
107 107 E E3  JX028695  
108 108 D D4  KC978793 
109 109 E E4 JX028697 
110 110 E E2 KC978779 
111 111 D Single protein emm-cluster clade Y  JX028699 
112 112 E E4 KC978773 
113 113 E E3  JX028701 
114 114 E E4  KC978791 
115 115 D D2  JX028703 
116 116 D D4  KC978774 
117 117 E E2  JX028705 
118 118 E E3  KC978822 
119 119 D D4 JX028707 
120 120 D D4  JX028708  
121 121 D D4  JX028709 
122 122 D Single protein emm-cluster clade Y  KC978784 
123 123 D D3  KC978777 
124 124 E E4  JX028712 
133 st1692 nd A-C5  JX028730  
134 st2105 D E5  JX028734 
137 st465 A-C E5  JX028723  
139 st7323 A-C E6  JX028750 
140 st7395 D Single protein emm-cluster clade Y  JX028751 
142 st818 A-C A-C1  JX028726  
144 stknb1 E E3 JX028763 
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157 stn165 A-C D5 JX028765 
158 stxh1 D E6  JX028772 
163 st412 A-C A-C3  JX028722 
164 st106M E Single protein emm-cluster clade X JX028716 
165 st11014 E E1  KC978789 
166 st1207 E E2  JX028728  
168 st1389 E E2  JX028729  
169 st1731 E E4  JX028731 
170 st1815 REA E5  KC978824 
172 st2037 D E6  JX028733  
174 st211 REA E5  JX028717  
175 st212 E E4  JX028718  
176 st213 E E1  JX028719 
177 st2147 E E6  JX028735  
178 st22 nd D4  JX028713 
179 st221 D Single protein emm-cluster clade Y  JX028720  
180 st2460 E E3 KC978778 
182 st2861UK D E6  JX028737  
183 st2904 E E3  KC978825 
184 st2911 D D5  JX028739  
185 st2917 D Single protein emm-cluster clade X JX028740 
186 st2940 D D4  KC978782 
191 st369 D E6  JX028721 
192 st3757 D D4  JX028743  
193 st3765 A-C A-C4  JX028744 
194 st38 D D4  JX028714 
197 st4119 A-C A-C2  JX028746 
205 st5282 D E5  JX028747   
207 st6030 D D1  KC978776 
208 st62 D D4  JX028715 
209 st6735 E E3  JX028749  
211 st7406 E Single protein emm-cluster clade X JX028752 
213 st7700 D D2  JX028753 
215 st804 E Single protein emm-cluster clade Y  JX028724  
217 st809 D D3  JX028725  
218 st854 D Single protein emm-cluster clade Y  JX028727   
219 st9505 nd E3  JX028754 
221 stck249 D Single protein emm-cluster clade Y  JX028756 
222 stck401 A-C Single protein emm-cluster clade Y  JX028757  
223 std432 D D4  JX028758 
224 std631 D D4 JX028759 
225 std633 D D4  KC978802 
227 stil103 nd A-C3  JX028762 
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228 stil62 A-C A-C4  JX028761 
229 stmd216 A-C A-C4  JX028764 
230 stns1033 D D4  JX028769 
231 stns292 E E3  JX028767 
232 stns554 E E4  JX028768 
233 stns90 A-C Single protein emm-cluster clade Y  JX028766 
234 stpa57 nd Single protein emm-cluster clade Y  JX028770 
236 sts104 E Single protein emm-cluster clade X  JX028771 
238 1.2 A-C A-C3 JX028600 
239 1.4 A-C A-C3 JX028601 
242 st2926 D D4  JX028741  
 
REA, rearranged emm pattern (atypical amplification patterns). ND, not determined. 
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Appendix D: Vector construction and protein purification 
 
Primer pairs used for all PCR reactions listed here are given in parentheses, and sequences 
are given in Appendix B. 
 
 
 
 
 
 
 
 
 
 
 
Figure D.1: Exemplar construction of emm-pGEX2T via ligation independent cloning. (A) PCR 
amplification of emm 85 gene (i) using M85 pGEX2T F and M85 pGEX2T R primers. (B) Agarose 
gel showing EcoRI/BamHI digested (i) and non-digested (ii) pGEX2T. (C) Representative agarose gel 
showing plasmid extraction of pGEX2T vector (i) and emm85 positive tranformant (ii). PCR 
amplification of emm85 gene from emm85 pGEX2T positive tranformant using M85 pGEX2T F and 
M85 pGEX2T R primers. Molecular size markers are from Hyperladder I (Bioline, Australia), with 
sizes indicated in base pairs. 
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Figure D.2: Exemplar construction of emm1 fragment-pET-28b(+) via ligation independent 
cloning. (A) Agarose gel showing non-digested (i) and XhoI/NcoI enzyme digested (ii) pET-28b(+) 
along with PCR amplified A and B repeat coding sequence from emm1. (B) PCR amplification of 
emm1 A-B fragment gene from emm1 AB pET-28b(+) positive transformant. (C) Due to the low 
molecular weight of emm1 A-B, restricition enzyme digestion of emm1 AB pET-28b(+) was 
undertaken via XhoI/NcoI restriction enzyme digestion. PCR amplification was achived using M1 A-
B pET-28b(+) F and M1 A-B pET-28b(+) R primers. Molecular size markers are from Hyperladder I 
(Bioline, Australia), with sizes indicated in base pairs. 
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Figure D.3: Exemplar M protein expression and purification. (A) Glutathione sepharose 
chromatography showing representative expression and purification of the pGEX2T-emm 58 vector in 
Top10 E. coli with uninduced crude lysate (i) and culture induced with 0.1 mM IPTG for 2 h (ii) and 
4 h (iii). Bacterial suspensions were pelleted and lysed in 50 mL lysis buffer and were incubated with 
glutathione sepharose resin for 30 min at 4˚C with end over end rotation, with pre-purification (iv) 
and post-purification (v) samples taken. M protein was released from the glutathione sepharose resin 
upon incubation with 100 U human thrombin and eluted with 1 × PBS (vi). (B) To facilitate the 
separation of human thrombin and M protein, samples were added in batch to 2 mL 50 % Nickel-
NTA resin, incubated for 1 h at 4˚C with end over end rotation. After incubation, wash samples (i) 
and elution fractions (ii-iv) were collected. Results are shown from a 12% SDS-PAGE gel, Molecular 
weight markers are from Unstained Pageruler with weights indicated in kilo-Daltons.  
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Figure D.4: Exemplar M1 fragment protein expression and purification. (A) Representative 
expression and purification of the pET-28b(+)-emm1 A-B vector in BL21(DE3) E. coli with 
uninduced crude lysate (i) and culture induced with 1 mM IPTG for 4 h (ii). (B) Bacterial suspensions 
were pelleted and lysed in 50 mL lysis buffer and batch incubated with 2 mL nickel-NTA resin for 1 h 
at 4˚C with end over end rotation with pre-purification (i) and post purification (ii) samples taken. 
Elutions of bound M1 A-B fragment were collected (iii-v). Results are shown from a 10% SDS-
PAGE gel, Molecular weight markers are from Unstained Pageruler with weights indicated in kilo-
Daltons.  
 
 
 
 
 
 
 
 
 
A B 
50 
40 
30 
25 
20 
15 
10 
50 
40 
30 
25 
20 
15 
10 
i ii iv iii ii i v 
197 
 
Appendix E: M protein sequence analysis and binding 
affinity constants 
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Figure E.1: Alignment 26 translated M protein amino acid sequences. M protein sequences were 
trimmed from the first codon/amino acid of the mature protein to the first codon/amino acid of the D 
repeat domain adjacent the LPXTG motif. Representational graphs highlighting the sequence identity 
between all M proteins are given at the beginning of each figure section. A, B and C repeat domains 
are indicated in blue. Characterised M protein IgA, IgG, plasminogen, fibrinogen, and albumin 
binding motifs are annotated within respective sequences. M54 amino acid sequences were only 
included once as M protein sequences from GAS strains NS178 and TVU5 are identical. Sequence 
alignment was undertaken with Geneious 6.0 using a MUSCLE alignment with default settings. 
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Table E.1: Binding raw data pertaining to the phylogenetic classification of full length M 
protein. Interactions were analysed by non-linear fitting of the single cycle kinetic sensograms 
according to a 1:1 Langmuir binding model using Biacore T200 evaluation software (Biacore AB). 
GAS 
strain 
emm-
type 
emm 
pattern 
Major 
Clade 
emm-
cluster 
Plg  
(KD) 
IgA  
(KD) 
IgG 
(KD) 
Fg. 
(KD) 
Alb. 
(KD) 
C4BP 
(KD) 
           
PRS20 60 E X E1 NB 
0.84 
± 0.04 nM 
20.07 
± 9.70 nM 
NB 
6.62 
± 0.14 nM 
7.09 
± 3.75 pM 
NS226 4.2 E X E1 NB 
5.36 
± 0.20 nM 
12.95 
± 0.45 nM 
NB 
4.18 
± 0.12 nM 
9.81 
± 4.76 pM 
NS730 90 E X E2 NB NB 
10.96 
± 1.29 nM 
NB 
7.54 
± 0.45 nM 
NB 
NS192 106 E X E2 NB NB 
18.54 
± 0.53 nM 
NB 
9.33 
± 0.85 nM 
NB 
PRS18 58 E X E3 NB NB 
5.75 
± 0.22 nM 
NB 
8.76 
± 0.59 nM 
5.93 
± 2.40 pM 
PRS55 9 E X E3 NB NB 
4.17 
± 0.66 nM 
NB 
5.93 
± 0.21nM 
4.70 
± 1.59 pM 
NS179 9.1 E X E3 NB NB 
6.45 
± 0.95 nM 
NB 
6.45 
± 0.25 nM 
5.18 
± 1.10 pM 
PRS66 102 E X E4 NB NB 
82.69 
± 13.87nM 
NB NB NB 
PRS2 2 E X E4 NB NB 
29.76 
± 7.33 nM 
NB NB 
45.42 
± 8.62 pM 
NS8 85 D X E6 NB 
1.73 
± 0.78 nM 
2.06 
± 0.11 nM 
NB 
3.89 
± 0.16 nM 
6.99 
± 1.22 pM 
NS414 11 E X E6 NB 
1.77 
± 0.09 nM 
10.44 
± 0.78 nM 
NB 
18.14 
± 0.51 nM 
119.93 
± 23.13 pM 
NS931 65 D X E6 NB NB 
4.51 
± 0.18 nM 
NB 
6.38 
± 0.01 nM 
5.10 
± 1.28 pM 
PRS15 48 E X E6 NB 
0.66 
± 0.02 nM 
3.11 
± 0.08 nM 
NB 
11.67 
± 0.22 nM 
7.21 
± 1.70 pM 
NS1140 57 A-C Y1 M57 NB NB 
7.18 
± 0.17 nM 
0.10 
± 0.01 nM 
4.68 
± 0.23 nM 
NB 
NS178 54 
A-C 
and D 
Y1 D1 NB NB NB 
0.11 
± 0.02 nM 
2.24 
± 0.16 nM 
NB 
TVU5 54 
A-C 
and D 
Y1 D1 NB NB NB 
0.09 
± 0.01 nM 
4.74 
± 0.14 nM 
NB 
PRS9 19 A-C Y1 M19 NB NB NB 
0.64 
± 0.04 nM 
3.02 
± 0.15 nM 
NB 
NS501 14 A-C Y1 M14 NB NB 
18.64 
± 0.69 nM 
0.45 
± 0.07 nM 
2.17 
± 0.03 nM 
NB 
NS80 70 D Y2 D4 
3.06 
± 0.37 nM 
NB NB NB 
4.43 
± 1.08 nM 
NB 
PRS30 83 D Y2 D4 
1.66 
± 0.31 nM 
NB NB NB 
5.94 
±0.15 nM 
NB 
NS13 53 D Y2 D4 
2.19 
± 0.73 nM 
NB NB NB NB NB 
NS88.2 98 D Y2 D4 
1.33 
± 0.32 nM 
NB NB NB NB NB 
88/30 97 D Y2 D5 NB NB NB 
0.45 
± 0.06 nM 
4.82 
± 0.06 nM 
NB 
NS696 1 A-C Y2 AC3 NB NB 
5.53 
±0.13nM 
0.15 
± 0.03 nM 
4.36 
± 0.43 nM 
NB 
PRS8 12 A-C Y2 AC4 NB NB NB 
0.20 
± 0.01 nM 
2.77 
± 0.09 nM 
NB 
M3 3 A-C Y2 AC5 NB NB NB 
0.20 
± 0.08 nM 
2.86 
± 0.05 nM 
NB 
 
NB: Non-binder. Plg.; Fg.; and Alb.; stands for plasminogen, fibrinogen and albumin respectively. No 
difference in binding phenotype was observed between two different isolates from both M9 (PRS55 
and NS179) and M54 (NS178 and TVU5). 
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Table E.2:  α-SV1 competitive binding affinity data. Competitive binding analysis between M 
protein and α-SV1 IgG was assessed using host proteins plasminogen, fibrinogen, albumin, IgG and 
IgA. Interactions were analysed by non-linear fitting of the single cycle kinetic sensograms according 
to a 1:1 Langmuir binding model using Biacore T200 evaluation software (Biacore AB). 
GAS 
strain 
emm-type emm 
cluster 
α-SV1        
(KD - nM) 
Host protein - 
α-SV1   (KD - 
nM) 
α-SV1 – 
Host protein 
(KD - nM) 
Host protein  
(KD - nM) 
 
IgA 
PRS20 M60 E1 142.3 ± 29.8 n.b. * 0.35 ± 0.05 0.84 ± 0.04 
NS226 M4.2 E1 129.4 ± 2.80 n.b. * 0.90 ± 0.02 5.36 ± 0.20 
NS8 M85 E6  36.27 ± 9.85  48.76 ± 4.44 2.22 ± 0.27  1.73 ± 0.78 
NS414 M11 E6 45.74 ± 0.27 34.52 ± 10.73 1.41 ± 0.07 1.77 ± 0.09 
PRS15 M48 E6 14.76 ± 1.20 18.65 ± 3.09 0.56 ± 0.03 0.66 ± 0.02 
        
IgG 
PRS20 M60 E1 60.14 ± 6.55 50.86 ± 5.29 33.35 ± 9.29 20.07 ± 9.70  
NS226 M4.2 E1 56.12 ± 5.99 56.60 ± 10.51 24.6 ± 1.32 12.95 ± 0.45 
PRS18 M58 E3 8.62 ± 1.02 10.29 ± 0.95 6.64 ± 0.54 5.75 ± 0.22 
PRS55 M9 E3 14.54 ± 2.04 26.79 ± 6.50 6.29 ± 0.43 4.17 ± 0.66 
NS179 M9.1 E3 49.63 ± 4.25 31.15 ± 5.85 8.45 ± 1.02 6.45 ± 0.95 
PRS66 M102 E4 34.62 ± 2.52 71.18 ± 1.31 69.35 ± 2.99 82.69 ± 13.87 
PRS2  M2 E4 14.84 ± 0.49 29.52 ± 2.32 21.81 ± 4.64 29.67 ± 7.33 
NS8 M85 E6 6.82 ± 0.51 51.24 ± 33.47 9.22 ± 2.66 2.06 ± 0.11 
NS414 M11 E6 45.74 ± 0.27 36.88 ± 15.28 75.45 ± 16.40 10.44 ± 0.78 
NS931 M65 E6 10.78 ± 0.85 22.62 ± 13.24 9.14 ± 0.44 4.51 ± 0.18 
PRS15 M48 E6 14.76 ± 1.20 61.64 ± 13.10 102.63 ± 
39.81 
3.11 ± 0.08 
NS1140 M57 M57 61.65 ± 1.35 64.81 ± 5.52 9.21 ± 1.24 7.18 ± 0.17 
NS501 M14 M14 86.04 ± 7.27 59.85 ± 20.39 49.71 ± 14.32 18.64 ± 0.69 
NS696 M1 A-C3 10.24 ± 1.07 39.62 ± 3.20 8.04 ± 1.60 5.53 ± 0.13 
       
Plasminogen 
NS13 M53 D4 28.59 ± 3.91 31.23 ± 2.35 39.29 ± 5.61 26.43 ± 2.62 
NS88.2 M98 D4 96.12 ± 5.88 83.18 ± 13.29 11.10 ± 3.72 15.61 ± 2.10 
PRS30 M83 D4 102.22 ± 6.38 91.84 ± 6.32 24.10 ± 3.51 22.90 ± 3.14 
NS80 M70 D4 108.75 ± 3.65 106.95 ± 3.15 17.00 ± 1.97 15.35 ± 1.84 
       
Fibrinogen 
NS1140 M57 M57 61.65 ± 1.35 112.85 ± 2.65 0.06 ± 0.01 0.10 ± 0.01  
NS178 M54 D1 87.13 ± 6.14 76.58 ± 3.95 0.25 ± 0.04 0.11 ± 0.02 
TVU5 M54 D1 84.54 ± 7.42 88.86 ± 4.86 0.09 ± 0.01 0.12 ± 0.03 
PRS9 M19 M19 74.86 ± 3.87 92.29 ± 6.43 0.64 ± 0.04 0.64 ± 0.04 
NS501 M14 M14 86.04 ± 7.27 129.15 ± 3.60 0.28 ± 0.02 0.45 ± 0.07 
88/30 M97 D5 61.20 ± 5.93 64.84 ± 3.15 0.13 ± 0.01 0.45 ± 0.06 
NS696 M1 A-C3 10.24 ± 1.07 10.87 ± 0.50  0.61 ± 0.05 0.15 ± 0.03 
PRS8 M12 A-C4 98.78 ± 4.13 105.23 ± 8.45 1.50 ± 0.18 0.20 ± 0.01 
SSI-1 M3 A-C5 97.87 ± 3.45 116.35 ± 6.55 0.17 ± 0.03 0.20 ± 0.08 
       
Albumin 
PRS20 M60 E1 60.14 ± 6.55 60.68 ± 6.81 3.97 ± 0.09 6.62 ± 0.14 
NS226 M4.2 E1 56.12 ± 5.99 50.7 ± 2.05 10.79 ± 3.06 4.18 ± 0.12 
NS730 M90 E2 45.94 ± 5.94 64.12 ± 5.38 8.36 ± 2.14 7.54 ± 0.45 
NS192 M106 E2 57.81 ± 9.99 71.36 ± 7.66 17.98 ± 1.15 9.33 ± 0.85  
PRS18 M58 E3 8.62 ± 1.02 9.10 ± 1.30 4.70 ± 0.26 8.76 ± 0.59 
PRS55 M9 E3 14.54 ± 2.04 26.92 ± 1.60 7.31 ± 0.36  5.93 ± 0.21 
NS179 M9.1 E3 13.46 ± 0.80 28.38 ± 1.66 9.15 ± 0.27 6.45 ± 0.25 
NS8 M85 E6 6.82 ± 0.51 32.24 ± 1.97 70.25 ± 2.85 3.89 ± 0.16 
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NS414 M11 E6 45.74 ± 0.27 34.09 ± 2.81 13.99 ± 1.37 18.14 ± 0.51 
NS931 M65 E6 10.78 ± 0.85 9.42 ± 0.72 4.78 ± 0.10 6.38 ± 0.01 
PRS15 M48 E6 14.76 ± 1.20 12.18 ± 0.47 4.45 ± 0.17 11.67 ± 0.22 
NS1140 M57 M57 61.65 ± 1.35 58.56 ± 4.86 4.85 ± 2.19 4.68 ± 0.23 
NS178 M54 D1 87.13 ± 6.14 89.45 ± 10.31 2.63 ± 0.11 2.24 ± 0.16 
TVU5 M54 D1 60.48 ± 3.90 58.68 ± 2.91 3.89 ± 0.32 4.74 ± 0.14 
PRS9 M19 M19 74.86 ± 3.87 68.34 ± 5.78 1.32 ± 0.14 3.02 ± 0.15 
NS501 M14 M14 86.04 ± 7.27 98.76 ± 10.09 1.37 ± 0.07 2.17 ± 0.03 
NS80 M70 D4 108.75 ± 3.65 103.56 ± 5.02 4.25 ± 0.18 4.43 ± 1.08  
PRS30 M83 D4 102.22 ± 6.38 158 ± 26.36 4.49 ± 0.16 5.94 ± 0.15 
88/30 M97 D5 61.20 ± 5.93 73.34 ± 3.69 3.54 ± 0.14 4.82 ± 0.06 
NS696 M1 A-C3 10.24 ± 1.07 13.69 ±  0.85 3.87 ± 1.21 4.36 ± 0.43 
PRS8 M12 A-C4 98.78 ± 4.13   73.25 ± 7.20 1.69 ± 0.10 2.77 ± 0.09 
SSI-1 M3 A-C5 97.87 ± 3.45 80.02 ± 4.70 2.82 ± 0.07 2.86 ± 0.05 
 
NB: Non-binder. No difference in binding phenotype was observed between two different isolates 
from both M9 (PRS55 and NS179) and M54 (NS178 and TVU5). 
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Appendix F: PAM – GI- GII-plasminogen interactions 
 
Table F.1: Summary of PAM – GI- GII-plasminogen binding affinities  
Analyte/condition KD (nM) 
  
GI-Plg 37.0 ± 6.6 
GI-Plg+ 5 mM ε 33.2 ± 4.4 
GI-Plg + 100 mM εACA Nb
* 
GI-Plg + 5 mM BZ 20.0 ± 6.3 
GI-Plg + 5 mM BZ/εACA 54.5 ± 12.2 
GII-Plg 27.4 ± 1.6 
GII-Plg + 5 mM εACA 2.8 ± 0.6 
GII-Plg + 100 mM εACA 16.7 ± 7.0 
GII-Plg + 400 mM εACA 94.1 ± 4.7 
GII-Plg + 5 mM BZ 20.8 ± 1.6 
GII-Plg + 5 mM BZ/εACA 2.2 ± 0.1 
GI-Plg – GII-Plg Nb
*
 
GII-Plg – GI-Plg Nb
*
 
GI-Plg – GII-Plg + 5 mM εACA 5.1 ± 1.9 
GII-Plg – GI-Plg + 5 mM εACA Nb
*
 
Lys-Plg 0.44 ± 0.1 
Lys-Plg + 10 mM εACA 3.8 ± 0.1 
GII-Plg KR1-3 14.6 ± 1.6 
GII-Plg KR1-3 + 0.5 mM εACA 28.2 ± 2.1 
GII-Plg KR1-3 + 1 mM εACA 101.8 ± 9.6 
GII-Plg KR1-3 + 5 mM εACA Nb
*
 
 
NB: Non-binder; binding fit could not be determined. 
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Appendix G: M protein-glycan array analysis  
 
Glycan structures present on the glycan array are given in table G.1 
From the 26 M proteins expressed in study, 20 were chosen for glycan microarray analysis 
representing 20 different M-types from 11 major cluster groups. Positive binding was 
determined when binding fluorescence was above the mean background fluorescence 
(defined as greater than one fold increase of the mean background plus 3 standard 
deviations). Statistical analysis of the data was performed by a Student’s t-test with a 
confidence level of 99.99% (p ≤ 0.0001) and only glycans that met these criteria for three 
biologically independent samples (n = 12 glycans spot replicates) were interpreted as positive 
binding interactions (Fig. G1-20). 
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Table G.1: Glycan structures present on the array 
  
Index Name Structure 
 Terminal Galactose  
1 α-Galactose Galα 
2 β-Galactose Galβ 
3 Galα1-2Galβ Galα1-2Galβ 
4 B
di
 Galα1-3Galβ 
5 Tαβ Galα1-3GalNAcβ 
6 Tαα Galα1-3GalNAcα 
7 - Galα1-3GlcNAcβ 
8 α-LacNAc Galα1-4GlcNAcβ 
9 Melibiose Galα1-6Glcβ 
10 B
di
 Galβ1-2Galβ 
11 Le
c
 Galβ1-3GlcNaAcβ 
12 - Galβ1-3Galβ 
13 Tββ Galβ1-3GalNAcβ 
14 TF Galβ1-3GalNAcα 
15 Lac Galβ1-4Glcβ 
16 Fs-2 GalNAcα1-3GalNAcβ 
17 Adi GalNAcα1-3Galβ 
18 core 5 GalNAcα1-3GalNAcα 
19 LacdiNAc GalNAcβ1-4GlcNAcβ 
20 Ab2aLN Galβ1-2Galα1-4GlcNAcβ 
21 Ab3`LN Galβ1-3Galβ1-4GlcNAcβ 
22 LN3Tn Galβ1-4GlcNAcβ1-3GalNAcα 
23 LN6Tn Galβ1-4GlcNAcβ1-6GalNAcα 
24 GA2, GgOse3 GalNAcβ1-4Galβ1-4Glcβ 
25 Tbb-A Galβ1-3GalNAcβ1-3Gal 
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26 Ab4`LN Galβ1-4Galβ1-4GlcNAc 
27 Galili (tetra) Galα1-3Galβ1-4GlcNAcβ1-3Galβ 
28 - Galα1-4GlcNAcβ1-3Galβ1-4GlcNAcβ 
29 - Galβ1-3GlcNAcβ1-3Galβ1-3GlcNAcβ 
30 - Galβ1-3GlcNAcα1-3Galβ1-4GlcNAcβ 
31 - Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ 
32 - Galβ1-3GlcNAcα1-6Galβ1-4GlcNAcβ 
33 - Galβ1-3GlcNAcβ1-6Galβ1-4GlcNAcβ 
34 Asialo-GM1 Galβ1-3GalNAcβ1-4Galβ1-4Glcβ 
35 LN2 Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ 
36 - Galβ1-4GlcNAcβ1-6Galβ1-4GlcNAcβ 
37 H (type IV) Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAcα 
38 Gb4, P GalNacβ1-3GalαGalβ1-4Glcβ 
39 Le
c
3Le
c
 Galβ1-3GlcNAcβ1-3Galβ1-3GlcNAcβ 
40 Galili (penta) Galα1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ 
41 - Galβ1-4GlcNAcβ1-6(Galβ1-4GlcNAcβ1-3)GalNAcα 
42 - Galβ1-4GlcNAcβ1-3(GlcNAcβ1-6)Galβ1-4GlcNAcβ 
43 - Galβ1-4GlcNAcβ1-6(GlcNAcβ1-3)Galβ1-4GlcNAcβ 
44 (LN)3 (Galβ1-4GlcNAcβ1-3)3 
45 - 
Galβ1-4GlcNAcβ1-6(Galβ1-4GlcNAcβ1-3)Galβ1-
4GlcNAc 
46 Gb5 Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ 
47 Lacto-N-Biose I Galβ1-3GlcNAc 
48 N-Acetyllactosamine Galβ1-4GlcNAc 
49 β1-4galactosyl-galactose Galβ1-4Gal 
50 β1-6galactosyl-N-acetylglucosamine Galβ1-6GlcNAc 
51 β1-3galactosyl-N-acetylgalactosamine Galβ1-3GlcNAc 
52 Galb1-3GalNAcβ1-4Galβ1-4Glc  
53 Lacto-N-tetraose Galβ1-3GlcNAcβ1-3Galβ1-4Glc 
54 Lacto-N-neotetraose Galβ1-4GlcNAcβ1-3Galβ1-4Glc 
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55 Lacto-N-neohexaose Galβ1-4GlcNAcβ1-6(Galβ1-4GlcNAcβ1-3)Galβ1-4Glc 
56 Lacto-N-hexaose Galβ1-4GlcNAcβ1-6(Galβ1-3GlcNAcβ1-3)Galβ1-4Glc 
57 Globotriose Galα1-4Galβ1-4Glc 
58 Tn Antigen GalNAcα1-O-Ser 
59 Galactosyl-Tn Antigen Galβ1-3GalNAcα1-O-Ser 
60 α1-3 Galactobiose Galα1-3Gal 
61 Linear B-2 Trisaccharide Galα1-3Galβ1-4GlcNAc 
62 Linear B-6 Trisaccharide Galα1-3Galβ1-4Glc 
63 α1-3, β1-4, α1-3 Galactotetraose Galα1-3Galβ1-4Galα1-3Gal 
64 β1-6Galactobiose Galβ1-6Gal 
65 Terminal disaccharide of globotriose GalNAcβ1-3Gal 
66 Receptor for pili of P. aeruginosa GalNAcβ1-4Gal 
67 P1 Antigen Galα1-4Galβ1-4GlcNAc 
68 
α-D-N-acetylgalactosaminyl-1-3Gal-β1-
4Glc 
GalNAcα1-3Galβ1-4Glc 
69 iso-Lacto-N-octaose 
Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ1-6(Galβ1-
3GlcNAcβ1-3)Galβ1-4Glc 
 Terminal glucose structures  
70 α-Glc Glcα 
71 β-Glc Glcβ 
72 β-GlcN(Gc) GlcN(Gc)β 
73 aminoglucitol HOCH2(HOCH)4CH2NH2 
74 α-glucoronic acid GlcAα 
75 β-glucoronic acid GlcAβ 
76 maltose Glcα1-4Glcβ 
77 cellobiose Glcβ1-4Glcβ 
78 gentiobiose Glcβ1-6Glcβ 
79 GUb3GN GlcAβ1-3GlcNAcβ 
80 GUb3A GlcAβ1-3Galβ 
81 GUb6A GlcAβ1-6Galβ 
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82 maltotriose (Glcα1-4)3β 
83 isomaltotriose (Glcα1-6)3β 
84 maltotetraose (Glcα1-4)4β 
85 isomaltotetraose (Glcα1-6)4β 
86 isomaltopentaose (Glcα1-6)5β 
87 maltohexaose (Glcα1-6)6β 
 Terminal N`Acetyl glucosamine  
88 N-Acetyl-D-glucosamine α GalNAcα 
89 N-Acetyl-D-glucosamine β GlcNAcβ 
90 core 3 GlcNAcβ1-3GalNAcα 
91 chitobiose GlcNAcβ1-4GlcNAcβ 
92 core 6 GlcNAcβ1-6GalNAcα 
93 GlcNAc-Mur GlcNAcβ1-4-[HOOC(CH3)CH]-3-O-GlcNAcβ 
94 GMDP-Lys 
GlcNAcβ1-[HOOC(CH3)CH]-3-O-GlcNAcβ-L-alanyl-
D-i-glutaminyl-L-lysine 
95 GN2`TF GlcNAcβ1-2Galβ1-3GalNAcα 
96 GN3`TF GlcNAcβ1-3Galβ1-3GalNAcα 
97 GN3`Lac GlcNAcβ1-3Galβ1-4Glcβ 
98 GN3`LN GlcNAcβ1-3Galβ1-4GlcNAcβ 
99 GN4`LN GlcNAcβ1-4Galβ1-4GlcNAcβ 
100 GN6`LN GlcNAcβ1-6Galβ1-4GlcNAcβ 
101 core 2 GlcNAcβ1-6(Galβ1-3)GalNAcα 
102 Core 4 GlcNAcβ1-6(GlcNAcβ1-3)GalNAcα 
103 Tk GlcNAcβ1-6(GlcNAcβ1-3)Galβ1-4GlcNAcβ 
104 chitopentaose (GlcNAcβ1-4)5β 
105 chitohexaose (GlcNAcβ1-4)6β 
106 N,N'-Diacetyl chitobiose GlcNAcβ1-4GlcNAc 
107 N,N',N''-Triacetyl chitotriose GlcNAcβ1-4GlcNAcβ1-4GlcNAc 
108 N,N',N'',N'''-Tetraacetyl chitotetraose GlcNAcβ1-4GlcNAcβ1-4GlcNAcβ1-4GlcNAc 
109 
N,N',N'',N''',N'''',N'''''-Hexaacetyl GlcNAcβ1-4GlcNAcβ1-4GlcNAcβ1-4GlcNAcβ1-
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chitohexaose 4GlcNAcβ1-4GlcNAc 
110 Bacterial cell wall muramyl disaccharide GlcNAcβ1-4MurNAc 
 Mannose containing structures  
111 Manα-sp3 Manα 
112 Manβ-sp4 Manβ 
113 ManNAcβ-sp4 ManNAcβ 
114 α-Man6P 6-H2PO3Manα 
115 GN3M GlcNAcβ1-3Manβ 
116 Mb4GN Manβ1-4GlcNAcβ 
117 β1-2-N-Acetylglucosamine-mannose GlcNAcβ1-2Man 
118 Bianntennary N-linked core pentasaccharide GlcNAcβ1-2Manα1-6(GlcNAcβ1-2Manα1-3)Man 
119 α1-2-Mannobiose Manα1-2Man 
120 α1-3-Mannobiose Manα1-3Man 
121 α1-4-Mannobiose Manα1-4Man 
122 α1-6-Mannobiose Manα1-6Man 
123 α1-3, a1-6-Mannobiose Manα1-6(Manα1-3)Man 
124 α1-3, α1-3, α1-6-Mannopentaose Manα1-6(Manα1-3)Manα1-6(Manα1-3)Man 
 Fucosylated structures  
125 L-α-Fuc Fucα 
126 Fa3GN Fucα1-3GlcNAcβ 
127 LeC Fucα1-4GlcNAcβ 
128 H (type 2) Fucα1-2Galβ1-4GlcNAcβ 
129 H (type 3) Fucα1-2Galβ1-3GalNAcα 
130 H (type 6) Fucα1-2Galβ1-4Glcβ 
131 Btri Galα1-3(Fucα1-2)Galβ 
132 B (type I) Galα1-3(Fucα1-2)Galβ1-3GlcNAcβ 
133 B (type II) Galα1-3(Fucα1-2)Galβ1-4GlcNAcβ 
134 B (type III) Galα1-3(Fucα1-2)Galβ1-3GalNAcα 
135 B (type IV) Galα1-3(Fucα1-2)Galβ1-3GalNAcβ 
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136 αGalLe
x
 Galα1-3Galβ1-4(Fucα1-3)GlcNAcβ 
137 A (type 1) GalNAcα1-3(Fucα1-2)Galβ1-3GlcNAcβ 
138 A (type 2) GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ 
139 A (type 3) GalNAcα1-6(Fucα1-2)Galβ1-3GalNAcα 
140 H (type1) penta Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ 
141 BLe
Y
 Galα1-3( Galβ1-4)Fucα1-2(Fucα1-3) GlcNAcβ 
142 Le
b
-Lac Fucα1-4(Fucα1-2Galβ1-3)GlcNAcβ1-3Galβ1-4Glcβ 
143 Le
y
-Lac Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ 
144 MFLNH III Le
x
1-6'(Le
c
1-3')Lac 
145 MFLNH I LacNAc1-6'(Le
d
1-3')Lac 
146 MSMFLNnH Le
x
1-6'(6'SLN1-3')Lac 
147 DFLNH (a) Le
x
1-6'(Le
d
1-3')Lac 
148 MF(1-3)iLNO Le
c
Le
x
1-6'(Le
c
1-3')Lac 
149 TFLNH Le
x
1-6'(Le
b
1-3')Lac 
150 Lacto-N-fucopentaose I Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc 
151 Lacto-N-fucopentaose II Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc 
152 Lacto-N-fucopentaose III Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc 
153 Lacto-N-difucohexaose I Fucα1-2Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc 
154 Lacto-N-difucohexaose II Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc 
155 H-disaccharide Fucα1-2Gal 
156 2'-Fucosyllactose Fucα1-2Galβ1-4Glc 
157 3'-Fucosyllactose Galβ1-4(Fucα1-3)Glc 
158 Lewis
x
 Galβ1-4(Fucα1-3)GlcNAc 
159 Lewis
a
 Galβ1-3(Fucα1-4)GlcNAc 
160 Blood Group A-trisaccharide GalNAcα1-3(Fucα1-2)Gal 
161 Lactodifucotetraose Fucα1-2Galβ1-4(Fucα1-3)Glc 
162 Blood Group B-Trisaccharide Galβ1-3(Fucα1-2)Gal 
163 Lewis
y
 Fucα1-2Galβ1-4(Fucα1-3)GlcNAc 
164 Blood Group H Type II Trisaccharide Fucα1-2Galβ1-3GlcNAc 
165 Lewis
b
 tetrasaccharide Fucα1-2Galβ1-3(Fucα1-4)GlcNAc 
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166 Sulpho Lewis
a
 SO3-3Galβ1-3(Fucα1-4)GlcNAc 
167 Sulpho Lewis
x
 SO3-3Galβ1-4(Fucα1-3)GlcNAc 
168 Monofucosyl-para-Lacto-N-hexaose IV 
Galβ1-3GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-
3Galβ1-4Glc 
169 Monofucosyllacto-N-hexaose III 
Galβ1-4(Fucα1-3)GlcNAcβ1-6(Galβ1-3GlcNAcβ1-
3)Galβ1-4Glc 
170 Difucosyllacto-N-hexaose 
Galβ1-4(Fucα1-3)GlcNAcβ1-6(Fucα1-2Galβ1-
3GlcNAcβ1-3)Galβ1-4Glc 
171 Trifucosyllacto-N-hexaose 
Galβ1-4(Fucα1-3)GlcNAcβ1-6(Fucα1-2Galβ1-
3(Fucα1-4)GlcNAcβ1-3)Galβ1-4Glc 
 Neu5Ac containing structures  
172 Sia Neu5Acα 
173 Sia-Bn Neu5Acα 
174 aNeuGc Neu5Gcα 
175 9NAcSia 9-NAc-Neu5Acα 
176 GM4 Neu5Acα2-3Galβ 
177 Sia6A Neu5Acα2-6Galβ 
178 3-SiaTn Neu5Acα2-3GalNAcα 
179 SiaTn Neu5Acα2-6GalNAcα 
180 Neu5GCTn Neu5Gcα2-6GalNAcα 
181 (Sia)2 Neu5Acα2-8Neu5Acα2 
182 6SiaANb Neu5Acα2-6GalNAcβ 
183 Neu5Gc3A Neu5Gcα2-3Gal 
184 6-SiaTF Neu5Acα2-6(Galα1-3)GalNAcα 
185 A3a(Sia)Tn Neu5Acα2-6(Galβ1-3)GalNAcα 
186 3`-Sia-TF Neu5Acα2-3Galβ1-3GalNAcα 
187 3`-SiaLe
c
 Neu5Acα2-3Galβ1-3GlcNAcβ 
188 3`SLN(Gc) Neu5Gcα2-3Galβ1-4GlcNAcβ 
189 6`SLN(Gc) Neu5Gcα2-6Galβ1-4GlcNAcβ 
190 9NAc-6`SLN 9-NAc-Neu5Acα2-6Galβ1-4GlcNAcβ 
191 3`SLN6Su Neu5Acα2-3Galβ1-4-(6-O-Su)GlcNAcβ 
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192 3`SiaTF6Su Neu5Acα2-3Galβ1-3-(6-O-Su)GalNAcβ 
193 6`SLN6Su Neu5Acα2-6Galβ1-4-(6-O-Su)GlcNAcβ 
194 3`SLN6`Su Neu5Acα2-3-(6-O-Su)Galβ1-4GlcNAcβ 
195 (Sia)3 (Neu5Acα2-8)3 
196 6`SiaLeC Neu5Acα2-6Galβ1-3GlcNAc 
197 6`SiaLeC6Su Neu5Acα2-6Galβ1-3(6-O-Su)GlcNAc 
198 3`SiaLeC(GC) Neu5Gcα2-3Galβ1-3GlcNAcβ 
199 GM2 GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ 
200 3`SLNb3A Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ 
201 SiaLeX6Su Neu5Acα2-3Galβ1-4(Fucα1-3)6-O-Su-GlcNAcβ 
202 SiaLeX6`Su Neu5Acα2-3(6-O-Su)Galβ1-4(Fucα1-3)GlcNAcβ 
203 Sia2-3`,6TF Neu5Acα2-6(Neu5Acα2-3Galβ1-3)GalNAcα 
204 GC3 Neu5Acα2-8Neu5Acα2-3Galβ1-4Glcβ 
205 3`SLN-LacNAc Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ 
206 SiaLe
x
-3Gal Neu5Acα2-3 Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ 
207 LSTb Neu5Acα2-6(Galβ1-3)GlcNAcβ1-3Galβ1-4Glcβ 
208 GD2 GalNAcβ1-4(Neu5Acα2-8Neu5Acα2-3)Galβ1-4Glc 
209 GT3 Neu5Acα2-8Neu5Acα2-8Neu5Acα2-3Galβ1-4Glc 
210 GT2 GalNAcβ1-4(Neu5Acα2-8)2Neu5Acα2-3Galβ1-4Glc 
211 6`SLN-LacNAc Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ 
212 LSTa Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ 
213 Sialyl Lewis
a
 Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAc 
214 Sialyl Lewis
x
 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAc 
215 Sialyllacto-N-tetraose a Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-4Glc 
216 
Monosialyl, monofucosyllacto-N-
neohexaose 
Galβ1-4(Fucα1-3)GlcNAcβ1-6(Neu5Acα2-6Galβ1-
4GlcNAcβ1-3)Galb1-4Glc 
217 - Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAc 
218 - Neu5Acα2-6Galβ1-3GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc 
219 2,3'-Sialyllactosamine Neu5Acα2-3Galβ1-4GlcNAc 
220 2,6'-Sialyllactosamine Neu5Acα2-6Galβ1-4GlcNAc 
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221 LS-Tetrasaccharide a Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-4Glc 
222 LS-Tetrasaccharide b Galβ1-3(Neu5Acα2-6)GlcNAcβ1-3Galβ1-4Glc 
223 LS-Tetrasaccharide c Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4Glc 
224 Disialyllacto-N-tetraose 
Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GlcNAcβ1-3Galβ1-
4Glc 
225 2,3'-Sialyllactose Neu5Acα2-3Galβ1-4Glc 
226 2,6'-Sialyllactose Neu5Acα2-6Galβ1-4Glc 
227 Colominic acid (Neu5Acα2-8Neu5Ac)n (n<50) 
228 Biantennary 2,6-sialylated-N-glycan-Asn 
Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6(Neu5Acα2-
6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-
4GlcNAc-Asn 
 Sulphate containing glycans  
229 3-O-Su-Galβ-sp3 3-O-Su-Galβ 
230 3-O-Su-GalNAcα-sp3 3-O-Su-GalNAcα 
231 6-O-Su-GlcNAcβ-sp3 6-O-Su-GlcNAcβ 
232 GN3Su 3-O-Su-GlcNAcβ 
233 LeC6Su Galβ1-3(6-O-Su)GlcNAcβ 
234 Lac6Su Galβ1-4(6-O-Su)Glcβ 
235 LN6Su Galβ1-4(6-O-Su)GlcNAcβ 
236 Ch2-6Su GlcNAcβ1-4(6-O-Su)GlcNAcβ 
237 TF3`Su 3-O-Su-Galβ1-3GalNAcα 
238 TF6`Su 6-O-Su-Galβ1-3GalNAc 
239 Lac3`Su 3-O-Su-Galβ1-4Glcβ 
240 Lac6`Su 6-O-Su-Galβ1-4Glcβ 
241 LeC3`Su 3-O-Su-Galβ1-3GlcNAcβ 
242 LN3`Su 3-O-Su-Galβ1-4GlcNAcβ 
243 LN4`Su 4-O-Su-Galβ1-4GlcNAcβ 
244 LeC6`Su 6-O-Su-Galβ1-3GlcNAcβ 
245 LN6`Su 6-O-Su-Galβ1-4GlcNAcβ 
246 Lac3`,6Su2 3-O-Su-Galβ1-4(6-O-Su)Glcβ 
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247 LN3`6Su2 3-O-Su-Galβ1-4(6-O-Su)GlcNAcβ 
248 Lac6,6`Su2 6-O-Su-Galβ1-4(6-O-Su)Glcβ 
249 LeC6,6`Su2 6-O-Su-Galβ1-3(6-O-Su)GlcNAcβ 
250 LN66`Su2 6-O-Su-Galβ1-4(6-O-Su)GlcNAcβ 
251 LN3`4`Su2 3,4-O-Su2-Galβ1-4GlcNAcβ 
252 LN3`6`Su2 3,6-O-Su2-Galβ1-4GlcNAcβ 
253 LN4`6`Su2 4,6-O-Su2-Galβ1-4GlcNAcβ 
254 LN4`6`Su2-C3 4,6-O-Su2-Galβ1-4GlcNAcβ 
255 LN3`66`Su3 3,6-O-Su2-Galβ1-4(6-O-Su)GlcNAcβ 
256 LacdiNAc6Su GalNAcβ1-4(6-O-Su)GlcNAcβ 
257 LacdiNAc3`Su 3-O-Su-GalNAcβ1-4GlcNAcβ 
258 LacdiNAc6`Su 6-O-Su-GalNAcβ1-4GlcNAcβ 
259 3Ac-LacdiNAc6`Su 6-O-Su-GalNAcβ1-4-(3-O-Su)GlcNAcβ 
260 LacdiNAc3,3`Su2 3-O-Su-GalNAcβ1-4(3-O-Su)-GlcNAcβ 
261 LacdiNAc3`,6`Su2 3,6-O-Su2-GalNAcβ1-4GlcNAcβ 
262 LacdiNAc4`,6`Su2 4,6-O-Su2-GalNAcβ1-4GlcNAcβ 
263 3Ac-LacdiNAc4`,6`Su2 4,6-O-Su2-GalNAcβ1-4-(3-O-Ac)GlcNAcβ 
264 LacdiNAc4`Su 4-O-Su-GalNAcβ1-4GlcNAcβ 
265 LacdiNAc3`,4`Su2 3,4-O-Su2-Galβ1-4GlcNAcβ 
266 LacdiNAc6,6`Su2 6-O-Su-GalNAcβ1-4(6-O-Su)GlcNAcβ 
267 LN6Su Galβ1-4(6-O-Su)GlcNAcβ 
268 LacdiNAc4`Su-C2 4-O-Su-GalNAcβ1-4GlcNAcβ 
269 (3`SuLN)3`LN 3-O-SuGalβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ 
270 (4`SuLN)3`LN 4-O-SuGalβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ 
 Carrageenan and Glycosaminoglycans  
271 hyaluronic acid (GlcAβ1-4GlcNAcβ1-3)8-NH2-ol 
272 11-OS, YDS (Sia2-6A-GN-M)2-3,6-M-GN-GNβ 
273 Neocarratetraose-41, 3-di-O-sulphate (Na
+
) 
C24H36O25S2Na2 (Mixed anomers. Tetrasaccharide of 
regular κ - carrageenan) 
274 Neocarratetraose-41-O-sulphate (Na
+
) 
C24H37O22SNa (Mixed anomers. Derived from C1003 
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by removal of  the non-reducing terminal 4-sulphate) 
275 
Neocarrahexaose-24,41, 3, 5-tetra-O-
sulphate (Na
+
) 
C36H52O40S4Na4 (Mixed anomers. A hybrid sequence 
comprising carrageenan disaccharides in the order κ -i- 
κ, derived from the carrageenan from Chondrus crispus) 
276 
Neocarrahexaose-41, 3, 5-tri-O-sulphate 
(Na
+
) 
C36H53O37S3Na3 (Mixed anomers. Hexasaccharide of 
regular κ -carrageenan) 
277 
Neocarraoctaose-41, 3, 5, 7-tetra-O-sulphate 
(Na
+
) 
C48H70O49S4Na4 (Mixed anomers. Octasaccharide of 
regular κ -carrageenan) 
278 
Neocarradecaose-41, 3, 5, 7, 9-penta-O-
sulphate (Na
+
) 
C60H87O61S5Na5 (Mixed anomers. Decasaccharide of 
regular κ - carrageenan) 
279 ΔUA-2S  GlcNS-6S Na4 (I-S) 
C12H15NO19S3Na4 (Predominant disaccharide  produced 
from heparin by heparinase I and II) 
280 ΔUA  GlucNS-6S Na3 (II-S) 
C12H16NO16S2Na3 (Produced from heparinase II 
digestion of heparin and heparin sulphate) 
281 ΔUA  2S-GlcNS Na3 (III-S) 
C12H16NO16S2Na3 (Produced from heparin by digestion 
with heparinase I and II) 
282 ΔUA  2S-GlcNAc-6S Na3 (I-A) 
C14H18NO17S2Na3 (Minor component produced from 
heparin by heparinase II) 
283 ΔUA  GlcNAc-6S Na2 (II-A) 
C14H19NO14SNa2 (Product of the action of  heparinases 
II and III on heparin and heparan sulphate) 
284 ΔUA  2S-GlcNAc Na2 (III-A) 
C14H19NO14SNa2 (Minor product of the action of 
heparinase II on heparin) 
285 ΔUA  GlcNAc Na (IV-A) 
C14H20NO11Na (Produced from heparin sulphate by 
digestion With heparinase III) 
286 ΔUA  GalNAc-4S Na2 (Δ Di-4S) 
C14H19NO14SNa2 (Produced from various chondroitin 
sulphates By the action of chondroitinases ABC, B and 
AC-1) 
287 ΔUA  GalNAc-6S Na2 (Δ Di-6S) 
C14H19NO14SNa2 (Produced from various 
chondroitin sulphates By the action of chondroitinases 
ABC, AC-1 and C) 
288 ΔUA  GalNAc-4S,6S Na3 (Δ Di-disE) 
C14H18NO17S2Na3 (Produced from various chondroitin 
sulphates By the action of chondroitinases ABC, B and 
AC-1) 
289 ΔUA  2S-GalNAc-4S Na2 (Δ Di-disB) 
C14H18NO17S2Na3 (Produced from various chondroitin 
sulphates by action of chondroitinase ABC and/or B. 
Most typically from chondroitin sulphate B  (dermatan 
sulphate) 
290 ΔUA  2S-GalNAc-6S Na3 (Δ Di-disD) 
C14H18NO17S2Na3 (Produced from various chondroitin 
sulphates by the action of chondroitinase ABC) 
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291 ΔUA  2S-GalNAc-4S-6S Na4 (Δ Di-tisS) 
C14H17NO20S3Na4 (Produced as a minor component by 
the action of chondroitinase ABC on various 
chondroitin sulphates, particularly B) 
292 ΔUA  2S-GalNAc-6S Na2  (ΔDi-UA2S) 
C14H19NO14SNa2 (Produced as a minor component from 
various chondroitin sulphates by the action of 
chondroitinase ABC) 
293 ΔUA  GlcNAc Na (Δ Di-HA) 
C14H20NO11Na (The only unsaturated disaccharide 
produced from hyaluronic acid by the action of 
chondroitinase ABC or AC-1) 
294 Hyaluronan fragments (4mer) (GlcAβ1-3GlcNAcβ1-4)n (n=4) 
295 Hyaluronan fragments (8mer) (GlcAβ1-3GlcNAcβ1-4)n (n=8) 
296 Hyaluronan fragments (10mer) (GlcAβ1-3GlcNAcβ1-4)n (n=10) 
297 Hyaluronan fragments (12mer) (GlcAβ1-3GlcNAcβ1-4)n (n=12) 
298 Heparin (GlcA/IdoAα/β1-4GlcNAcα1-4)n (n=200) 
299 Chondroitin sulfate (GlcA/IdoAβ1-3(±4/6S)GalNAcβ1-4)n (n<250) 
300 Dermatan sulfate ((±2S)GlcA/IdoAα/b1-3(±4S)GalNAcβ1-4)n (n<250) 
301 Chondroitin 6-Sulfate (GlcA/IdoAβ1-3(±6S)GalNAcβ1-4)n (n<250) 
302 HA-4 (10mM) (GlcAβ1-3GlcNAcβ1-4)n (n=4) 
303 HA-6 (10mM) (GlcAβ1-3GlcNAcβ1-4)n (n=6) 
304 HA-8 (9.7mM) (GlcAβ1-3GlcNAcβ1-4)n (n=8) 
305 HA-10 (7.83mM) (GlcAβ1-3GlcNAcβ1-4)n (n=10) 
306 HA-12 (6.5mM) (GlcAβ1-3GlcNAcβ1-4)n (n=12) 
307 HA-14 (5.6mM) (GlcAβ1-3GlcNAcβ1-4)n (n=14) 
308 HA-16 (4.9mM) (GlcAβ1-3GlcNAcβ1-4)n (n=16) 
309 HA-30,000da 2.5mg/ml (GlcAβ1-3GlcNAc β1-4)n 
310 HA-107,000da 2.5mg/ml (GlcAβ1-3GlcNAc β1-4)n 
311 HA-190,000da 2.5mg/ml (GlcAβ1-3GlcNAc β1-4)n 
312 HA-220,000da 2.5mg/ml (GlcAβ1-3GlcNAc β1-4)n 
313 HA-1,600,000da 2.5mg/ml (GlcAβ1-3GlcNAc β1-4)n 
314 Heparin Sulfate 5mg/ml (GlcA/IdoAα/ IdoASα/β1-
4GlcNAc/GlcNS/GlcNAc6Sα1-4)n 
315 Beta-1-3Glucan (Glcβ1-3Glcβ1-3)n 
 Non-categorised glycans  
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316 Rhamnose 
Rhaα 
317 G6P 6-H2PO3Glcβ 
318 9-OS (A-GN-M)2-3,6-M-GN-GNβ 
319 7-OS (GN-M)2-3,6-M-GN-GNβ 
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Figure G.1: M60 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures.   
D 
C A 
E F 
G I H 
B 
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Figure G.2:  M90 binding glycan profileof (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
E F 
G I H 
B 
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Figure G.3: M106 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
E F 
G I 
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Figure G.4: M58 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
E F 
G I H 
B 
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Figure G.5: M9 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
E F 
G I H 
B 
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Figure G.6: M102 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
E F 
G I H 
B 
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Figure G.7: M2 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
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E F 
G I H 
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Figure G.8:  M11 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
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G I H 
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Figure G.9:  M65 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
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Figure G.10: M57 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
E F 
G I H 
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Figure G.11: M54 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
E F 
G I H 
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Figure G.12: M14 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
E F 
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Figure G.13: M19 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
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B 
234 
 
1 2 3 4 5 6 7 8 9
1
0
1
1
1
2
1
3
1
4
1
5
1
6
1
7
1
8
1
9
2
0
2
1
2
2
2
3
2
4
2
5
2
6
2
7
2
8
2
9
3
0
3
1
3
2
3
3
3
4
3
5
3
6
3
7
3
8
3
9
4
0
4
1
4
2
4
3
4
4
4
5
4
6
4
7
4
8
4
9
5
0
5
1
5
2
5
3
5
4
5
5
5
6
5
7
5
8
5
9
6
0
6
1
6
2
6
3
6
4
6
5
6
6
6
7
6
8
6
9
0
1
2
3
4
5
Glycan Index number
F
o
ld
 F
lu
o
re
s
c
e
n
e
 I
n
c
re
a
s
e
 A
b
o
v
e
 B
a
c
k
g
ro
u
n
d
7
0
7
1
7
2
7
3
7
4
7
5
7
6
7
7
7
8
7
9
8
0
8
1
8
2
8
3
8
4
8
5
8
6
8
7
0
1
2
3
4
Glycan Index number
F
o
ld
 F
lu
o
re
s
c
e
n
e
 I
n
c
re
a
s
e
 A
b
o
v
e
 B
a
c
k
g
ro
u
n
d
8
8
8
9
9
0
9
1
9
2
9
3
9
4
9
5
9
6
9
7
9
8
9
9
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
5
1
0
6
1
0
7
1
0
8
1
0
9
1
1
0
0
1
2
3
4
Glycan Index number
F
o
ld
 F
lu
o
re
s
c
e
n
e
 I
n
c
re
a
s
e
 A
b
o
v
e
 B
a
c
k
g
ro
u
n
d
1
1
1
1
1
2
1
1
3
1
1
4
1
1
5
1
1
6
1
1
7
1
1
8
1
1
9
1
2
0
1
2
1
1
2
2
1
2
3
1
2
4
0
2
4
6
8
Glycan Index number
F
o
ld
 F
lu
o
re
s
c
e
n
e
 I
n
c
re
a
s
e
 A
b
o
v
e
 B
a
c
k
g
ro
u
n
d
1
2
5
1
2
6
1
2
7
1
2
8
1
2
9
1
3
0
1
3
1
1
3
2
1
3
3
1
3
4
1
3
5
1
3
6
1
3
7
1
3
8
1
3
9
1
4
0
1
4
1
1
4
2
1
4
3
1
4
4
1
4
5
1
4
6
1
4
7
1
4
8
1
4
9
1
5
0
1
5
1
1
5
2
1
5
3
1
5
4
1
5
5
1
5
6
1
5
7
1
5
8
1
5
9
1
6
0
1
6
1
1
6
2
1
6
3
1
6
4
1
6
5
1
6
6
1
6
7
1
6
8
1
6
9
1
7
0
1
7
1
0
2
4
6
Glycan Index number
F
o
ld
 F
lu
o
re
s
c
e
n
e
 I
n
c
re
a
s
e
 A
b
o
v
e
 B
a
c
k
g
ro
u
n
d
1
7
2
1
7
3
1
7
4
1
7
5
1
7
6
1
7
7
1
7
8
1
7
9
1
8
0
1
8
1
1
8
2
1
8
3
1
8
4
1
8
5
1
8
6
1
8
7
1
8
8
1
8
9
1
9
0
1
9
1
1
9
2
1
9
3
1
9
4
1
9
5
1
9
6
1
9
7
1
9
8
1
9
9
2
0
0
2
0
1
2
0
2
2
0
3
2
0
4
2
0
5
2
0
6
2
0
7
2
0
8
2
0
9
2
1
0
2
1
1
2
1
2
2
1
3
2
1
4
2
1
5
2
1
6
2
1
7
2
1
8
2
1
9
2
2
0
2
2
1
2
2
2
2
2
3
2
2
4
2
2
5
2
2
6
2
2
7
2
2
8
0
1
2
3
Glycan Index number
F
o
ld
 F
lu
o
re
s
c
e
n
e
 I
n
c
re
a
s
e
 A
b
o
v
e
 B
a
c
k
g
ro
u
n
d
2
2
9
2
3
0
2
3
1
2
3
2
2
3
3
2
3
4
2
3
5
2
3
6
2
3
7
2
3
8
2
3
9
2
4
0
2
4
1
2
4
2
2
4
3
2
4
4
2
4
5
2
4
6
2
4
7
2
4
8
2
4
9
2
5
0
2
5
1
2
5
2
2
5
3
2
5
4
2
5
5
2
5
6
2
5
7
2
5
8
2
5
9
2
6
0
2
6
1
2
6
2
2
6
3
2
6
4
2
6
5
2
6
6
2
6
7
2
6
8
2
6
9
2
7
0
0
1
2
3
4
Glycan Index number
F
o
ld
 F
lu
o
re
s
c
e
n
e
 I
n
c
re
a
s
e
 A
b
o
v
e
 B
a
c
k
g
ro
u
n
d
2
7
1
2
7
2
2
7
3
2
7
4
2
7
5
2
7
6
2
7
7
2
7
8
2
7
9
2
8
0
2
8
1
2
8
2
2
8
3
2
8
4
2
8
5
2
8
6
2
8
7
2
8
8
2
8
9
2
9
0
2
9
1
2
9
2
2
9
3
2
9
4
2
9
5
2
9
6
2
9
7
2
9
8
2
9
9
3
0
0
3
0
1
3
0
2
3
0
3
3
0
4
3
0
5
3
0
6
3
0
7
3
0
8
3
0
9
3
1
0
3
1
1
3
1
2
3
1
3
3
1
4
3
1
5
0
2
4
6
8
Glycan Index number
F
o
ld
 F
lu
o
re
s
c
e
n
e
 I
n
c
re
a
s
e
 A
b
o
v
e
 B
a
c
k
g
ro
u
n
d
3
1
6
3
1
7
3
1
8
3
1
9
0
2
4
6
8
Glycan Index number
F
o
ld
 F
lu
o
re
s
c
e
n
e
 I
n
c
re
a
s
e
 A
b
o
v
e
 B
a
c
k
g
ro
u
n
d
 
Figure G.14: M70 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
E F 
G I H 
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Figure G.15: M53 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
E F 
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Figure G.16: M98 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
E F 
G I H 
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Figure G.17: M97 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G)  sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
E F 
G I H 
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Figure G.18: M1 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
D 
C A 
E F 
G I H 
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Figure G.19: M12 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures. 
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Figure G.20: M3 binding glycan profile of (A) terminal galactose, (B) terminal glucose, (C) terminal N acetyl glucosamine, (D) mannose, (E) fucosylated, 
(F) Sialic acid containing, (G) sulphated, (H) GAG’s and (I) non-categorised structures.
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Figure G.21: Glycan binding profile of M1T1 clone GAS strains 5448 and 5448ΔM1 to blood 
group antigen A and B related structures. Glycan binding was analysed using ProScanArray 
imaging software, ScanArray Express (PerkinElmer, USA) before data was exported to Microsoft 
Excel for further analysis. Bacterial binding to a glycan was defined as a value > 1 fold increase above 
mean background RFU. The mean background was calculated from the average RFU of all empty 
spots on the array plus three standard deviations. Furthermore, statistical analysis of the data was 
performed by a Student’s t-test with a confidence level of 99.99% (p ≤ 0.0001) and only glycans that 
met these criteria for three biologically independent samples (n = 12 glycans spot replicates) were 
interpreted as positive binding interactions. Glycan index: 131, Galα1-3(Fucα1-2)Galβ; 132, Galα1-
3(Fucα1-2)Galβ1-3GlcNAcβ; 133, Galα1-3(Fucα1-2)Galβ1-4GlcNAcβ; 134, Galα1-3(Fucα1-
2)Galβ1-3GalNAcα; 135, Galα1-3(Fucα1-2)Galβ1-3GalNAcβ; 138, GalNAcα1-3(Fucα1-2)Galβ1-
4GlcNAcβ; 160, GalNAcα1-3(Fucα1-2)Gal.
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Appendix H: Blood group antigen typing from human 
saliva 
 
In this study, the blood group antigen status of each donor was typed via capillary carbon LC-
ESI-IT MS/MS. 
 
 
 
Figure H.1: Representative mass spectra of N-glycans released from salivary glycoproteins 
proteins which is subsequently indicative of donor blood group type and secretor status. Released N-
linked glycans were analysed by capillary carbon LC-ESI-IT MS/MS. 
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Figure H.2: Representative mass spectra of O-glycans released from salivary glycoproteins 
proteins which is subsequently indicative of donor blood group type and secretor status. Released O-
linked glycans were analysed by capillary carbon LC-ESI-IT MS/MS. 
 
 
 
